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Summary 
Cardiovascular diseases (CVD) are united in pathology by atherosclerosis; 
signal transduction is essential in this process for the expression of cell 
adhesion molecules early in the disease, capturing, tethering and transmigrating 
monocytes into the sub-endothelial space. The local recruitment of inflammatory 
cells and release of pro-inflammatory mediators induces endothelial 
dysfunction, an early functional abnormality in CVD.  
Plasma cytokines have been used to stratify CVD risk in humans. Studies have 
shown associations between pro-inflammatory tumour necrosis factor (TNF) 
and interleukin-6 (IL-6) and adverse cardiovascular events. However, the early 
pathophysiological signalling responsible for the expression of inflammatory 
molecules in vascular dysfunction remains poorly defined with limited in vivo 
studies.  
The ability to quantify endothelial dysfunction in animal models is limited by the 
need to cull animals in order to obtain vascular tissue, prohibiting longitudinal 
studies. The development of an in vivo non-invasive technique in this thesis has 
allowed the longitudinal assessment of microvascular responses in mouse 
models of inflammation.  
Candidate kinases in innate inflammatory signalling were assessed in vivo to 
better understand their role in endothelial dysfunction. These proteins are either 
essential in inflammatory homeostasis (A20 binding inhibitor of NF-ĸB-1 and 
mitogen and stress activated kinase 1/ 2) through negative regulation of 
inflammation or are fundamental in the cascade for cytokines synthesis 
(myeloid differentiation primary response gene 88, mitogen activated protein 
kinase activated-protein kinase 2/ 3). Through genetic alteration these models 
19 
 
produced a hyper-inflammatory CVD prone phenotype or one that is 
cardiovascular protective, respectively. Endothelium-dependent vasodilatation 
was attenuated in the presence of dyslipidaemia through reduced of nitric oxide 
(NO), cholesterol feeding induced increased expression of IL-6, IL-1α and TNF-
α. Importantly, through abrogation of cytokine signalling, NO was preserved in 
the presence of dyslipidaemia through reduced cytokine release of IL-6 and IL-
1α. 
This data provides a novel insight into the cellular signalling in inflammation and 
subsequent cardiovascular health, with a translational potential to effectively 
enhance the understanding of clinical pathology and inflammatory risk. These 
pathways offer unique therapeutic avenues for pharmacological intervention to 
potentially limit CVD in the human population. 
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Chapter 1 
Introduction 
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Preface 
CVD remains a leading cause of death, it is estimated that 17.3 million people 
died in 2008 from all cause CVD, representing 30% of all global deaths (World 
Health Organisation). CVD is mostly preventable, but the significant increase in 
morbidity and death are often associated with western civilisation, attributing 
disease prevalence to a sedentary lifestyle, a diet high in cholesterol and 
smoking, thus these factors are associated with CVD risk. The biological basis 
for CVD remains poorly defined and the pathological basis for the significant 
heterogeneity in CVD risk remains an unanswered question (Libby et al., 2011). 
Inflammation is regarded as an underlying cause for CVD, contributing 
significantly to functional and structural changes throughout the cardiovascular 
system. The aim of this thesis is to contribute to the knowledge of inflammation 
induced CVD. The effects are measured by the release of cytokines into the 
systemic circulation of mice that have undergone genetic and diet alterations to 
study the effects of particular proteins of interest.  
The thesis is structured, providing an introduction to CVD where the role of 
early endothelial dysfunction in atherosclerotic plaque formation is described, 
emphasis is placed on animal models and techniques used for the assessment 
of CVD, this is followed by the project aims and hypothesis. Subsequently, 
detailed descriptions of the experimental methods used to address the project 
objectives and meet the thesis aims are defined. Following chapters are 
organised into detailed studies and are summarised sequentially, discussing the 
significance of key findings relevant to the role of inflammation in the 
pathogenesis in CVD. A final discussion links together the relevance of the work 
contained within this thesis and draws on the major conclusions and 
contributions made to the field of cardiovascular medicine. 
22 
 
Background 
CVD accounts for significant morbidity and mortality worldwide, accounting for 
17.3 million deaths in 2008 (World Health Organisation). Within the European 
Union (EU) CVD causes 47% of all death; totalling 1.9 million individual cases 
and costs €196 billion per annum. Luengo-fernandez et al (2004) has previously 
reported a total cost of £29.1 billion to the United Kingdom economy,  23% of all 
expenditure is associated with a loss of productivity due to death and morbidity 
(Luengo-Fernandez et al., 2006). It was previously thought that males have a 
greater prevalent risk for CVD (Weidner and Cain, 2003) but recent statistics 
show women are more likely to suffer an adverse cardiovascular event in all 
countries within EU when compared to men (British Heart Foundation, 2012).  
CVD broadly refers to a pathological state of dysfunction encompassing both 
the myocardium and the circulatory system. Albeit in the later stages of CVD 
other tissues may become severely affected in a process termed end organ 
damage. In this advanced stage the renal and/or retinal vascular system may 
become impaired leading to renal dysfunction or blindness respectively (London 
et al., 2003).  
CVDs are plentiful and are named after the region of the body they affect, major 
CVDs include: myocardial infarction (MI), coronary heart disease (CHD), 
ischaemic stroke (of the cortex), aortic aneurysm and atherosclerosis. Patients 
are likely to display significant dysfunction in more than one vascular bed at any 
given time (van Kuijk et al., 2010). Nonetheless, CHD remains the number one 
cause of death in the EU followed closely by stroke (British Heart Foundation, 
2012). 
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The progression and development of CVD is attributed to numerous lifestyle risk 
factors such as smoking, the intake of high dietary cholesterol, salt, alcohol as 
well as physical inactivity and obesity. Thus the dogma clinically encouraged for 
a healthy cardiovascular system is a diet that is low in salt, which maintains a 
significant reduction in dietary cholesterol, abstinence from smoking and 
moderate levels of exercise.  
Traditional risk factors such as a diet high in cholesterol, obesity (body mass 
index (BMI) >30) and smoking may further exacerbate CVD risk in individuals 
that possess genetic polymorphisms, a genetic variation in genes associated 
with an increased risk of CVD. The exact dysfunction may vary from individual 
to individual, however the body’s inability to metabolise cholesterol successfully 
has been studied and gene variations associated with irregularities in 
cholesterol efflux results in lipid accumulation in the plasma, an established 
factor for CVD (Eichner et al., 2002). 
In addition to the aforementioned modifiable risk factors and inheritable genetic 
predispositions, other pathologies, so called co-morbidities such as diabetes 
type II (Grundy et al., 1999),  rheumatic diseases including rheumatoid arthritis 
(RA) and systemic lupus erythematosus (SLE) are associated with elevated 
CVD risk (Turesson et al., 2008, Turesson and Matteson, 2013). Treatment or 
management of each factor (lifestyle, genetic or co-pathology) alone or in 
synergy have shown to reduce CVD. CVD risk is often calculated by 
measurements of plasma cholesterol, blood glucose, BMI and blood pressure. 
These parameters have been used widely in clinical trials and are routinely 
assessed in the clinic. On the contrary, early detection of CVD continues to be a 
clinical challenge. The above guidelines are therefore determined on the 
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treatment of risk factors and focus on those individuals who are regarded as ‘at 
risk’ i.e. diabetic patients, overweight persons and those who display an 
elevated blood pressure or have a family history for CVD. 
One way in which the risk is calculated is based on the Framingham Risk 
Score, a population based study that examined the onset on of arterial 
fibrillation, congestive heart failure, CHD, diabetes, hypertension, intermittent 
claudication (angina) and stroke (Dawber et al., 1951). The Framingham Heart 
Study (1948) was initially set up to identify the factors that cause CVD. The 
study was strengthened by the participation of individuals who had not 
developed CVD or suffered a MI, allowing researchers to monitor change over 
time. The repeated testing nature of the Framingham study allowed physical 
and lifestyle factors to be tracked and related them to mortality, in doing so 
identifying elevated blood pressure, cholesterol, obesity, smoking, physical 
inactivity and co-morbidities such as diabetes as major risk factors in the 
pathogenesis of CVD. Further factors including age, socioeconomic status and 
gender have provided insight into the aetiology of CVD. Limitations within the 
Framingham risk study are widely accepted, study participants were not 
randomly selected, were Caucasian and may have been healthier than the 
general population. Nonetheless the major factors identified as detailed above 
have been applied to different ethnic groups and similar trends have been 
identified, although the pattern of distribution various considerably. For example 
individuals of south Asian descent (Afghanistan, India, Pakistan, Maldives and 
Bangladesh) are at greater risk of adverse cardiovascular events and are more 
likely to experience these at an earlier age when compared to equivalent 
Caucasian individuals (Hussain et al., 2013). Body fat composition and body fat 
distribution is believed to be a factor responsible for this accelerated risk. South 
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Asian men are more likely to hold 6% greater abdominal body fat when 
compared to Caucasian men, a result of enlarged abdominal adipocytes, a risk 
factor for diabetes and insulin resistance, which are in turn CVD risk factors. 
Importantly the distribution of body fat has important pathophysiological 
implications, visceral adiposity is independently associated with increased CVD 
risk (Britton et al., 2013). Although risk factors are routinely used to assess CVD 
risk in individuals, the ability to identify disease early remains a clinical 
challenge. Patients are often treated for CVD after a major event such as MI or 
stroke, thus the ability to hinder early pathophysiological events that cause 
progressive diseases such as atherosclerotic plaque formation is limited. 
Importantly studies have identified the onset of early CVD in patients with 
known risk factors such as diabetes (Khan et al., 2000), therefore the ability to 
detect early disease manifestation holds great therapeutic promise. A potential 
avenue to retard pathophysiological disease processes before the onset of 
overt clinical disease. 
The role of risk factors, genetic predisposition and co-morbidities in the 
aetiology of CVD share common physiological responses of inflammation.  
Inflammation specifically refers to the local recruitment of leucocytes from the 
plasma to tissues. Leucocyte recruitment and the sustained release of pro-
inflammatory cytokines have been correlated with a wide range of clinical 
conditions including: hyperglycaemia, obesity, hypertension, hyperlipidaemia, 
periodontal disease and in particular diseases of the vascular system including 
atherosclerosis, CHD and endothelial dysfunction (Ait-Oufella et al., 2011, 
Mallat et al., 1999, Mallat and Tedgui, 2007, Tedgui and Mallat, 2006, Borel et 
al., 2009, Minet et al., 2012, Piconi et al., 2009, Rueda-Clausen et al., 2009). 
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Cardiovascular Disease and Inflammation 
The role of inflammation in CVD development is complex. Patients displaying 
traditional risk factors (Herrera et al., 2010, Kathiresan et al., 2006, Roifman et 
al., 2011, Singhal, 2005) and those suffering from chronic inflammatory disease 
conditions such as RA (Galarraga et al., 2008) and SLE (Barbulescu et al., 
2012) display elevated levels of circulating pro-inflammatory cytokines such as 
TNF-α and have an elevated risk for CVD. Plasma cytokines including TNF-α, 
IL-6 and C-reactive protein (CRP)  have been used as prognostic markers for 
future adverse cardiovascular events in patient trials (Barbulescu et al., 2012, 
Clapp et al., 2005, Fernandez-Real et al., 2001, Fichtlscherer et al., 2004, 
Galarraga et al., 2008, Liu et al., Lu et al., 2007, Naya et al., 2007, Pradhan et 
al., 2001), in combination with the traditional risk factors such as BMI and 
plasma cholesterol. The efficacy of these plasma molecules as prognostic 
markers for future adverse cardiovascular events such as MI or stroke remains 
contentious, with some studies showing good, little or no predictive value. 
Inflammatory molecules can be synthesised from a number of cell types 
including specialised leucocytes in response to both endogenous and noxious 
stimuli. In particular, the macrophage is regarded as the predominant 
inflammatory cell in the pathogenesis of CVD. Macrophage infiltration into the 
vascular lumen is regarded as an early event in CVD development and 
macrophages are readily detected in damaged and diseased tissues. 
Macrophages are recruited to the damaged myocardium following infarction 
where they propagate damage and mediate repair (Swirski et al., 2009, 
Nahrendorf et al., 2007).  Macrophage depletion or abrogation of macrophage 
recruitment has shown cardio-protection (Leuschner et al., 2010b, Swirski et al., 
2009). The infiltration of macrophages into damaged tissues remains 
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multifaceted. There are numerous signalling cascades that capture these highly 
specialised cells and induce transmigration deep into tissues, a prerequisite for 
atherosclerotic plaque formation. It has previously been established that 
macrophages are sensitive to activation. Inflammatory molecules such as 
Interferon-γ (IFN-γ) and TNF-α through receptor stimulation can activate 
macrophages and induce the production of reactive radicals, such as the 
reactive oxygen species (ROS) NO, through up regulation of inducible nitric 
oxide synthase (iNOS). Classically (M1) activated macrophages are associated 
with increased phagocytic behaviour and secrete high levels of pro-
inflammatory molecules IL-1, IL-6 and IL-12  (Mosser, 2003). Conversely, 
molecules such as IL-4 can alternatively activate macrophage and induce an 
M2 or an anti-inflammatory phenotype. The induction of an M2 phenotype is 
associated with reduced phagocytic behaviour, silenced iNOS induction and a 
high production of anti-inflammatory IL-10 and IL-1 receptor antagonist (IL-1ra). 
Although the phenotype of macrophages appears to be definitive, numerous 
sub-subdivisions exist and have been associated with various physiological 
roles (Zawada et al., 2012). 
Vascular lesions affect the arterial system and contrary to what was previously 
thought atherogenic lesions are multifaceted and not just the quiescent 
accumulation of lipids at arterials bends and bifurcations.  The macrophage 
contributes to lesion development and progression through foam cell formation. 
Atherosclerotic plaques are the outcome of prolonged inflammatory signalling 
that results in the continual recruitment of lymphocytes, increased oxidative 
stress and the synthesis of collagen, forming a cell dense lesion that which 
reduces lumen diameter (Zhao and Qin, 2011, Libby et al., 2009). 
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Leucocyte extravasation is a specialised process and subsequent 
transmigration into the sub-endothelial space is achieved though activation of 
receptor-mediated pathways. Damaged or stimulated cells can express pro-
inflammatory cytokines, inducing the expression of cell adhesion molecules 
such as vascular cell adhesion molecule-1 (VCAM-1), intracellular cell adhesion 
molecule-1 (ICAM-1), E-selectin, P-selectin and in combination with 
chemokines such as macrophage chemoattractant protein-1 (MCP-1) recruit 
macrophages to the area of tissue injury.  
Macrophages captured from the circulating blood are adhered to the vascular 
endothelium and a process of transmigration through endothelial cell gap 
junctions (Figure 1.1) results in leucocyte recruitment.  Infiltrated macrophages 
can occupy the sub-endothelial space; over time these cells encounter 
numerous physiological stimuli that induce the expression of pro-inflammatory 
genes. Oxidised lipids such as low density lipoproteins (LDL) are associated 
with adverse CVD events and can stimulate macrophage to release pro-
inflammatory molecules. Infiltrated leucocytes are able to release a number of 
mediators into their surroundings including ROS and proteolytic enzymes. The 
release of cytokines is important in the removal of infections agents such as 
bacteria from tissues and the elimination of apoptotic cells; however extended 
or inappropriate activation of these pathways can be deleterious leading to 
profound injury to the vascular bed and more importantly the endothelial lining.  
Elevated level of ROS can oxidise lipids such as LDL forming oxidised-LDL 
(oxLDL) in the blood. The oxLDL is recognised by the macrophage and 
ingested for removal, oxLDL accumulates within the growing macrophage to 
form a characteristic atherosclerotic foam cell (Figure 1.2). Progressively large 
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numbers of macrophages accumulate within the vessel wall. Sequentially these 
cells promote vascular inflammation through the release of pro-inflammatory 
cytokines and promote further cell recruitment. Atherosclerotic foam cells 
accumulate in such numbers that vascular remodelling is required to support 
the advancing cell mass, through the synthesis of collagen atherosclerotic 
plaque is formed.  
Over time (decades in humans and months in genetically altered mice) these 
foam cells die and form a central highly noxious necrotic core. The growing 
vascular lesion, through increased cell recruitment and apoptotic mass extends 
towards the vascular lumen, reducing lumen diameter. Obstructed vessels are 
associated with the onset of ischaemia, end organ damage and even organ 
failure. Although numerous pathways have now been identified that contribute 
to atherosclerotic lesion formation there remains limited pharmacologically 
active drugs for the treatment of patients. Thus the ability to hinder these 
processes early before the onset of overt disease is of key clinical significance. 
The process of atherosclerosis begins with early endothelial dysfunction, a 
termed given to an imbalance in endogenous vasodilators and vasoconstrictors, 
VCAM-1 expression and the activation of platelets. Therapeutic strategies to 
limit the activation of the vascular endothelium through attenuation of 
inflammatory mediators offers a novel approach to retard pathophysiology early 
in the human population. 
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Figure 1.1. Leucocyte extravasation: Leucocyte adherence, tethering, 
attachment to the vascular endothelium and transmigration through endothelial 
cell gap junctions. Adapted from (Ley et al., 2007). 
 
Figure 1.2. Atherosclerotic plaque formation: Oxidised lipids are recognised 
and engulfed by vascular macrophages. This cycle perpetuates and forms 
characteristic atherosclerotic foam cells, developing into a dense, toxic necrotic 
core that obstructs the vascular lumen. 
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Vascular Endothelium  
The vascular endothelium has a number of specialised features that are 
accompanied by specific metabolic and synthetic functions. Molecules secreted 
from endothelial cells are able to significantly affect the behaviour of underlying 
vascular smooth muscle cells (VSMCs) and circulating white blood cells (Walker 
et al., 2010). Endothelial cells form one of the most important structures within 
the vascular tree and in turn pathogenesis (Cherry et al., 1982, Furchgott, 1984, 
Furchgott, 1983, Furchgott and Zawadzki, 1980). The mass endothelial cell 
weight in an adult human is approximately 1kg, equating to a total surface area 
of 1.7m2 (Cines et al., 1998). Endothelial cells have a flattened structure and 
vary between 10-20µm in diameter. Overlaps between adjacent cells form tight 
junctions; in combination with their semi-permeable nature, the movement of 
molecules is strictly regulated. The squamous cells are composed around a 
central nucleus with organelles concentrated in the perinuclear area. 
Endothelial cells form a physical barrier between blood, bodily tissues and also 
serve as a functional component important in vessel integrity with a role in 
angiogenesis (Lamalice et al., 2007).  
The vascular endothelium interfaces between circulating blood and the vessel 
wall to maintain an anti-inflammatory, anti-thrombotic phenotype. Endothelial 
cells are responsible for numerous biological processes, most importantly 
maintaining vascular basal tone (modulation of lumen diameter) and the 
adequate perfusion of tissues. Endothelial cells are able to regulate their 
environment locally through the release of biologically active mediators such as 
histamine as well as NO. Both molecules are essential factors in oedema 
formation and leucocyte recruitment (Leach et al., 1995, Duran et al., 2010) 
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Endothelial cells produce NO as a bi-product of the amino acid L-arginine 
oxidation to L-citrulline by enzymatic action of endothelial cell specific nitric 
oxide synthase (eNOS) (Figure 3).  eNOS is highly expressed in endothelial 
cells within the vasculature and for this reason primarily contributes to vascular 
tone under basal conditions through generation of NO.  
Figure 1.3. Bioavailability of nitric oxide: Enzymatic oxidation of L-arginine to 
L-citrulline through endothelial nitric oxide synthase (eNOS) produces nitric 
oxide (NO). 
 
eNOS can be activated in response to  changes in shear stress (Corson et al., 
1996, Gallis et al., 1999) or by appropriate receptor stimulation from a range of 
agonist drugs including acetylcholine (ACh) and bradykinin (Cherry et al., 1982, 
Furchgott and Zawadzki, 1980).  
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eNOS activity requires oxygen, nicotinamide adenine dinucleotide phosphatase 
(NADP), tetra-hydro-biopterin (BH4) and other cofactors including cysteine. NO 
is able to bind to the haem of guanylyl-cyclase found on VSMCs, converting 
GTP to cyclic GMP (cGMP), an important second messenger in VSMC 
relaxation. cGMP activates both potassium (K+) and calcium (Ca2+) channels 
and induces cell hyperpolarisation and cytoskeleton relaxation. cGMP inhibits 
cellular Ca2+ entry and further depletes intracellular sub-sarcolemmal storage 
sites causing VSMC fibre relaxation by activating an enzyme to 
dephosphorylate myosin light chains (Esper et al., 2006, Palmer et al., 1988). 
NO plays a further role in hemodynamic and platelet: adhesion, activation, 
secretion, aggregation and disaggregation, VSMC migration and proliferation 
(Inglessis et al., 2004, Semigran et al., 1994, Riddell and Owen, 1999). 
NO is a heterodiatomic molecule, its low molecular weight and lipophilic 
properties allow passive diffusion through biological systems making it an 
important signalling molecule (Lamattina et al., 2003). The loss of NO 
bioavailability is thus associated with endothelial dysfunction and is 
subsequently associated with altered vasomotion, an early event in the 
development of atherosclerosis (Bonetti et al., 2003, Naseem, 2005). Shifting 
the phenotype of the vascular endothelium from a quiescent non-adherent 
surface, to one that induces the tethering of monocytes an early event in the 
atherosclerotic plaque formation. 
Several lines of evidence currently support the loss of NO and the onset of 
endothelial dysfunction. Impaired vasoreactivity maybe the outcome of a direct 
decrease in L-arginine (Kamada et al., 2001) an increase in the number of 
endogenous vasoconstrictors such as endothelin-1 (ET-1) (de Andrade et al., 
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2009) the opposing mechanism to NO mediated vasodilatation; eNOS loss by 
apoptosis of endothelial cells (Winn and Harlan, 2005) or the quenching of NO 
by ROS formation or a loss of one or more of the essential co-factors (Herrera 
et al., 2010, Alp and Channon, 2004). 
Importantly evidence suggests that inflammation even at subclinical levels is 
correlated with a reduction in the bioavailability of NO and impaired 
endothelium-dependent vasodilatation (Clapp et al., 2004, Clapp et al., 2005). 
Research has shown pro-inflammatory molecules such TNF-α have a pivotal 
role in reducing the biological potency of NO (Zemse et al., 2010). Studies 
suggest that patients suffering from atherogenesis are likely to have widespread 
problems throughout the vascular system, with damage significantly affecting 
more than one vascular bed including endothelial dysfunction, neointimal 
proliferation and atheroma development, all which may be mediated by the loss 
of NO bioavailability (Tedgui and Mallat, 2006). The ability to test for endothelial 
function, as an early event in CVD has been used as a marker of vascular 
health and as a prognostic marker for future adverse cardiovascular events in 
humans. 
 
In vivo Models of Endothelial Dysfunction  
Methodologies for the assessment of endothelial function have been 
established to asses CVD risk in patients. Endothelial dysfunction remains the 
earliest detectable functional abnormality in vascular tissue and has been 
prominently reported in a wide range of clinical diseases including: diabetes 
(Jones and Dewan, 2003), RA (Galarraga et al., 2008) and in patients with 
known CVD risk factors (Hadi et al., 2005, Khan et al., 2000). 
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Invasive and non-invasive techniques have been described for the assessment 
of endothelial function in humans. Studies examining the role of coronary artery 
dysfunction in CVD have infused agents such as adenosine and papaverine to 
elicit endothelium-dependent responses in a technique called flow-mediated 
vasodilatation (FMD). The method evaluates coronary circulation, measuring 
changes in endothelium-dependent vasodilatation. In healthy individuals 
increased flow is associated with greater shear stress and a greater release of 
NO, inducing vasodilatation in proximal epicedial arteries; whereas reduced flow 
is indicative of endothelial dysfunction through altered NO bioavailability. The 
technique is limited by the assessment of flow through larger conduit coronary 
arteries, thus the technique does not distinguish between impaired function and 
obstructed flow. Flow may be impaired by the presence of atherosclerotic 
lesions, however impaired endothelial function contributes significantly to 
diseases such as hypertension through diminished vascular function in small 
vessels. Functional testing of the coronary bed can be performed through 
insertion of a Doppler wire into a coronary artery and followed by the infusion of 
vasoactive chemicals i.e. ACh and bradykinin, delineating impaired flow to 
specific agonist as impaired endothelial function. The major limitation to the 
assessment of coronary macro and microcirculation is the invasive nature of the 
technique and thus these patients are often pre-selected and studied under a 
routine clinical screen, introducing selection bias for research studies. 
Techniques for the assessment of the peripheral circulation are therefore 
favoured. Blood vessels can be imaged non-invasively using high frequency 
ultrasound and there is no need for radioactive tracers. FMD can be used to 
assess function in numerous vascular beds including the brachial or femoral 
arteries. Similarly, peripheral FMD monitors the changes in vessel diameter, 
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before and after application of stimulant. A sphygmomanometer cuff is placed 
above the anterior cubital fossa and inflated to induce vascular occlusion, pre- 
and post-vessel diameters are compared and nitro-glycerine, a NO donor can 
be used as an internal control for endothelium-independent vasodilatation. This 
technique has been used in large clinical trials for the assessment of CVD. 
Although non-invasive, the technique is highly operator dependent and values 
can vary considerably, a period of months is needed for training and there is 
currently no agreement on a standardised protocol. Images are prone to 
artefact and image quality is of key importance, high resolution images must be 
obtained to accurately evaluate changes in vessel diameter (Barac et al., 2007). 
In an effort to reduce operator variation and to reduce image artefacts the skin, 
microcirculation has been used as alternative method to assess systemic CVD 
burden and endothelial function. The small vessels in the skin can be assessed 
through laser scattering methods that are comparatively cheaper and more 
operator friendly than brachial FMD, but maintain the advantage of being non-
invasive. Laser Doppler flowmetry (LDF) has been used to assess endothelial 
function in a range of clinical diseases including chronic kidney disease(Babos 
et al., 2013, Wilson et al., 1992, Khan et al., 1999, Khan et al., 1991). The 
technique is founded upon the static scattering of a stable laser beam by the 
movement of red blood cells in the skin microcirculation. Using a similar 
principle to FMD, perfusion can be increased with the use of vasodilators and 
decreased with vasoconstrictors. Changes in perfusion can be related to 
underlying pathobiology, with attenuated responses to ACh associated with 
decreased NO bioavailability.  The technique has previously been compared to 
FMD and has shown good correlation (Debbabi et al., 2010). Although cheaper 
and more user friendly, LDF is not the optimal technique. The technique suffers 
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from the poor spatial and temporal heterogeneity of skin microcirculation. The 
small region of interest measured by the LDF probe can often represent local 
changes, and/or variation in the skin microenvironment and not necessary be 
indicative of any underlying pathophysiology.  As an alternative, Laser Doppler 
Imaging (LDI) uses a scanning stable laser, which assesses a larger region of 
interest than LDF, reducing spatial heterogeneity. LDI has shown good 
correlation with underlying cardiovascular function in humans (Khan et al., 
2008) and has shown good temporal reproducibility. Importantly, LDI in 
combination with vasoactive chemicals has allowed researchers to non-
invasively assess disease severity before the onset of overt clinical disease 
(Khan et al., 2005, Khan et al., 2000). 
Endothelial function testing has been used as a prognostic marker for adverse 
future cardiovascular events in clinical trials; an intimate relationship between 
systemic inflammation and cardiovascular health has been reported. However 
the initial pathological events that lead to endothelial dysfunction remain poorly 
defined. The ability to interrogate specific cellular signalling pathways of 
pathophysiology is limited in human clinical trials. Often patients are selected 
from pre-requisite criteria for inclusion or exclusion and therefore clinical trials 
measure outcome based on assessment of risk factors or mortality. Research 
groups over the past two decades have shifted their research interests away 
from the patient scenario and capitalised on the ability to genetically modify 
rodents, altering their risk profile to CVD through diet and pharmacological 
intervention, exacerbating disease scenarios to model prevalence and severity, 
as observed in the human population.  
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Cardiovascular Disease: Human to Murine 
Recombinant DNA technology in the 1970s gave rise to genetic manipulation, 
with the ability to test factors of many diseases observed in the human 
population including CVD. The relatively easy genomic application of DNA 
recombination to rodents, in harmony with their species specific attributes, such 
as short gestation periods (18-21 days) and low maintenance costs, reinstated 
the suitability of mice as experimental models (Russell, 2003). 
Numerous groups have used experimental mouse models of CVD to better 
understand a variety of cellular changes in the myocardium and vascular 
system. Operator interventions have been used to mimic established 
cardiovascular risk factors as observed in the human population. For example, 
the effects of oxidative stress are associated with the attenuation of 
endothelium-dependent vasodilatation in humans and rodents (Lesniewski et 
al., 2009, George et al., 2006). Talukder et al (2011) (Talukder et al., 2011) 
demonstrated the pathophysiological effects of oxidative stress in wild-type 
(WT) C57Black/6 (C57BL/6) mice, a routinely used experimental mouse model. 
Animals exposed to cigarette smoke showed cardiac hypertrophy, hypertension, 
leucocyte activation, ROS generation and a significant reduction in NO 
availability, a multimodal risk factor for CVD originally described by the 
Framingham Heart Study.  
During the 1990s the development of homologous apolipoprotein E (ApoE) 
gene targeted knock-out (KO) mouse by Jan Breslow (Nakashima et al., 1994, 
Plump et al., 1992) resulted in a plethora of studies looking at CVD and lipid 
homeostasis. Apolipoprotein transport lipids in the blood and deficiency in 
humans is associated with atherosclerosis. Breslow and his team generated 
animals deficient in ApoE, and studies showed significant differences between 
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gene targeted KO and control groups in plasma cholesterol. Importantly, ApoE 
KO animals had significantly greater plasma lipids and these 
hypercholesterolaemia changes were supported by atherosclerotic lesion 
presentation in KO mice (Nakashima et al., 1994). 
In addition to the generation of ApoE KO mouse, the low density lipoprotein 
receptor (LDLr) deficient mouse was developed (Ishibashi et al., 1993). LDLr 
receptor mice show significant elevation for plasma cholesterol when compared 
to WT control mice and the onset of atherosclerotic lesions, similar to ApoE KO 
mice (Ishibashi et al., 1994a). ApoE KO mice display significantly greater 
plasma lipids when compared to LDLr KO mice on a chow diet (Ishibashi et al., 
1994b). However, double KO of ApoE and LDLr failed to show a greater onset 
of hypercholesterolaemia when compared to single ApoE KO animals (Ishibashi 
et al., 1994b).  
Although the two genetic models of CVD (ApoE and LDLr KO) have provided 
insight into the manifestation of CVD, ApoE and LDLr deficient mice only serve 
as an experimental model for an aggressive form of CVD, induced by high 
physiological hypercholesterolaemia. The study of genes, proteins and 
pathways that are not innately based on irregularities in cholesterol metabolism 
are then unfavourably tested using these models. Genetic irregularities in lipid 
metabolism result in plaque formation in humans, in the absence of high dietary 
cholesterol. Thus, these models of CVD are inherently based on genetic 
abnormalities in lipid metabolism, a factor which limits the contribution to the 
overall CVD cases in the human population and limits translational science.  
The aggressive phenotype observed in ApoE and LDLr KO mice is more 
indicative of a latent stage of CVD in humans, one where early intervention is 
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less applicable. The spontaneous lipid accumulation in the plasma of these 
animals is not necessarily representative of health in the human population. 
Individuals may consume high levels of dietary cholesterol intermittently and not 
necessarily repeatedly or for prolonged durations, such as a single high 
cholesterol meal at breakfast, lunch and dinner. Thus, the ApoE and LDLr KO 
mouse models are representative of a chronic state of hypercholesterolaemia. 
Animal studies using these models have however highlighted the importance of 
initial dyslipidaemia and its contribution to future adverse CVD events. Crucially, 
plaque progression can be observed after plasma lipids have normalised 
through the cessation of dietary cholesterol in animal models (Khanna et al., 
2013), suggesting significant modulation of pathological processes within 
physiological systems that are not based on elevated plasma levels; this is 
believed to be inflammation. Importantly, patients who do not display elevated 
plasma levels of cholesterol display elevated CVD risk profiles; this is potentially 
mediated through inflammation. 
 
Inflammation and Endothelial Dysfunction 
The generation of pathophysiological signals involved in the development and 
progression of CVD remains poorly defined. Although plaque formation is 
known to span many decades, the initial pathological events leading to lesion 
formation remain poorly understood. Cellular communication is achieved 
through conserved evolutionary biological signalling pathways responsible for 
cell growth, cell survival as well as the expression of inflammatory genes.  
Inflammation and its propagation involve the interplay of many molecules; this in 
turn mediates numerous cell responses and contributes to the development of 
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atherosclerosis. Scientific manipulation of animal models to study this process 
continues to provide invaluable knowledge, aiding both the basic understanding 
of disease evolution and supporting the innovation of new therapies. 
Pre-clinical studies have used gene targeted models, manipulating the 
expression of inflammatory cytokines such as IL-10, IL-1 (Mallat et al., 1999, 
Mallat and Tedgui, 2007, Isoda et al., 2003) and TNF-α (Branen et al., 2004) to 
better understand their role in endothelial dysfunction, as a surrogate marker for 
CVD.  Researchers have developed numerous techniques to assess CVD 
disease burden in both, clinical medicine and in investigative cardiovascular 
physiology. Physiological studies of CVD are ordinarily performed post mortem 
using histological techniques for the assessment of atherosclerotic lesions or ex 
vivo in organ baths, without the control of tissue and system homeostasis. 
Furthermore, there remain limited translational techniques that are both 
applicable to human clinical medicine for the interrogation of CVD and for aiding 
research utility in animal models. Therefore, the translational efficacy of 
inflammatory molecules as prognostic markers for future adverse 
cardiovascular events, such as MI or stroke, is unclear. There is uncertainty due 
to a lack of standardisation amongst research groups, a number of 
methodological differences such as the use of plasma or serum, differences in 
the use of anti-coagulations such as heparin or EDTA (ethylene diamine tetra 
acetic acid), the time frame of measurements (i.e. baseline, monthly, bi-
annually, annually) and which inflammatory markers to use (TNF-α, IL-6, IL-10, 
IL-1, CRP and high sensitive-CRP (hs-CRP)). Furthermore, there are 
inconsistencies in the large scale epidemiological studies and the evidence for 
novel markers as accurate predictors above and beyond that of traditional 
factors, such as blood pressure and plasma cholesterol, for future adverse 
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cardiovascular events continue to be uncertain, largely due to differences 
observed in individuals during repeated testing (Pearson et al., 2003, Evora et 
al., 2013).  
In particular, TNF-α has produced conflicting results, although established as a 
pro-inflammatory cytokine with an integral role in immunity, bacterial clearance 
and clinical conditions including diabetes, RA and atherosclerosis (Popa et al., 
2007) evidence from human studies varies considerably. TNF-α polymorphic 
analysis suggests a strong, weak or no association to CVD for various TNF 
alleles (Cho et al., 2013, Asifa et al., 2013, Keso et al., 2001). This is further 
complicated by research studying the contribution of TNF-α in atherogenesis. 
Mice deficient in both TNF-α and ApoE display a 50% reduction in atherogenic 
lesions after 10 weeks on a western type diet (Branen et al., 2004), suggesting 
a role for this cytokine in CVD, when risk factors are combined. 
To better understand the role of cytokines in CVD is therefore necessary to 
study the pathways that stimulate inflammatory cytokines. Cytokine expression 
can be induced through numerous pathways, such as macrophage toll-like 
receptors (TLRs) that are able to signal pro-inflammatory gene expression 
associated with atherosclerosis (Tobias and Curtiss, 2007). As previously 
discussed, macrophages are highly abundant in atherogenic plaques and 
contribute to the latent stage of atherosclerosis, with the formation of a necrotic 
core that is densely filled with lipid. TLRs transduce signals through numerous 
mediators of inflammation, including p38 mitogen-activated protein kinase 
(MAPK), suggesting a role for this pathway in atherogenesis. Inhibition of p38 in 
a model of atherosclerosis has shown to reduce plaque formation (Seeger et 
al., 2010). Therefore, a greater study of the pathways controlling the expression 
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of inflammatory genes may aid the current understanding of inflammation-
induced CVD and the increased CVD risk associated with inflammation as 
evidenced in patients suffering from RA and SLE. 
 
Toll-like Receptors and Inflammation 
Innate immune signalling is dependent on cell surface receptors, providing an 
interface between the extracellular space and the intracellular domain of cells. 
TLRs were initially documented for their role in the recognition of invading 
microbial pathogens. More specifically, TLRs are able to recognise pathogen 
associated molecular patterns (PAMPs) on the cell surface of microbes, which 
are absent from mammalian tissue. Lipopolysaccharide (LPS) is released by 
gram negative bacteria during cell lysis and recognised by a specific type of 
TLR (TLR-4). There are many documented members of the TLR family (TLR 1-
13 in mouse and TLRs1-10 in man (Falck-Hansen et al., 2013). The 
extracellular TLRs are: TLR1-2, TLR4-6 and TLR11, for the detection of 
lipoproteins. Conversely, the TLRs expressed in the cell cytoplasm include: 
TLR3, TLR7-9 and the mouse TLR12-13 (Figure 1.4), these intracellular TLRs 
are involved in the detection of bacterial and viral nucleic acids. Intracellular 
TLRs are expressed on cellular organelles such as the endoplasmic reticulum, 
endosomes and lysosomes, suggesting specific extracellular and intracellular 
function for each of these receptors (Figure 1.4). 
 
44 
 
 Figure 1.4. Extracellular and intracellular expression of TLRs: Extracellular 
TLR’s are 1-2,4-6,10 and the mouse TLR11, intracellular TLRs are 3,7-9 and 
the mouse 12-13, species differences between man and mouse as denoted. 
LRR= leucine-rich repeat. TIR= toll\IL-1 receptor domain. 
 
TLRs are membrane-spanning receptors with a leucine-rich repeat (LRR) 
extracellular motif. TLRs have a horse-shoe like ectodomain that can interact 
with agonists such as LPS through a string of LRR.  The copy number of LRR 
varies and is typically between 20-25 amino acids in length which maintain the 
horse-shoe like structure. The ectodomain is followed by a trans-membrane 
helix and initiates downstream effects through a toll\IL-1 receptor (TIR) domain. 
This LRR repeated domain serves as an integral part for recognition of PAMPS 
and danger associated molecular patterns (DAMPs), forming protein-to-protein 
interactions activating downstream events. 
The physiological relevance of TLRs have previously been studied. TLRs show 
specificity to particular pathogen components, demonstrating the highly 
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specialised nature of the mammalian immune system, with an ability to 
distinguish between pathogens and pathogenic components i.e. PAMPs and 
LPS. 
Transmembrane signalling via TLRs causes homodimer formation, except for 
TLR1/2, 2/6, 4/6/CD36 that forms heterodimers. The TLRs share LRR and a 
TIR domain for signalling downstream, which is achieved through adaptor 
molecules. The cytoplasmic TIR domain that governs the TLR signalling 
pathway for all TLRs except TLR-3 rely on a proline residue. Trans-cytoplasmic 
signalling by TLRs is achieved by TIR and myeloid primary response gene 88 
(MyD88).  
MyD88 is a universal adaptor molecule and is used by all TLRs, except TLR-3 
and thus TLR-3 activation is regarded as being MyD88 independent, as 
opposed to MyD88 dependent signalling. Other adaptors include TIR domain-
containing adaptor inducing interferon (IFN-β) (TRIF), MyD88-like adaptor 
(Mal)/TIR domain containing adaptor protein (TIRAP), and TRIF-related adaptor 
molecule (TRAM) (Cole et al., 2013).  
TLR2 and TLR4 require Mal/TIRAP to bridge the TIR domain with MyD88. 
MyD88 also has a TIR and death domain (DD); following TLR activation, the 
MyD88 DD interacts with the DD of intracellular receptor associated kinase-4 
(IRAK-4), IRAK-1 and IRAK-2. IRAK kinases phosphorylate tumour necrosis 
factor receptor associated factor-6 (TRAF-6) and E3 ligase (Figure 1.5) (Cole et 
al., 2013). Polyubiquitin binding results in transforming growth factor TGF-β-
activated kinase-1 (TAK-1) binding proteins (TAB2-3) activating TAK-1. 
Activation of TRAF-6 causes polyubiquitination of TAK-1 as well as itself 
(TRAF-6) assisting binding to the inhibitors of kB (IκB). Phosphorylation of IκB 
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promotes its degradation. The loss of IκB induces nuclear translocation of 
nuclear factor kappa B (NF-κB) from the cytoplasm, activating transcription and 
induces the expression of inflammatory genes (Figure 1.5). This innate 
signalling cascade causes the production of many inflammatory genes that are 
non-specific and thus, this is regarded as an early phase response in immunity. 
 
Figure 1.5. MyD88-dependent TLR Signalling: A: inactive, resting cell and 
B: activated/stimulated  cell Toll-like receptor (TLR), interactions with 
toll/interlukein-1 receptor (TIR) and MyD88 for NF-κB activation. Adapted from 
(Han, 2006). 
 
The integral role of MyD88 in the inflammatory responses has previously been 
established. Animals deficient in MyD88 show depleted inflammatory responses 
to LPS, peptidoglycan, imidazoquinoline and flagellin, specific TLRs agonists. 
Furthermore, animals deficient in MyD88 display depleted responses for the 
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production of IL-6 and TNF-α, supporting the role of MyD88 in the mediation of 
inflammatory responses via TLRs. 
TLR signalling, specifically TLR1/2, TLR4 and TLR5 expression is highly 
evident in atherogenic lesions. TLR4 accumulation can be specifically observed 
in regions that are prone to rupture through the increased expression and 
release of matrix metalloproteinase-9 (MMP-9), that possess the ability to 
instigate plaque rupture through protein lysis. Within atherogenic lesions, 
numerous research groups have shown increased expression of TLR4, which is 
specifically up regulated in macrophages in responses to oxLDL (Bjorkbacka et 
al., 2004, Cole et al., 2013, Tobias and Curtiss, 2007). 
The ability of TLRs to detect oxLDL makes them important signalling molecules 
in CVD. Elevated plasma cholesterol is an established risk factor for future 
adverse cardiovascular events, and thus blockade of TLRs may provide a novel 
avenue for attenuating/ alleviating early CVD. TLR4 further signals for a number 
of pro-inflammatory molecules, including adhesion molecules, VCAM-1 and 
ICAM-1 that are relevant to CVD in the capture and transmigration of 
monocytes into the sub-endothelial space. 
Animals deficient in the adaptor MyD88 display reduced atherosclerosis and a 
significant reduction in the infiltration of macrophages into the arterial lumen, 
when backcrossed onto the ApoE KO CVD-prone mouse (Bjorkbacka et al., 
2004). Under shear flow, where flow is laminar, the production of NO maintains 
a non-adherent, quiescent phenotype.  Duzendorfer et al (2004) (Dunzendorfer 
et al., 2004) demonstrated the up regulation of TLRs during disturbed laminar 
flow or static flow (no flow), representative of no/low flow conditions during MI.  
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Without MI, endogenous flow differences exist throughout the cardiovascular 
system, due to the natural curvature of the aorta. Flow differences produce sites 
that are either prone to atherogenesis and those that are essentially athero-
protective (mid-thoracic aorta) early in atherosclerosis development. Pulsated 
blood from the left ventricle remains laminar until the aortic arch; here the flow 
and direction of blood changes and a more turbulent pattern can be observed 
(Figure 1.6). Thus a reduction in laminar flow reduces shear stress and 
depletes NO bioavailability, promoting an altered vascular phenotype that is 
pro-inflammatory and activated, inducing the adherence of monocytes for 
subsequent infiltration, a pre-requisite for the development of atherosclerosis.  
 
Figure 1.6. Aortic blood flow: Blood entering the aorta remains laminar until 
the aortic arch; the curvature of the aortic arch induces turbulent flow producing 
haemodynamic variation and reduces shear stress. Yellow lines denote 
turbulent flow; black arrows show median direction of blood flow without 
disruption. 
 
TLR2 inhibition has shown promising results with a reduction in infarct size in an 
ischaemic model of reperfusion injury in the pig (Arslan et al., 2012). Inhibition 
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of TLR2 in the study by Arslan et al demonstrated reduced inflammation and 
macrophage infiltration with a significant reduction in MMP-9. Further to this, 
experimental groups that are double KO for ApoE and MYD88 displayed no 
significant changes in plasma triglycerides and total plasma cholesterol when 
compared to controls ApoE KO mice (Bjorkbacka et al., 2004). Supporting the 
notion that pathophysiology in atherogenesis are a direct results of the innate 
immune response, as opposed to a secondary outcome or change in plasma 
lipid metabolism, mediated through a similar pathway. The role of MyD88 
activation in endothelial dysfunction has not previously been described. 
Importantly, MyD88 inactivation early in CVD may be a novel therapeutic 
avenue to limit inflammatory responses, protecting against overt inflammatory-
mediated diseases, such as atherosclerotic plaque formation. There are other 
regulators of inflammation after TLR activation that can induce the synthesis of 
inflammatory genes associated with CVD; these include the MAPK pathway 
(Muslin., 2008). 
 
Mitogen Activated Protein Kinases in Inflammation 
MAPKs are involved in a large number of biological functions from cell 
proliferation, differentiation, cell survival and programmed cell death. Biological 
signalling in this group relays extracellular events to the intracellular domain of 
cells, a process which is underpinned by phosphorylation cascades and 
negatively regulated by MAPK phosphatases. Activation of MAPK can be 
induced by TLR stimulation. There are three well established MAPKs family 
groups; extracellular signal-regulated kinases (ERK) isoforms 1 and 2; the  c-
Jun-N terminal kinases (JNK) of which there are isoforms 1-3 and MAPKs p38, 
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isoforms α, β, γ and δ (Figure 1.7). Because these pathways are involved in the 
development, growth and apoptosis of cells, the tight regulation of 
phosphorylation cascades is essential to ensure cell survival, as unabated 
signalling could result in excessive cell proliferation and/or cell death.  
 
Figure 1.7. MAPK activation: A: inactive, resting cell and B: 
activated/stimulated cell. MAPK; ERK, JNK and p38 kinases are activated 
after TLR stimulation. 
 
Activation of ERK 1/ 2 is associated with the development of cardiovascular 
hypertrophy (Zhang et al., 2003). The involvement of JNK and MAPK p38 
pathways in physical/chemical stress, infections and cytokine release makes 
them an effective target for vascular study. JNK subfamilies JNK1&2 are 
ubiquitously expressed in physiology: signalling immune activation, cytokine 
production and inflammation. Additionally, physiological roles of JNKs in 
atherosclerosis have been documented (Sumara et al., 2005).  
51 
 
MAPK p38 is of particular interest due to its subfamily expression of p38α. Like 
the JNK pathway, p38 kinases are concerned with immunity, triggered by the 
inflammation cascade which in turn leads to the signalling promotion of 
inflammatory molecules including: IL-1, TNF-α, IL-6, VCAM-1, proliferation, 
differentiation and the function of leucocytes. Physiologically, the regulatory 
functions of the p38 pathways make it an important precursor in chronic 
inflammatory conditions such as atherosclerosis (Mei et al., 2012, Yang et al., 
2014) .  
While p38α is known to have inflammatory roles, recent work has also revealed 
that it can also have anti-inflammatory functions (Arthur and Ley, 2013, Guma 
et al., 2012). For example, mice with a myeloid specific deletion in p38α show 
increased pathology in an ultraviolet-B (UV-B) induced skin inflammation model 
(Kim et al., 2008) and in a model of RA (Guma et al., 2012). The anti-
inflammatory effects of p38α are mediated, in part, via the activation of mitogen 
and stress kinase (MSK) 1 and 2 (Kim et al., 2008). MSK1 and MSK2 are 
nuclear kinases that are activated downstream of the ERK1/2 and p38α MAPKs 
and serve to help regulate the induction of immediate early genes (Arthur, 2008) 
(Figure 1.8).  
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Figure 1.8. MSK 1/ 2 induction of anti-inflammatory genes: A: inactive 
resting cell and B: stimulated cell. TLR stimulation stimulates MAPK p38 and 
ERK phosphorylation of MSK 1/ 2 and the induction of anti-inflammatory genes. 
 
TLR signalling in macrophages has shown to activate MSKs and this promotes 
the transcription of several genes with anti-inflammatory functions, including the 
cytokines IL-10 and IL-1ra (Kim et al., 2008, Darragh et al., 2010) (Figure 1.8). 
MSKs also regulate the induction of a dual specificity phosphatase (DUSP1) 
(Kim et al., 2008) (Figure 1.8), involved in deactivation of p38α and JNK, 
downstream of TLR signalling (Wang and Liu, 2007). As a result of this, MSK1/2 
double KO mice exhibit increased sensitivity to LPS-induced endotoxin shock, 
which is accompanied by an increase in TNF-α, IL-6 and IL-12 relative to WT 
animals (Kim et al., 2008). The role of MSK 1/ 2 in CVD has not previously been 
addressed. TNF-α, IL-6, -10 have previously been reported in the pathogenesis 
of CVD. The MSK 1/ 2 kinases may provide novel insights into the downstream 
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signalling of inflammation in the development of CVD. 
Mitogen Activated Protein Activated-protein kinases in Inflammation 
The ability to modulate inflammation holds the potential to alleviate 
inflammatory disease burden. In particular, it may stop the progression of 
inflammatory diseases, such as SLE, RA and inflammation induced CVD.  
The MAPK p38 inhibitor SB-203580 has shown favourable results in limiting 
inflammation. Koyo et al (Kyoi et al., 2006) reported an improvement in heart 
failure in a hamster model using the SB-203580 compound and exacerbated 
damage when a JNK inhibitor (SP600125) was used. It is important to 
remember that MAPK p38 has numerous roles; as previously discussed, it is 
able to phosphorylate MSK 1/ 2 that have anti-inflammatory properties, a loss 
may lead to undesired effects such as the perpetuation of inflammation as 
observed in the MSK 1/ 2 KO mouse when compared to WT cells. The genetic 
deficiency of MAPK p38 emphasises the incompatibility of this molecule as a 
target for inflammatory mediated diseases, as MAPK p38 KO murines are 
embryonic lethal (Allen et al., 2000).  
Mitogen activated protein activated-protein kinases (MAPKAP) 2/ 3 are 
downstream substrates of p38. These two kinases are important messengers in 
the inflammation cascade, and their involvement is mainly in regulation of gene 
expression (Ronkina et al, 2010). Deficiency of either MAPKAP 2 or 3 does not 
produce a discernible phenotype and off-spring are otherwise healthy. 
As discussed previously, macrophages are able to recognise both exogenous 
and endogenous molecules, and elicit an inflammatory response through TLRs, 
acting downstream on NF-kB or MAPK p38 respectively, giving rise to the 
release of inflammatory cytokines. 
54 
 
Importantly MAPKAP 2 deficient animals display a significant attenuation of 
TNF-α production in response to LPS, a response which is a fraction of that 
observed in WT animals (10% of WT response) (Ronkina et al., 2007. The 
MAPKAP 2 KO model has shown translational potential, with resistance to the 
development of RA in an animal model (Hegen et al 2007).  
Although MAPKAP 2 is physiologically more abundant than MAPKAP 3, there 
remains some compensatory mechanisms. In the absence of MAPKAP 2, 
MAPKAP 3 will induce TNF-α synthesis (Ronkina et al 2007). The double 
homologous KO yields a TNF-α response that is 1-3% when compared to the 
single MAPKAP 2 KO in macrophages, a >90% decreased in comparison to WT 
cells. The double KO does not yield an alternative phenotype, suggesting that 
the physiological function of these kinases is similar, although their expression 
levels vary considerably. 
MAPKAP 2 is essential for the generation of inflammatory cytokines; however 
mRNA levels for TNF-α do not vary considerably from WT mice (Ronkina et al 
2010). Under basal conditions these kinases are localised in the nuclear 
envelope. Upon an appropriate signal from MAPKP p38, MAPKAP 2/3 are 
activated and exported from the nucleus. MAPKAP 2/3 equally lead to 
stabilisation of MAPK p38.   
One mechanism by which MAPKAP prolongs inflammation is by the modulation 
of inflammatory mRNA-stability of cytokines such as TNF-α. MAPKAP 2/3 target 
specific adenosine and uridine(AU)-rich elements (ARE) of TNF-mRNA that 
were shown to be essential for the post-translational regulation of TNF 
synthesis, suggesting a modulatory role for MAPKAP 2/3 in ARE binding. One 
member of this group is tristetraprolin (TTP), important in TNFα-mRNA-ARE-
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binding. TTP can act on the 3’-unsaturated region of the RNA of protein 
inflammatory mediators, via phosphorylation, thus inducing stability. 
The regulation of inflammation is of key importance in physiological systems 
and this is largely achieved through activation of STAT3 (signal transducer and 
activator of transcription 3) through IL-10 synthesis. IFNs are regarded as key 
mediators of IL-10 production in macrophages and thus potent initiators of anti-
inflammatory effects.  Importantly, MAPKAP 2/3 activation suppresses IL-10 
production..  
MAPKAP 2 deficient mice have shown a reduction in atherosclerotic lesion 
presentation when back-crossed on to an LDLr KO mouse. These double KO 
animals show significantly reduced lipid deposition after 16 weeks on a 
cholesterol diet, with reduced expression of VCAM-1, macrophage infiltration 
and reduced foam cell formation (Jagavelu et al 2007). Although the role of 
these kinases has been assessed in atherosclerosis, their role in development 
of early endothelial dysfunction in vivo has not previously been reported. 
 
NF-κB Regulation in Inflammation 
As previously discussed, the activation of TLRs can induce the activation of NF-
kB and mediate the release of pro-inflammatory genes relevant to CVD. In 
mammalian tissues, the NF-κB family consists of: RelA (p65), RelB (RelB), C-
Rel (Rel), NF-κB1 (p50 and the precursor p105) and NF-κB2 (p52 and the 
precursor p100). These family members are involved in a wide range of 
biological activities including immune function and inflammatory responses.  
Under basal conditions, NF-κB is sequestered in the cytoplasm; however 
stimulation of appropriate receptors such as MyD88 dependent activation of 
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TLRs causes nuclear translocation, through a phosphorylation cascade where 
IκBs are degraded (Van der Heiden et al., 2010) (Figure 5).  
All members of the NF-kB family share a conserved region called the N-terminal 
rel-homology-domain (RHD). The N-terminus of the RHD is the DNA-binding 
domain. The transportation of NF-κB from the cell cytosol to the nucleus is 
dependent on a nuclear localisation signal (NLS), which is situated at the C-
terminal end of RHD. IκBs sequester NF-κB dimers in the cell cytosol by non-
covalent interactions containing a repeated amino acid sequence termed 
ankyrin repeats. IκB inhibitors interact with the RHD region through the ankyrin 
repeats and conceal the NLS, maintaining the dimer in the cell cytosol. 
The degradation of IκB permits the movement of NF-κB to the nucleus; however 
IκB activation is complex and involves phosphorylation by the Iκκ complex. This 
Iκκ complex is composed of an Iκκ-α, Iκκ-β and Iκκ-γ subunit; Both the Iκκ-α/β 
subunits possess catalytic properties whereas the Iκκ-γ is non-catalytic and is 
also termed NEMO (NF-kB essential modulator) (Figure 1.9). 
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Figure 1.9. NF-κB activation: A: inactivated and B: activated cell. TLR 
activation through MyD88 induces IRAK4 phosphorylation of TRAF6 and the 
activation of Iκκ. Iκκ phosphorylates IκB and NF-κB translocate to the nucleus to 
stimulate transcription. 
 
NF-κB activation mediates the release of inflammatory molecules associated 
with atherosclerosis, including IL-6, IL-10 and TNF (Mallat et al., 1999, Huber et 
al., 1999, Boesten et al., 2005). Under physiological conditions, NF-kB inhibitors 
maintain inflammatory homeostasis, silencing gene expression after appropriate 
receptor stimulation, such as the activation of TLRs. The A20-binding inhibitors 
of NF-κB (ABINs1-3) are suppressors of inflammation.  Recent work suggests 
that ABIN1 restricts the activation of the canonical IKK complex and MAPK, by 
binding to Lys63-linked and linear ubiquitin chains (Nanda et al., 2011). 
Human polymorphisms in the gene encoding the ABIN1 protein have been 
identified and are associated with a pre-disposition for autoimmune disease 
(Caster et al., 2013). The clinical manifestations of polymorphisms in ABIN1 are 
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wide spread and can resemble SLE (Vaughn et al., 2012, Adrianto et al., 2012). 
Mutations in ABIN1 are associated with psoriasis, psoriatic arthritis and 
importantly in the context of CVD, He et al (He et al., 2010) reported an 
enhanced risk of vasculitis. The TNIP1 (TNFAIP3-interacting protein 1) gene 
locus that encodes for the protein ABIN1 is associated with the predisposition to 
SLE (Adrianto et al., 2012), and it is also thought to be significantly associated 
with other inflammatory mediated pathologies including CHD and MI (Ozaki et 
al., 2002, Ozaki and Tanaka, 2005, Boonyasrisawat et al., 2007). Wolfrum et al 
(2007) (Wolfrum et al., 2007) studied mice that were haploinsufficient for A20, a 
protein that interacts with ABIN1, and backcrossed them on to the CVD prone 
apolipoprotein E KO mouse.  These mice showed significant exacerbation in 
atherosclerotic lesion presentation, mediated through NF-κB activation 
(Wolfrum et al., 2007). 
 
The important roles of ABINs in physiology are highlighted in gene targeted KO 
mice that display organ failure and premature death (Zhou et al., 2011). A 
knock-in mouse in which WT ABIN1 was replaced by the polyubiquitin-binding-
defective mutant ABIN1[D485N]  has previously been described (Nanda et al., 
2011). Several types of immune cells from these mice show enhanced NF-κB 
and MAP kinase activation after TLR stimulation and display an SLE-like 
phenotype (Nanda et al., 2011). The ABIN1[D485N] knock-in mice show 
significant expansion of myeloid cells in various organs (Nanda et al., 2011). 
Caster et al (Caster et al., 2013) reported similarity between the ABIN1[D485N] 
mice and SLE patients in the context of lupus nephritis, a leading cause of 
morbidity and mortality in chronic inflammation. However, the onset of CVD 
relevant to this mutation has not been addressed. 
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In conclusion the development of CVD is attributed to CVD risk factors such as 
dietary cholesterol, smoking and physical inactivity. Risk factors share common 
physiological responses of inflammation. Through receptor stimulation of innate 
immune signalling pathways such as TLRs, transcription factors are activated 
and signal the synthesis and release of pro-inflammatory cytokines. Importantly, 
these cytokines are also present in chronic inflammatory disease conditions 
such as RA and SLE; two patient groups that display elevated risk profiles for 
CVD that is not fully explained by the Framingham risk score (Esdaile et al., 
2001). Systemic cytokine expression in humans has suggested a causal 
relationship to the onset of CVD. Animal models of CVD, where inflammatory 
gene expression is in part abrogated have shown protection to CVD. There 
remains limited information on the role of intracellular signalling pathways and 
the development of endothelial dysfunction, an early event in CVD. Importantly 
the modulation of endothelial function by the expression of systemic cytokine 
expression remains understudied, with limited in vivo studies. Animal models of 
CVD for specific pathway analysis are further limited by the deployment of 
translational techniques, which would allow laboratory findings to be related to 
those in human clinical trials. 
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Thesis Aim 
The overall aim of this thesis is to longitudinally measure vascular responses in 
the skin microcirculation of mice, using LDI and drug iontophoresis of 
vasoactive chemical in vivo, that have undergone genetic and dietary 
alterations. This thesis aims to assess the role of underlying signalling pathways 
that are responsible for the expression of inflammatory molecules early in the 
pathogenesis of CVD through the use of innate immune models of protein 
phosphorylation. 
 
Hypothesis 
The main hypothesis is that systemic cytokine expression is implicated in the 
pathogenesis of endothelial dysfunction and can be hindered/ exacerbated 
through alterations in innate immune pathways. 
 
 
Specific Aims 
1. To measure microvascular responses in the skin microcirculation of mice 
longitudinally, using LDI and iontophoresis of vasoactive chemicals in vivo. 
2. To better understand the complexity between microvascular responses and 
systemic cytokine expression. 
3. To better understand the role of mitogen and stress kinases (1/ 2) in the 
pathogenesis of endothelial dysfunction. 
4. To better understand the role of TLR activation in the pathogenesis of 
endothelial dysfunction. 
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5. To better understand the role of MAPKAP 2/3 in the pathogenesis of 
endothelial dysfunction. 
6. To better understand the role of ABIN1 in the pathogenesis of endothelial 
dysfunction. 
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Chapter 2  
Materials and Methods 
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Mouse Generation 
Breeding 
Animal colonies were established by housing mice of appropriate age (minimum 
6 weeks) for copulation. All mating animals were genotyped before pairings. 
First litters were also genotyped to confirm transgenic knock-in, KO or WT 
status. Offspring were weaned at 21 days of age and utilised in studies as 
described (Table 2.1). Additional WT C57BL/6 males were purchased from 
Charles River Laboratories at 8-10 weeks of age. 
 
Table 2.1. Summary of mouse models and study groups used for investigations 
detailed in this thesis. 
Study/Chapter Animal 
group 
Group 1 Group 2 Group 3 Group 4 
Blood 
pressure/ 
Chapter 3 
C57/blac
k/6 
WT-chow – 
Habitualizatio
n 
WT-chow – 
Anaesthesi
a 
 
- 
 
- 
Blood 
pressure and 
iontophoresis
/ Chapter 3 
C57/blac
k/6 
Vehicle 
iontophoresis 
ACh 
iontophores
is 
SNP 
iontophores
is 
 
 
- 
Blood 
Glucose/ 
Chapter 3 
C57/blac
k/6 
WT-chow WT-
cholesterol 
- - 
MSK1/ 2 / 
Chapter 4 
MSK 1/ 
2 
WT-chow WT-
cholesterol 
KO-chow KO-
cholesterol 
MyD88/ 
Chapter 5 
MyD88 WT-chow WT-
cholesterol 
KO-chow KO-
cholesterol 
MAPKAP2/3 / 
Chapter 6 
MAPKA
P 
WT-chow WT-
cholesterol 
KO-chow KO-
cholesterol 
ABIN1(D485N)
/ Chapter 7 
ABIN1 
(D485N) 
WT-chow WT-
cholesterol 
ABIN1(D48
5N)-chow 
ABIN1(D48
5N)-
cholesterol 
Vitamin D 
supplementati
on/ Chapter 8 
MSK 1/2 KO-
cholesterol – 
Vehicle 
KO-
cholesterol 
- Calcitrol 
 
- 
 
- 
 
Genotyping 
The genotype of offspring and mating pairs was determined by polymerase 
chain reaction (PCR). Whole genomic DNA was obtained from tail biopsies and 
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genotyped according to previously published sequences and PCR methods as 
detailed in Table 2.2 by animal facility personnel. 
 
Table 2.2. References for genotyping sequences for genetically modified mice. 
Animal Strain Primer sequences  Reference 
Mitogen and stress 
kinases activated  
(MSK) 1/ 2 
MSK1 knockout mice, primers: 
CACTTCGCCCAATAGCAGCCAGTCCCTTCC 
(targeted), 
TCCGCAGCTCGTGCTTGACAGTAAGGAGC 
(wild type), and 
AATAGCGCTGGTGGCTCAGGGCTGT.  
Genotyping for MSK2 knockout mice, primers: 
CGTTGGCTACCCGTAATATTGCTGAAGAGC 
(targeted), 
AAGATCTTCAGGGCATCTCTTTATCCTACG 
(wild type), and 
TTGTGCTCCCCATGCTGCAGCCCGGCCTTC 
(targeted or wild type). 
(Wiggin et 
al., 2002) 
Myeloid 
differentiation 
primary response 
gene-88 (MyD88) 
FORWARD (K/W) = 5’GGT CCA TTG CCA 
GCG AGC TAA TTG AG 3’   
REVERSE (W) = 5’ CTG GGA AAG TCC TTC 
TTC ATC GCC TTG T 3’ 
REVERSE (KO)  = 5’ ATC GCC TTC TAT CGC 
CTT CTT GAC GAG 3’ 
(Adachi et 
al., 1998) 
Mitogen activated 
protein kinase 
activated-protein 
(MAPKAP) 2/3 
MK2 forward (5’-
CATGCCATGATGAGGTGCCTCTGC-3’) and 
MK2 reverse (wild-type allele, 5’-
CCCTCTCTACCTCTTTCTGTGAATGCC-3’; 
knockout allele, 5’-
CTGTTGTGCCCAGTCATAGCCG-3’); and 
MK3 forward 
(5’-GCCAATGTCCCGCATTATCTCTGC-3’) 
and MK3 reverse (wildtype 
allele, 5’-
CAGGGAGCACTCACAGAGCAGTGGGC-3’; 
knockout allele, 
5’-CTGTTGTGCCCAGTCATAGCCG-3’) 
(Ronkina et 
al., 2007) 
A20 binding inhibitor 
of NF-ĸB-1 (ABIN-
1)(D485N) 
P1 5′ LoxP sense (5′-
ATCCAACTCTCCAGCCAATAACC-3′), P2 5′ 
LoxP antisense (5′-
GAGGCGTGTGGAAGTCTGC-3′), P3 mRNA 
sense (5′-CGTTGTGAGTTGGATAGTTGTGG-
3′), P4 mRNA antisense (5′-
AGCTGGCTCTGAAAGATGAAGG-3′), P5 3′ 
LoxP sense (5′-
CCTATCCCTATGCCTACCCACCCATG-3′), 
P6 3′ LoxP antisense (5′-
AGCTGACTCGGCAGCCGATGGTACTC-3′), 
and P7 neo-IRES sense (5′-
CGTATTCAACAAGGGGCTGAAGGATGC-3′). 
(Nanda et al., 
2011) 
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Animal Housing and Husbandry 
All listed procedures were carried out under the authority of a U.K. Home Office 
project license by Personal License Holders. Prior approval was granted by the 
institutions ethics committee for all studies (University of Dundee). Animals 
were generated in specific pathogen free conditions within the transgenic 
laboratories at the Wellcome Trust (University of Dundee) and were specifically 
all C57BL/6 male mice. 
Animals were housed together in groups of up to six. Diets consisted of 
standard rodent chow (Special Diets Services: Rat&Mouse diet number 1 fed as 
a standard or Rat&Mouse diet number 3 for breeding animals, United Kingdom) 
and sterilised distilled water fed ad libitum after weaning, for all animals and for 
the total study duration unless otherwise stated. Cages were kept in a room that 
maintained a 12hour light/dark cycle and a constant temperature of 22±2 oC. 
Animals were transferred from a barrier breeding facility to the experimental 
facility (in which the necessary equipment was installed) at least one week 
before vascular function testing, to allow acclimation and to avoid stress. Upon 
arrival animals were acclimated to the Medical School Resource Unit (MSRU) at 
Ninewells Hospital unit for at least 7 days prior to any experimental testing. 
A specifically tailored pro-atherogenic diet (TD.01383 diet, Harlan-Teklad) (18% 
protein rodent chow with added cholesterol, 2% by weight) that has been used 
in previous studies (Singer et al., 2013) was used for all cholesterol challenged 
experiments. The diet consisted of (by weight) 18% protein, 47% carbohydrates 
and 6% fat. Previous studies have reported the presence of 
hypercholesterolaemia after one week of cholesterol feeding (Tsuda et al., 
1983). 
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In Vivo Vascular Assessment  
 Laser Doppler Imaging (LDI) 
LDI was the primary technique used in all experimental study chapters for 
assessment of endothelium-dependent responses to vasoactive chemicals 
(Belch et al., 2013). LDI is an automated computerised system that allows the 
assessment of perfusion in very fine arterioles, venules and capillaries 
supplying the skin. LDI allows changes in blood flow to be monitored overtime 
or in relation to particular stimuli i.e. agonist drugs. 
Numerous animal studies have used ApoE KO mice that spontaneously show 
dyslipidaemia on a standard rodent chow diet (Boesten et al., 2005, Bjorkbacka 
et al., 2004, Nakashima et al., 1994. These investigations have largely focused 
their studies on medium-large sized vessels, showing lipid streaks within the 
aorta, carotid and brachial artery. Johansson et al (2005) effectively 
communicated the importance of intra-vascular differences in endothelial 
dysfunction in the presence of hypercholesterolaemia in large vessels. Impaired 
endothelial function is apparent in lipid prone regions of the aorta including the 
proximal ascending aorta and the aortic roots in cholesterol fed animals. 
However, the mid-thoracic aorta does not show impairment and is effectively 
preserved in the same mice early in the disease process. These differences 
hinder the effective study of early changes relevant to endothelial dysfunction 
using traditional technologies such as the tension based organ bath system 
(Akbar et al., 2011). Vascular rings cut from the aortic arch, thoracic and 
abdominal aorta may produce significantly different responses early in 
pathophysiology. The uncertainty of intravascular pathology results in tissue 
homogeneity, an experimental limitation in ex vivo studies. Most importantly 
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vessel segments may not represent the entire vascular system and may only be 
representative of turbulent flow, an established factor for atherogenesis (Prado 
et al., 2008). As previously discussed in the Introduction (Toll-like Receptors 
and Inflammation),  turbulent flow is associated with reduced shear stress. 
Turbulent flow is progressively lost and becomes less significant as blood is 
ejected from the left ventricle and travels through the arterial system, producing 
the least hemodynamic variation in peripheral blood.  Shear flow is a stimulator 
of NO production, inducing basal vasomotion and maintains the endothelium as 
a quiescent no adherent surface.  
The skin microcirculation has been utilised in numerous clinical studies and has 
shown good correlation with central cardiac function (Khan et al., 2008), and 
has been used as a biomarker in CVD (Galarraga et al., 2008, Khan et al., 
2000). The small vessels in the skin microvasculature are relevant to whole 
body physiology and the cardiovascular system as important regulators of blood 
pressure through the modulation of peripheral resistance.  
Although LDI has been used successfully in numerous clinical trials to 
interrogate the skin microcirculation in humans (Kruger et al., 2006), the use of 
LDI in animal studies is limited (Turner et al., 2008). Numerous groups have 
utilised the single LDF system that is not the optimal technique due to 
significant perfusion heterogeneity in the skin (Turner et al., 2008, Sigaudo-
Roussel et al., 2004). Furthermore, previously described studies have utilised 
experimental methods (anaesthetic agents) that do not easily permit the 
recovery of animals after scientific interrogation, such as the use of 
pentobarbital (Sigaudo-Roussel et al., 2004). 
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LDI uses a stable helium neon (HeNe) laser source (633nm and a 2mW 
nominal power), coupled with a diode laser source (780nm at a 1mW nominal 
power). The HeNe laser beam undergoes scattering by movement of red blood 
cells (RBCs), producing frequency broadened light (Figure 2.1). The movement 
of a 10cm mirror with rotation of two axes provides dexterity for optimal 
scanning within the laser head. Collected light is returned to an imaging lens 
and focused on two photo bodies. Laser speckle differences are automatically 
normalised by the software. Scattered light from moving RBCs and static 
scattering from the skin surface are detected and processed as a photocurrent, 
providing a relative measurement of blood flow. The average Doppler frequency 
shift is proportional to the average speed of RBCs in tissue and their 
concentration, output as an arbitrary value (AU) (Doppler Flux) in skin perfusion 
maps. Low flow is represented as blue and purple whilst increased or high flow 
is yellow, green and red (Figure 2.2). Colour coded maps are then converted 
into arbitrary perfusion values (0-1000 AU) (Figure 2.2). The laser was 
positioned 50cm above the animal, the internal mirror distance was accounted 
for and a height of 32cm from laser hood to tissue was maintained for all studies 
(Figure 2.3). The LDI was routinely calibrated at 4 week intervals, according to 
the manufacturer's instructions. 
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Figure 2.1. Laser beam scattering by moving red blood cells: Helium Neon 
(HeNe) laser beam undergoing scattering by the movement of red blood cells 
(RBCs) in the peripheral skin microcirculation. 
 
 
 
Figure 2.2. Perfusion map of blood flow: Colour coded maps of skin 
perfusion from the laser Doppler imager software v5.3 (Moor Instruments). (A) 
representative of low perfusion and (B) increased perfusion. Circular dimension 
(22mm) for region of interest and a flux scale showing arbitrary values of 
intensity for perfusion measurements (0-1000 arbitrary units). 
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Figure 2.3. LDI and iontophoresis: Laser Doppler imaging and drug 
iontophoresis set up for in vivo studies, detailing anaesthetic machine and nose 
cone for delivery of Isoflurane during peripheral assessment of skin 
microvascular responses in mice. 
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LDI Acquisitions Parameters  
For image acquisition the following parameters were set in the propriety 
software (Moor Instruments v5.3) for all acquired images.  
 Direct current (DC), flux (Flux) and concentration (Conc): Zero 
 Image scan: X0=90, Y0=90, dX=60,dY=60 (scan area 56mm2) 
 Scan resolution: X=60, Y=60, scan speed 10ms/pixel 
 Average scan time: 49seconds 
 Time between scans: 5seconds 
 Total scan time: 55seconds 
 
Anaesthesia  
Anaesthesia was necessary to prevent artefact movement confounding results 
during peripheral vascular assessment. Animals were weighed on an electronic 
balance (grams (g)) before all experimental procedures. Anaesthesia was 
achieved using a 5% combination of Isoflurane (Abbott Laboratories) in medical 
oxygen (BOC gases) (1.5-2 litres/minute), delivered using a standard Boyle’s 
Apparatus (Fluovac, Harvard Appratus Ltd.) intended for small animal/rodent 
use (Figure 2.4). Induction of anaesthesia was confirmed when the animal was 
supine and non-responsive (absence of rear foot reflexes). Anaesthesia was 
maintained by inhalation of 1.5-2.0 % concentration of Isoflurane in oxygen (1.5-
2 litres/minute), delivered via a nose cone covering the mandible/nasal area 
(Figure 2.3). Depth of anaesthesia was continually monitored, by observing the 
absence of rear foot reflexes to toe pinching. The animals body temperature 
was maintained at 37 oC using a heat mat (VetTech Solutions). Core body 
temperature was monitored using a lubricated (KY Jelly) electrical probe 
inserted into the animal’s rectum (VetTech Solution); peripheral skin 
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temperature was monitored by using an infrared thermometer (ThermoWorks). 
All experiments were carried out in a laboratory with a standardised room 
temperature of 22±2 oC. 
 
Figure 2.4. Anaesthetic machine: Standard Boyle’s apparatus and induction 
chamber intended for small rodent use. 
 
Anaesthetic recovery  
Animals were recovered from anaesthesia after vascular assessment for 
longitudinal studies by turning off the supply of inhalant Isoflurane and allowing 
the animal to breathe oxygen alone for one minute (1.5-2Litres/minute). Animals 
were then briefly transferred to a Thermacage (MK II, Datesand Ltd.) (30 oC) 
until fully motile. Animals were returned to their housing cages and monitored 
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for at least 48 hours for any signs of ill health, including but not limited to: 
restlessness, fatigue, hunched back, ruffled coats and weight loss.  
 
Iontophoresis 
Non-invasive drug delivery of vasoactive chemicals for all studies was achieved 
by iontophoresis. Iontophoresis is the unidirectional transportation of ions in a 
solution across the epidermal stratum corneum layer by a direct continuous 
current (Figure 2.5). A chamber containing an incorporated internal platinum 
ring electrode produces a painless, sterile and non-invasive technique, where 
drug delivery to specific areas is achieved and provides a safer alternative to 
intravenous injection. 
 
Figure 2.5. Iontophoresis: Iontophoresis chamber and gel electrode for non-
invasive drug delivery. 
 
Ion transportation during iontophoresis maintains a relatively constant 
concentration of drug within the intended tissue for a specified period of time 
(dependent on current duration). Ions are actively transported by repulsion of 
electrochemical forces; however,  transfer is dependent upon a number of 
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factors including: ionic concentration, molecular size, treatment duration 
(current duration) and pH. 
Ion movement is determined by polarity; the negatively charged electrode 
(cathode) repels negatively charged ions, attracts positively charged ions and 
accounts for the highest concentration of electrons. A positive charged 
electrode (anode) repels positively charged ions and attracts negatively charged 
ions and has a lower concentration of electrons. 
Ion movement into tissues is determined by electrical strength and electrical 
impedance of tissue to current flow (resistance); where the electrical field is a 
result of current density. A difference in current density between the active 
repelling electrode and its inactive counterpart produces a gradient potential 
encouraging ion migration. Current densities may be tainted by fluctuating 
current intensities and chamber size, an inverse relationship between chambers 
size and current density exists.  
Sweat ducts are ideal routes for ion movement through the dermis and 
decrease impedance by facilitating current flow and ion movement. Ion 
movement in iontophoresis is dependent on: current densities at the active 
electrode (repelling), the duration of current and the purity of the solution. 
Lower currents are recommended for an active repelling force, higher currents 
carry a greater risk of electrical burns, current intensity should be determined by 
chamber size (active electrode) and treatment duration which is standardised so 
that current density falls between 1-0.5 mA/cm2 of the active electrode surface.  
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Belanger (B©*langer, 2009) stated that current densities should not exceed 
0.5mA/cm2 at the anode and 1.0mA/cm2 at the cathode to safe guard against 
electrical burns and the following transposition provides a safe treatment. 
Maximum current (mA) = 
 Maximum safe current density (mA/cm2) x Electrode area (cm2) 
Electrodes should be adequately separated, wider differences ensures minimal 
differences in current densities and reduces the likelihood of burns. Negative 
ions accumulating at the positive pole produce acidic reactions through the 
formation of hydrochloric acid. This in turn produces tissue softening. Positive 
ions accumulating at the negative pole produce alkaline reactions with the 
formation of sodium hydroxide and may produce hardening of the skin. 
Continuous direct currents create an altered skin pH through the migration of 
ions, with chemical burns being the results of sodium hydroxide at the cathode. 
Thermal irritation and burns may be a result of poor skin contact between the 
active and inactive electrodes 
Skin presents high electrical resistances to current flow, conversely the 
underlying flesh and blood show a much lower electrical resistance. The 
nonspecific effect of blood flow on electrical activity is termed the galvanic 
effect, which is stronger at the cathode than the anode. Lower currents are 
recommended, however the therapeutic doses can be adequately achieved with 
a longer duration. 
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Skin preparation 
Vascular measurements were made on the flanks of anesthetised mice (Figure 
2.6). Maximum contact between skin and iontophoresis electrodes was 
achieved through shaving (Carmen 11740 Top to Toe Trimmer) and application 
of a depilatory lotion (Veet®, Reckitt-Benckiser) (Figure 2.6) 24-48 hours prior 
to vascular measurements to minimise skin irritation. Excess lotion was 
thoroughly washed off with warm water and cotton wool. Animals were then 
allowed to dry in a Thermacage (MK II),  before being returned to their 
respective housing cages. A small amount of extra bedding was provided to all 
cages for insulation after fur removal. Care was taken to avoid excessive 
abrasion during fur removal, as broken/damaged skin is more susceptible to 
burns. In human studies, skin resistance can be improved by gently removing 
dead skin cells by applying and removing an adhesive strip and natural oils may 
be cleansed with alcohol wipes. To avoid unnecessary irritation and to avoid the 
application of alcohol to the skin of mice, this was not carried out in all studies. 
 
Figure 2.6. Exposed mouse flanks: C57BL/6 mouse prepared for laser 
Doppler Imaging and drug iontophoresis. 
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Iontophoresis chambers were obtained from Moor Instruments (ION6 probe, 
Moor Instruments Ltd, Devon, U.K.). Each chamber had an internal diameter of 
20mm, providing a total surface area of 3.2cm2 and was securely attached to 
the flank of each animal, using doubled-sided adhesive rings (IAD, Moor 
Instruments) producing a water tight seal.  A second reference electrode (MIC-
CP, Moor Instruments) was positioned on the opposite flank of each animal to 
complete the circuit (Figure 2.6) and attached to the iontophoresis controller 
(MIC2 Iontophoresis Controller, Moor Instruments).  
 
Normalisation of baseline perfusion 
Iontophoresis chambers were initially filled with ~2ml of 1% solution of 
phenylephrine (PE) (Sigma-Aldrich) and sealed with a Perspex cap (MIC-ION6 
CAP, Moor Instruments). Three initial baseline measurements were taken 
without current; after this period, an anodal current of 100μA was applied to 
induce vasoconstriction of the peripheral vasculature, standardising baseline 
perfusion.  
Following constriction, microvessels were dilated using a 2% solution of 
endothelium-dependent agonist ACh (Sigma-Aldrich) with an anodal current of 
100µA (Figure 2.7). 
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Figure 2.7. Endothelium-dependent iontophoresis protocol: Acetylcholine 
(ACh) protocol and representative trace for vasodilator responses. 
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Endothelium-dependent vasodilatation to acetylcholine  
ACh is an ester of acetic acid and choline produced endogenously as a 
neurotransmitter in both the peripheral and central nervous systems. It is also 
well documented as an endothelium-dependent vasodilator. Studies conducted 
by Furchgott and Zadawski (1980) demonstrated the importance of the 
endothelium, by observing attenuated vasodilator responses in sections of 
rabbit aorta that had their lumens braised. ACh stimulates the release of NO 
(Figure 2.8) from endothelial cells and induces VSMCs cell vasodilatation. 
 
Figure 2.8. Endothelium-dependent release of NO: Acetylcholine (ACh) 
induced endothelium-dependent vasodilatation. 
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Endothelium-independent vasodilatation to sodium nitroprusside 
During vascular assessment it is necessary to obtain a maximal vasodilator 
reference value for comparison to endothelium-dependent vasodilatation. 
Sodium nitroprusside (SNP) is a complex inorganic anion that is a potent 
vasodilator. The octahedral molecule features a central ferrous core, 
surrounded by five tightly bound cyanide groups and one linear nitric oxide 
group. Upon metabolism, the five cyanide ions are cleaved and the NO group is 
released, that is able to diffuse to VSMCs and instigate vasodilatation 
irrespective of the endothelial lining, producing an endothelium-independent 
vasodilator response (Figure 2.9). To minimise drug exposure to experimental 
animals, SNP responses were only conducted under terminal measurements, 
after which animals were euthanized. 
 
Figure 2.9.Endothelium-independent iontophoresis protocol: Sodium 
nitroprusside (SNP) induced endothelium-independent vasodilatation. 
 
81 
 
Similar to the ACh protocol, three initial baseline measurements were taken 
without current, after this period an anodal current of 100μA was applied to 
induce vasoconstriction of the peripheral vascular network with PE, 
standardising baseline perfusion. Following constriction, microvessels were 
dilated using a 2% solution of endothelium-independent agonist SNP (Sigma-
Aldrich) with an anodal current of 100µA (Figure 2.10). 
82 
 
 
Figure 2.10. Endothelium-independent iontophoresis protocol: Sodium 
nitroprusside (SNP) protocol and representative trace for vasodilator responses. 
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Nitric oxide  
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) is a nonspecific NO 
inhibitor. Where appropriate, animals received L-NAME (Sigma-Aldrich) by 
intraperitoneal injection (20mg/kg) in deionised water (European 
Pharmacopoeia) 30 minutes prior to vascular assessment. The ACh protocol 
was then rerun to establish the role of NO in ACh mediated vasodilatation. This 
concentration has been previously reported and has shown attenuation of NO 
mediated responses in vivo (Sigaudo-Roussel et al., 2004). 
 
Maximal dilator capacity (localised skin heating) 
A maximal hyperaemic response was required from each animal for reference 
value of maximal dilator capacity at study baseline. This was achieved by 
localised heating of the skin using a specially designed heating probe (SH02™ 
Skin Heating Unit and SHP3 probe, Moor Instruments).  
A skin heating probe  had an internal diameter of 20mm and an inner ring 
heating electrode provided a total surface area of 3.2cm2 and was attached 
using double sided adhesive rings (IAD, Moor Instruments) (Figure 2.11).  
 
Figure 2.11. Localised heating chamber: Anaesthetised C57BL/6 mouse for 
assessment of maximal dilator capacity. 
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A localised heating protocol was followed (Figure 2.12). Baseline 
measurements were taken for five minutes by LDI, followed by the continual 
assessment of microvascular responses to localised heating of the skin as the 
temperature within the heating chamber was increased at a rate of 1 oC/minute 
until a maximum temperature of 44 oC was achieved. This was then maintained 
for a period of >ten minutes to assess maximal dilator response in the skin 
microcirculation (Figure 2.12). 
During localised skin heating experiments animal’s core body temperature was 
not acclimated to 37 oC for baseline scans. 37 oC was achieved through a 
combination of applied heat from the heat mat and the localised heating of the 
skin. Core body temperature was acclimated to 37 oC for maximal responses 
(440C). This combined approach to heating, allowed the capture of accurate 
data without lengthening the procedure and reduced prolonged anaesthetic 
exposure to experimental mice. 
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Figure 2.12. Maximal dilator capacity: Protocol for localised skin heating 
(maximal dilator response) and representative trace for vasodilator responses. 
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Blood Flow Analysis  
Blood flow images were analysed using propriety software (Moor Instruments, 
Version 5.3) and are expressed as group means in AU± standard error of the 
mean (SE). In certain circumstances, % change ±SE was used to express 
perfusion data (percentage change = (peak response (AU) – baseline 
(AU)/baseline (AU) x 100) where described. 
 
LDI validation with wire myography 
Belch et al (2013) previously demonstrated a correlation between LDI ACh, 
endothelium-dependent mediated vasodilatation in the skin micro circulation of 
mice after 24 weeks of cholesterol feeding when compared to post-mortem 
analysis of the tail artery by wire myography (r= 0.699, P<0.05). WT-chow and 
WT cholesterol fed mice were compared and no significant differences were 
found for vasoconstriction or endothelium-independent vasodilatation, 
confirming in vivo observations of endothelial dysfunction. Importantly the small 
resistance vessels used in this ex vivo study are comparable to the small 
resistance vessels found in the skin microvasculature. 
 
Blood Sampling 
Blood samples were collected after LDI and ACh iontophoresis. Animals were 
gently heated in a Thermacage (MK II) to promote peripheral vasodilation of the 
tail artery. Animals were then placed in a small rodent restrainer of appropriate 
size (VetTech solutions Ltd). A small incision was made to the lateral tail vein 
(located one-third along the tail from the tip) using a scalpel blade, gentle 
pressure was applied to promote bleeding.  
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Upon terminal measurements, larger blood samples were collected by cardiac 
puncture using a 2ml syringe attached to a 25 gauge needle. For cardiac 
puncture, animals were maintained under terminal anaesthesia by nose cone 
(3-5% Isoflurane in oxygen 1.5-2Litres/minute). The syringe was held at a 45o 
angle to the sternum and the needle inserted into the thoracic cavity at the 
region of maximum pulsation, maintaining a depth of 5-10mm. The presence of 
blood within the needle confirmed ventricle puncture; a vacuum was created by 
withdrawing air into the syringe and this was then allowed to fill with blood. All 
blood was collected in heparinised micro tubes (BD MicrotainerTM Lithium 
Heparin) and kept on ice until centrifuged at 1500 rounds per minute (RPM) 
(Hermle Z 230 M Centrifuge) for five minutes; plasma was decanted into freezer 
suitable tubes and stored at -80oC until analysed. 
Plasma Cholesterol 
Plasma was used to quantify total plasma cholesterol (mg/dl ±SE) (Biovision, 
catalog#: K603-100); or a specialist cholesterol assay kit which measured high 
density lipoproteins (HDL), low density lipoproteins and very low density 
lipoproteins (LDL/vLDL) (mg/dl ±SE) (AB65390, Abcam), as detailed in the 
manufacturer’s instructions. Assays were conducted under the supervision of 
Dr. Gwen Kennedy within the Core Facility, Ninewells Hospital, Dundee. 
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Plasma Cytokines 
Plasma was analysed by Luminex multiple bead-based assays using Bio-Plex® 
Precision ProkitsTM from BIO-RAD laboratories for: IL-1α, IL-6, IL-10, TNF-α, E-
selectin, soluble ICAM-1 (sICAM-1), and soluble VCAM-1 (sVCAM-1) (pg/ml 
±SE) as detailed in the manufacturer’s instructions. Assays were conducted 
under the supervision of Dr. Gwen Kennedy within the Core Facility, Ninewells 
Hospital, Dundee. 
 
Blood Pressure 
The CODA non-invasive blood pressure system (Kent Scientific, USA) was 
used to measure systolic blood pressure, diastolic blood pressure, mean arterial 
blood pressure  (MAP) in millimetres of mercury (mmHg) and heart rate in beats 
per minute (bpm) in mice. The system has previously been used for the in vivo 
assessment of blood pressure in mice (Talukder et al., 2011). 
CODA is a volume pressure recording (VPR) system. The two system cuff: 
occlusion cuff (O-cuff) and VPR cuff utilise tail volume (swelling) to determine 
parameters of blood pressure. The CODA system was validated against 
radiotelemtery and has demonstrated 99% accuracy (Feng et al., 2008a). The 
O-cuff is placed at the base of the tail and the VPR-cuff immediately below it 
(2mm distance) (Figure 2.13). 
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Figure 2.13. Blood pressure measurements: In vivo measurement of blood 
pressure using a tail cuff system: occlusion cuff (O-cuff) and volume pressure 
recording cuff (VPR-cuff). 
 
Session parameters on the propriety software were set as: 0 acclimation cycles, 
one set of cycles, 20 cycles per set (5 seconds between cycles); maximum 
occlusion pressure was 250 mmHg, deflation time was 20 seconds and a 
minimum detection of blood volume of 15μl was set. Results are expressed as 
group mean in mmHg for blood pressure parameters and bpm for heart rate 
±SE.  
Tissue Extraction 
Immediately preceding cardiac puncture, the animal was pinned to a 
polystyrene dissection board through its paws using 23 gauge needles. A small 
superficial cut was made at the level of the pubis and a median longitudinal cut 
superiorly to the chin, carefully separating underlying muscle to the skin using 
blunt dissection and exposing the thoracic and abdominal cavities.  
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To gain access to the thoracic cavity, the xiphoid process was gripped by 
forceps and the diaphragm carefully removed by making two cuts on either side 
of the rib cage, to reveal the posterior thoracic cavity. Perfusion of all tissues 
was achieved by insertion of a 23 gauge needle into the left ventricle, at an 
angle parallel to the septum of the heart. 20ml of ice cold heparinised (sodium 
heparin) (10 unit/ml) (Wockhard, United Kingdom) phosphate-buffered saline 
(PBS) (Fisher Bioreagents) was perfused gradually. The right ventricle was cut 
to allow blood/PBS to flush out of the animal. After perfusion, tissues were 
extracted. 
 
Heart and Aorta 
The abdominal aorta is the first section of the aorta to be dissected; it is freed 
from the region of the renal branches initially and this dissection is continued to 
the iliac bifurcation and up to the diaphragm. The thoracic aorta and heart are 
removed as an entire unit. With forceps, the heart is slightly lifted by grasping 
adipose tissue ordinarily found at the base of the heart (pericardial fat), with fine 
dissection scissors the aorta is cut free from the thoracic cavity by making 
gradual longitudinal cuts down the aorta moving towards the abdominal area. 
The aorta and heart were placed in ice cold heparinised PBS.  
The heart was cut free of the aorta at the base of the aortic arch. Remaining 
adipose and connective tissue were carefully removed with fine forceps and 
scissors. Hearts were momentarily blotted and rolled on gauze to eject any 
residual heparinised PBS and/or blood. Hearts were then weighed on an 
electronic balance (mg) and snap frozen in liquid nitrogen and stored at -80oC. 
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Perivascular tissue surrounding the adventitial layer of the aorta was 
meticulously removed under a stereomicroscope. The aorta was fixed in 10% 
buffered formalin overnight and then transferred to PBS for storage. 
 
Cardiac  Hypertrophy  
Cardiac mass was analysed to assess cardiac hypertrophy. Hearts were 
excised as described above. In order to standardise measurements, tibias were 
dissected out from the hind limbs, measured in millimetres (mm) using a digital 
calliper (Silverline 380224 Digital Vernier Professional Caliper, ToolBox, UK) 
and a ratio obtained (cardiac hypertrophy = total heart weight (mg)/ average 
length of tibia (mm)). 
 
En Face Staining of the Aorta  
In order to assess the level of lipid deposition within the aorta, the aorta was 
opened longitudinally and pinned down on to a paraffin wax block for en face 
analysis. Aortic tissue was stained with oil red O (0.5%) (Sigma-Aldrich) in 1, 2-
Propanediol (100%) (Sigma-Aldrich) according to the following protocol. Aortas 
were placed in absolute 1, 2-Propanediol for 5 minutes to avoid carrying water 
into the oil red O stain. Aortas were incubated in pre-warmed oil red O for 10 
minutes (60 oC in a water bath), after this tissues were differentiate in an 85% 1, 
2-Propanediol solution for 1 minute and rinsed in two changes of distilled water. 
En face tissues were digitally analysed by photographs and quantified by image 
software analysis (Volocity, PerkinElmer). Lipid deposition is analysed as a 
percentage of total analysed area (results are group means ±SE). Aortic tissue 
was processed by Tayside Tissue Bank, Ninewells Hospital, Dundee.  
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Power calculation 
A power calculation was performed for determination of sample size for LDI 
studies. Preliminary in house studies showed that WT chow fed animals display 
an endothelium-dependent response that is  350±24 (SD) AU n =19, a minimum 
difference of 16 AU is needed for statistical significance (P<0.05). Test value 
350 AU, sample average 335±24 SD, α error level 1% (confidence level) and a 
statistical power (1 - beta) sample size (n) = 14 . This reflects previously 
published group size for LDI of small rodents (Sigaudo-Roussel et al., 2004). 
  
Statistical Analysis 
All data are expressed as group means ±SE. Within and between group 
differences were compared using paired and unpaired t-tests. One-way and 
two-way ANOVA was used for comparisons of 3 or more groups. The 
associations between skin microvascular responses and plasma measures of 
cholesterol, cytokines and lipid deposition, parameters of cardiovascular 
hypertrophy and blood pressure were tested using Pearson correlation 
coefficients in the software package PASW Statistic (Version 18). Furthermore 
a step wise multiple linear regression model to ascertain the determinants of 
vascular dysfunction was conducted. The null hypothesis was rejected at 
P<0.05. 
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Chapter 3  
Development of Methods 
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Measurements of blood pressure in conscious trained and anaesthetised 
mice, an in vivo comparison. 
 
Introduction 
Blood pressure measurements are often made in conscious mice following a 
programme of training. In this study animals were acclimated to blood pressure 
measurements by implementation of a 7 day training programme. Blood 
pressure measurements were taken longitudinally (over several days) in the 
same mice and compared to blood pressure measurements obtained from 
anaesthetised mice. The study sought to establish whether the extensive 
training programme involved in blood pressure recordings could be avoided 
through the use of an inhalant anaesthetic, and secondly to establish the impact 
of an inhalant anaesthetic on blood pressure and heart rate in mice. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
 
Training 
WT C57BL/6 male mice (12 weeks of age) were trained to blood pressure 
measurements over a 7 day protocol. Each day, simultaneous (n =20) blood 
pressure measurements were made in the same animals (n =12). On days one 
and two, animals were placed in specifically designed blood pressure holders 
Figure 3.1 and placed on a heated platform that held the holder in place Figure 
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3.1. Animals were acclimated to the holder for 5 minutes and tail cuffs attached. 
On experimental days one and two sham measurements were made and 
animals returned to their housing cages.  Following this, on days three to seven 
(measurement days 1-5) animals were placed in holders on the heated platform 
and allowed to acclimatise for 5 minutes, tail cuffs were mounted and 
measurements recorded using the propriety software 
 
 
Figure 3.1. Heated platform for blood pressure measurements: Blood 
pressure heating platform and tube holders for mice. 
 
 
Anaesthetic 
The same mice from the training study (above) were anaesthetised (1.5-2% 
isoflurane in oxygen) without recovery, core body temperature was maintained 
at 37 oC. Blood pressure measurements were made by tail cuff and animals 
euthanised by cervical dislocation at the end of the procedure. 
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Results 
Training  
There were no significant differences between measurements on experimental 
recording day 1 (start of training) and day 5 (end of training) for all parameters: 
diastolic blood pressure (75±2 mmHg VS. 74±2 mmHg, P>0.05), systolic blood 
pressure (99±2 mmHg VS. 103±2 mmHg, P>0.05), MAP (83±2 mmHg VS. 84±2 
mmHg, P>0.05) and heart rate (671±41 bpm VS. 694±13 bpm, P>0.05), 
respectively Figure 3.2 A-D.   
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 Figure 3.2. Blood pressure training: Training measurements of wild-type 
mice over five consecutive days (n =12) for (A) diastolic blood pressure 
(mmHg), (B) systolic blood pressure (mmHg), (C) mean arterial blood pressure 
(MAP) (mmHg) and (C) heart rate (beats per minute) (bpm). Results are group 
means ±SE. One-way ANOVA with post-hoc Bonferroni correction. 
 
Training VS. anaesthesia  
Training data (experimental training day 5) data were compared to 
measurements obtained from anaesthetised mice. No significant differences 
were found for diastolic blood pressure (78±2 mmHg, P>0.05) or mean arterial 
pressure (89±2 mmHg, P>0.05) between the two groups Figure 3.3 A and B 
respectively. A significant differences was found for systolic blood pressure 
(111±2 mmHg, P<0.05) and heart rate 614±12 bpm, P<0.001) between the two 
groups (Figure 3.3 C and D respectively). 
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Figure 3.3. Training VS. anaesthesia: Comparison of blood pressure 
parameters obtained from trained conscious wild-type mice (n =12) to those 
obtained from the same animals under anaesthesia (Isoflurane). (A) diastolic 
blood pressure (mmHg), (B) mean arterial blood pressure (MAP) (mmHg), (C) 
systolic blood pressure (mmHg), (D) heart rate (beats per minute) (bpm). 
Results are group means ±SE. Unpaired Student’s t-test. *P<0.05, ***P<0.001. 
 
 
Discussion/conclusion  
A strict 7 day training programme in conscious mice does not significantly 
improve the efficacy of blood pressure data, suggesting the restraint needed to 
perform measurements in conscious mice does not subside over a period of 
training.  
There were no significant differences between diastolic and mean arterial blood 
pressures between conscious mice and anaesthetised animals; however, a 
significant reduction in heart rate and systolic blood pressure was observed in 
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anaesthetised mice. Values obtained from anaesthetised mice are in agreement 
with published radio telemetry values (Peotta et al., 2014).  
The measurement of blood pressure in vivo in anaesthetised mice may help 
reduce stress induced by animal handling that is otherwise associated with 
restraint and repeated handling. The measurement of blood pressure in 
anaesthetised mice using an inhalant anaesthetic is in line with radio telemetry 
published recordings, and thus maybe used as a suitable alternative.  
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Study of blood pressure changes and heart rate during the iontophoresis 
of vasoactive chemicals in vivo. 
 
Introduction 
LDI and the iontophoresis of vasoactive chemicals has previously been 
described in small rodents (Belch et al., 2013, Sigaudo-Roussel et al., 2004). 
Iontophoresis can be used to locally deliver drugs such as PE, ACh and SNP, 
agents that can significantly affect the cardiovascular system by inducing 
vasoconstriction and vasodilatation, respectively. Current methodologies have 
not established whether the iontophoresis of PE, ACh and SNP significantly 
affects heart rate and blood pressure in vivo. Blood pressure parameters were 
measured non-invasively before and after the iontophoresis of PE, ACh and 
SNP in vivo, to establish whether the iontophoresis of vasoactive chemicals 
induced systemic changes in the cardiovascular system. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
 
Iontophoresis and Blood pressure 
Blood pressure measurements were made in WT C57BL/6 (12 weeks of age) 
anaesthetised mice (1.5-2% isoflurane in oxygen) without recovery (n =6 per 
group) non-invasively by tail-cuff. Deionised water was used as a vehicle control 
for PE, ACh and SNP iontophoresis. Three sets of measurements were made 
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throughout the iontophoresis protocol: at baseline, before PE iontophoresis, 
mid-point (after PE iontophoresis but before iontophoresis of ACh and SNP) 
and after the iontophoresis of vasodilators ACh and SNP.  
 
Results 
Baseline Iontophoresis  
There were no significant differences for parameters between vehicle and drug 
iontophoresis groups at baseline Table 3.1 and Figure 3.4 A-D, before 
commencement of the iontophoresis protocol. 
Table 3.1. Baseline blood pressure parameters: Baseline blood pressure 
parameters in wild-type mice (n =6 per group) before the iontophoresis of 
phenylephrine (PE) in study groups vehicle, acetylcholine (ACh) and sodium 
nitroprusside (SNP). Diastolic blood pressure (mmHg), systolic blood pressure 
(mmHg), mean arterial blood pressure (MAP) (mmHg), heart rate (beats per 
minute) (bpm). Results are group means ±SE. One-way ANOVA. 
 
Baseline Parameters Vehicle ACh SNP P value 
Diastolic blood pressure (mmHg) 80±5 74±3 80±4 >0.05 
Systolic blood pressure (mmHg) 116±5 106±3 111±3 >0.05 
Mean arterial blood pressure (mmHg) 92±5 84±3 90±3 >0.05 
Heart rate (bpm) 616±22 609±24 618±21 >0.05 
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 Figure 3.4. Baseline blood pressure parameters: Baseline blood pressure 
parameters in wild-type mice (n =6 per group) before the iontophoresis of 
phenylephrine (PE) to study groups vehicle, acetylcholine (ACh) and sodium 
nitroprusside (SNP). (A) diastolic blood pressure (mmHg), (B) systolic blood 
pressure (mmHg), (C) mean arterial blood pressure (MAP) (mmHg), (D) heart 
rate (beats per minute) (bpm). Results are group means ±SE. One-way 
ANOVA. 
 
Mid-point Iontophoresis 
After the iontophoresis of PE, blood pressure and heart rate parameters were 
recorded to establish whether the described PE iontophoresis protocol impacted 
on blood pressure parameters and heart rate. There were no significant 
differences between the groups for all parameters Table 3.2 and Figure 3.5 A-
D. 
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Table 3.2. Mid-point blood pressure parameters: Blood pressure parameters 
in wild-type mice (n =6) after the iontophoresis of phenylephrine (PE) in study 
groups vehicle, acetylcholine (ACh) and sodium nitroprusside (SNP). Diastolic 
blood pressure (mmHg), systolic blood pressure (mmHg), mean arterial blood 
pressure (mmHg), heart rate (beats per minute) (bpm). Results are group 
means ±SE. One-way ANOVA. 
Midpoint Parameters Vehicle ACh SNP P value 
Diastolic blood pressure (mmHg) 82±3 75±4 73±3 >0.05 
Systolic blood pressure (mmHg) 118±3 108±5 107±2 >0.05 
Mean arterial blood pressure (mmHg) 94±3 86±4 84±3 >0.05 
Heart rate (bpm) 632±19 630±10 621±55 >0.05 
 
 Figure 3.5 Mid-point blood pressure parameters: Blood pressure 
parameters in wild-type mice (n =6 per group) after the iontophoresis of 
phenylephrine (PE) in study group’s vehicle, acetylcholine and sodium 
nitroprusside. (A) diastolic blood pressure (mmHg), (B) systolic blood pressure 
(mmHg), (C) MAP (mmHg), (D) heart rate (beats per minute) (bpm). Results are 
group means ±SE. One-way ANOVA. 
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End of Iontophoresis Protocol 
There were no significant differences for parameters between vehicle, ACh and 
SNP treated animals at the end of the iontophoresis protocol Table 3.3, Figure 
3.6 A-D. 
Table 3.3. After iontophoresis blood pressure parameters: Blood pressure 
parameters in wild-type mice (n =6) after the iontophoresis of vehicle, 
acetylcholine (ACh) and sodium nitroprusside (SNP). Diastolic blood pressure 
(mmHg), systolic blood pressure (mmHg), mean arterial blood pressure 
(mmHg), heart rate (beats per minute) (bpm). Results are group means ±SE. 
One-way ANOVA. 
End Parameters Vehicle ACh SNP P value 
Diastolic blood pressure (mmHg) 69±5 68±5 69±4 >0.05 
Systolic blood pressure (mmHg) 104±6 100±6 106±2 >0.05 
Mean arterial blood pressure (mmHg) 81±5 79±5 81±3 >0.05 
Heart rate (bpm) 643±70 673±17 658±46 >0.05 
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Figure 3.6. After iontophoresis blood pressure parameters: Blood pressure 
parameters in wild-type mice (n =6 per group) after the iontophoresis of vehicle, 
acetylcholine (ACh) and sodium nitroprusside (SNP). (A) diastolic blood 
pressure (mmHg), (B) systolic blood pressure (mmHg), (C) MAP (mmHg), (D) 
heart rate (beats per minute) (bpm). Results are group means ±SE. One-way 
ANOVA. 
 
Discussion/conclusion  
The use of vasoactive chemicals does not significantly affect cardiovascular 
function as measured by diastolic blood pressure, systolic blood pressure, 
mean arterial blood pressure and heart rate in WT mice undergoing 
iontophoresis. Microvascular function changes observed during the 
iontophoresis of PE, ACh and SNP in small rodents are representative of local 
changes in the peripheral skin microvascular network and not systemic, 
generalised changes in systemic blood pressure or heart rate. 
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Study of blood glucose in wild-type mice fed a cholesterol diet (2%). 
 
Introduction 
Chronic high fat feeding results in significant irregularities in glucose 
homeostasis in WT C57BL/6 mice and the onset of type two diabetes (Surwit et 
al., 1988, Park et al., 2005). Diabetes is an established risk factor for CVD in 
humans (D'Agostino et al., 2013) and has been previously studied through high 
fat feeding in WT mice relevant to CVD (Calligaris et al., 2013). The longitudinal 
studies detailed in this thesis endeavoured to answer whether dietary 
cholesterol could propagate CVD through activation of innate immune 
inflammatory cascades, without the presence of diabetes. This study sought to 
establish the suitability of a 2% added cholesterol diet in WT mice, and 
establish whether chronic feeding would results in significant plasma glucose 
elevations after 20 weeks of feeding. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
 
Measurements 
WT C57BL/6 male mice (12 weeks of age) (n =7 per group) were fed either 
normal rodent chow or a cholesterol diet for 20 weeks. Study end point body 
weight (g), plasma cholesterol (mg/dl) and blood glucose were measured.  
Blood collected from the tail vein was used for glucose measurements using a 
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blood glucose meter (mmol/l) (Ascensia Contour). Results are group means 
±SE. 
 
Results 
There were no significant differences between WT-chow (29±1g) and WT-
cholesterol (31±1g) fed animals in body weights at study end point (P>0.05) 
Figure  3.7A.  
There were no significant differences between WT-chow (5±1 mmol/L) and WT-
cholesterol (5±1 mmol/L) fed animals for blood glucose (P>0.05) Figure 3.7B. 
Cholesterol fed animals had significantly greater plasma LDL/vLDL (13±1 mg/dl) 
compared to WT-chow fed animals (5±1 mg/dl) (P<0.001) Figure 3.7C. 
However levels of HDL were not significantly different between the groups (WT-
chow 18±1 mg/dl VS. WT-cholesterol 19±1 mg/dl, P>0.05) Figure 3.7D. 
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Figure 3.7. Cholesterol feeding effect on body weight, blood glucose and 
plasma cholesterol: Study week 20 measurements of (A) body weight (g), (B) 
blood glucose (mmol/l), (C) LDL/vLDL and HDL (D) in wild-type chow (n =7) and 
cholesterol fed mice (n =7). Results are group means ±SE. Unpaired Student’s 
t-test. ***P<0.001 
 
Discussion/conclusion  
2% added cholesterol feeding in WT mice does not significantly alter body 
weight, blood glucose or HDL plasma cholesterol. Cholesterol feeding 
significantly induces dyslipidaemia through elevation of LDL/vLDL. The use of a 
2% cholesterol diet that is adjusted for calories is suitable for longitudinal in vivo 
studies, and does not result in a significantly altered plasma glucose level that is 
otherwise associated with diabetes, a risk factor for CVD. Nonetheless glucose 
homeostasis is tightly regulated by catabolic (glucagon, cortisol and 
catecholamines) and anabolic (insulin) hormones and further investigation is 
needed into the suitability of a 2% added cholesterol diet for endothelium-
dependent investigations to ensure against hyperinsulinemia, an early event in 
diet induced diabetes. 
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Chapter 4  
Deficiency of Mitogen and Stress-Activated Kinase 1 and 2 (MSK 1/2) 
Promotes Endothelial Dysfunction in vivo.  
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Introduction 
As previously discussed in the introduction (Mitogen and Protein Activated 
Kinases) the anti-inflammatory effects of p38α are mediated in part via the 
activation of MSK 1 and 2 (Kim et al., 2008, Darragh et al., 2010). MSK1/2 
double KO mice show increased sensitivity to LPS induced endotoxin shock, 
which is accompanied by an increase in the induction of TNF, IL-6 and IL-12 
relative to WT animals (Kim et al., 2008). TNF, IL-6, IL-1 and IL-6 are cytokines 
implicated in the pathogenesis of CVD, but the role of these kinases early in the 
development of CVD has not been studied. 
 
Aim 
The aim of this chapter was to assess endothelial function in MSK 1/ 2 gene 
targeted KO mice fed rodent chow or a cholesterol supplemented diet, and to 
explore the potential role of systemic cytokine expression early in the 
pathogenesis of CVD. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
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Animals 
Animals from the breeding strain MSK 1/ 2 were randomly allocated into four 
groups: WT control mice fed normal rodent chow, WT mice on a pro-
atherogenic diet and MSK 1/2 KO mice on normal rodent chow and on the pro-
atherogenic diet. 
 
Longitudinal Assessment of Vascular Function 
The following time points were used for vascular function testing: baseline 
(study week 0), 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 
weeks for in vivo assessment of endothelium-dependent, endothelium-
independent and maximal vasodilator capacity as described. The role of NO 
was further explored through application of L-NAME. 
 
Body Weight 
Animals were weighed at study baseline and week 24. 
 
Plasma Cholesterol 
Measurements were made at study baseline and 24 weeks. 
 
Cytokine Expression 
Measurements were made at study baseline and 24 weeks. 
 
Lipid Staining of the Aorta 
Lipid deposition within the aorta was achieved by oil red O staining at study 
week 24 weeks. 
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Results 
Baseline Body Weights 
Baseline body weights at 16 weeks of age were significantly greater in WT than 
in MSK1/2 KO mice (28±1g VS. 26±1g respectively, P<0.01.) (Figure 4.1A). 
This translated to a mean difference of 2g. 
 
Week 24 Body Weights 
WT-chow (baseline 27±1g VS. week 24 32±1g, P<0.001), WT-cholesterol 
(baseline 30±1g VS. week 24 36±1g, P<0.001), KO-chow (baseline 27±1g VS. 
week 24 32±1g, P<0.001) and KO-cholesterol (baseline 26±1g VS. week 24 
35±1g, P<0.001) fed mice significantly increased in body weight over the study 
duration. 
End-point body weights were significantly greater in cholesterol fed WT and 
MSK 1/ 2 KO mice (P<0.001) when compared to control chow fed mice (Figure 
4.1 B).  
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Figure 4.1. Body weights: (A) Baseline body weights (16 weeks of age) in WT 
(n =38) and MSK 1/ 2 KO (n =36) mice. Unpaired Student’s t-test. (B) week 24  
weights in WT-chow (n =19), WT-cholesterol (n =19), MSK 1/2 KO-chow (n =18) 
and MSK 1/2 KO-cholesterol (n =18) fed mice. Two-way ANOVA .  Results are 
group means ±SE in grams (g). **P<0.01, ***P<0.001. 
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Baseline Vascular Responses  
WT and MSK 1/2 KO mice showed skin microvascular responses to ACh and 
localized heating to 44ºC that were not significantly different between the 
groups (ACh: WT 349±4 AU VS. KO 338±6 AU P>0.05; localised skin heating: 
WT 394±4 AU VS. KO 396±6 AU P>0.05) (Figure 4.2 A/B respectively). 
 
Figure 4.2. Baseline vascular responses: Baseline (study week 0) 
microvascular responses in WT (n =38) and MSK 1/ 2 KO (n =36) animals: (A) 
endothelium-dependent responses and (B) maximal dilator capacity. Results 
are group means ±SE arbitrary units of skin perfusion (AU). Unpaired Student’s 
t-test.  
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Baseline Cytokines 
Cytokine analysis showed several differences in baseline levels between WT 
and MSK 1/2 KO mice. MSK 1/ 2 KO mice had significantly greater IL-1α, IL-6, 
reduced levels of IL-10 and higher sE-selectin when compared to WT mice 
(Table 4.1, Figure 4.1A-D). Whilst levels of TNF-α and sICAM-1 were not 
significantly different between the groups (Table 4.1, Figure 4.1 E/F 
respectively). 
Table 4.1. Baseline inflammatory markers. Baseline (study week 0) in WT (n 
=38) and MSK 1/ 2 KO (n =36) mice. Unpaired Student’s t-test. 
Cytokine WT MSK 1/ 2 KO P value 
IL-1α (pg/ml) 476±29 629±44 <0.01 
IL-6 (pg/ml) 392±49 660±45 <0.001 
IL-10 (pg/ml) 570±29 213±11 <0.001 
sE-selectin (pg/ml) 5±0.3 8±1 <0.01 
TNF-α (pg/ml) 4940±622 5628±442 >0.05 
sICAM-1 (pg/ml) 2±0.2 2±0.2 >0.05 
 
 
Plasma Cholesterol  
Total plasma cholesterol levels were similar in WT and MSK 1/2 KO mice at 
study week 0 (72±1 and 74±1 mg/dl, respectively) (Figure 4.4A). 
Chow fed WT mice showed no significant changes in total plasma cholesterol 
over the study duration (WT chow-fed week 0: 72±1 and 24 weeks: 71±1 
mg/dl). Whereas WT-cholesterol fed mice had significant elevations in plasma 
cholesterol (Figure 4.4B). MSK 1/ 2 KO-chow fed mice displayed similar levels 
of plasma cholesterol when compared to WT-chow fed mice (Figure 4.4B) and 
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MSK 1/ 2 KO-cholesterol fed mice displayed the greatest onset of dyslipidaemia 
(Figure 4.4).  
 
Figure 4.3. Baseline inflammatory markers. Baseline (16 weeks of age) 
plasma cytokines for (A) IL-1α (B) IL-6, (C) IL-10 (D) E-selectin (E) TNF-α and 
(F) sICAM-1 in WT (n =38) and MSK 1/ 2 KO (n =36). Results are group means 
±SE (pg/ml). Student’s t-test. **P<0.01, ***P<0.001. 
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Figure 4.4. Plasma cholesterol: Total plasma cholesterol, values are group 
means ±SE (mg/dl) at (A) study baseline (WT n =38, KO n =36), unpaired 
Student’s t-test and (B) 24 week measurements in WT-chow (n =19) WT-
cholesterol (n =19), MSK 1/2 KO-chow (n =18) and MSK 1/ 2 KO-cholesterol (n 
=18) fed mice, two-way ANOVA. ***P<0.001. 
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Changes in Endothelium-dependent Responses Over 24weeks 
WT mice on a chow diet showed no significant changes in skin microvascular 
responses to ACh over 24 weeks (Table 4.2), supporting the view that these 
mice show no signs of endothelial dysfunction (Figure 4.5A). In contrast, WT 
mice on a cholesterol diet showed significant attenuation of microvascular 
responses to ACh from 4 week onwards compared with baseline measurements 
(P<0.001 all time-points) (Figure 4.5A). Furthermore MSK 1/2 KO mice both on 
chow and cholesterol showed significant attenuation of ACh responses from 
week 4 onwards compared with week 0 measurements (P<0.001 all time-
points) (Figure 4.5A). Over the 24 week period, ANOVA showed that WT-chow 
mice had significantly greater ACh responses than WT-cholesterol, MSK 1/2 
KO-chow and MSK 1/2 KO-cholesterol fed mice (P<0.001 for all, Figure 4.5A). 
Additionally, MSK 1/2 KO mice on a high cholesterol diet had significantly 
poorer microvascular responses to ACh compared with WT mice on a 
cholesterol diet (P<0.01) and MSK 1/2 KO on chow (P<0.01) (Figure 4.5A). 
Table 4.2. Longitudinal endothelium dependent responses: Skin 
microvascular responses to ACh in WT-chow (n =19), WT-cholesterol (n =19), 
MSK 1/ 2 KO-chow (n =18) and MSK 1/ 2 KO-cholesterol (n =18) fed mice. 
Results are group means in arbitrary units (AU) ±SE. 
 
Group 
Baseline 
(Week 0) 
(AU) 
4 
weeks 
(AU) 
8 
weeks 
(AU) 
12 
weeks 
(AU) 
16 
weeks 
(AU) 
20 
weeks 
(AU) 
24 
weeks 
(AU) 
WT-chow 348±6 356±7 338±7 343±7 354±8 350±6 349±7 
WT-cholesterol 351±6 306±12 262±12 248±9 248±6 248±5 247±5 
KO-chow 339±8 284±8 279±7 254±8 225±10 239±6 230±6 
KO-cholesterol 338±9 294±6 222±6 213±4 235±11 216±4 233±6 
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Figure 4.5. Longitudinal microvascular responses: Microvascular responses 
in arbitrary units (AU), results are group means ±SE over 24 weeks to (A) ACh, 
(B) SNP at 24 weeks only and (C) localised 44°C heating (over 24 weeks) in 
WT-chow (n =19), WT-cholesterol (n =19), MSK 1/2 KO-chow (n =18) and MSK 
1/2 KO-cholesterol (n =18) fed animals. Changes were analysed by two-way 
ANOVA. 
***P<0.001 comparing genotype. 
# (P<0.05), ### (P<0.001) P<0.01 comparing diet 
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Effect of NO Inhibition on Endothelium-dependent Responses 
At week 0, administration of the NO synthase inhibitor, L-NAME produced a 
significant reduction in the peak ACh response (320±56 AU VS. 257±60 AU, 
P<0.05 in WT mice and 318±60 AU VS. 243±65 AU, P<0.05 in MSK 1/2 KO 
mice), supporting a role for endothelium-derived NO in ACh-mediated 
vasodilatation. L-NAME administration to chow fed WT mice at 12 weeks also 
caused significant attenuation in the peak ACh response compared with the 
response without L-NAME (248±51 AU VS. 310±65 AU, P<0.05), supporting the 
notion that NO in WT chow fed mice is preserved over time (with age). 
 
In WT mice fed a high cholesterol diet, L-NAME administration produced a 
smaller, but significant reduction in the peak ACh response compared with the 
response without L-NAME (180±21 AU VS. 226±21 AU, P<0.05), suggesting 
NO was diminished in part by cholesterol feeding. L-NAME administration to 
MSK 1/2 KO mice fed chow or cholesterol did not show any significant reduction 
in the peak ACh response compared with the response without L-NAME (chow-
fed 226±18 AU VS. 251±18 AU, P>0.05 and cholesterol-fed 235±19 AU VS. 
237±38 AU, P>0.05), indicating that NO was depleted in these groups. 
 
Endothelium-independent Responses to SNP at 24 Weeks 
Endothelium-independent microvascular responses to iontophoresis of SNP at 
week 24 were not significantly different amongst the groups (Figure 4.5B). No 
significant differences were found for this measurement, which suggests that 
cholesterol feeding in WT mice and the MSK 1/2 deficiency (cholesterol and 
chow groups) affects endothelial function without affecting smooth muscle 
function. 
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Changes in Maximum Vasodilator Response to 44ºC heating over 24 weeks  
Figure 4.5C shows that the maximum vasodilator response to localised 44ºC 
heating was not significantly different amongst the groups over 24 weeks. This 
further suggests that attenuated ACh responses are indicative of dysfunction at 
the level of the endothelium and not generalised vascular smooth muscle 
dysfunction.  
 
Changes in Plasma Cytokines Over 24 Weeks 
Compared with measurements at study baseline, IL-1α increased significantly 
over 24 weeks in WT cholesterol-fed (P <0.001), MSK 1/2 KO chow-fed 
(P<0.01) and MSK 1/2 KO-cholesterol fed (P<0.001) mice. The extent of 
change at 24 weeks was greatest in MSK 1/2 KO cholesterol-fed mice. Levels 
of IL-1α in MSK 1/2 KO cholesterol-fed mice were significantly greater than in 
WT chow-fed (P<0.001), WT cholesterol-fed (P<0.01) and KO chow-fed 
(P<0.001) mice (Figure 4.6A). 
IL-6 increased significantly over 24 weeks in WT cholesterol-fed, MSK 1/2 KO 
chow-fed and MSK 1/2 KO cholesterol-fed mice (P<0.001 for all) compared with 
levels at week 0. At 24 weeks, levels of IL-6 were significantly greater in WT 
cholesterol-fed, MSK 1/2 KO chow-fed and MSK 1/2 KO cholesterol-fed 
(P<0.001 for all) mice compared with WT chow-fed mice (Figure 4.6B). 
Plasma IL-10 levels for WT-chow and KO chow-fed mice showed no significant 
change over the study duration (0 VS. 24 weeks). IL-10 levels were significantly 
lower at 24 weeks in cholesterol-fed mice (WT P<0.01 and MSK 1/2 KO 
P<0.001) compared with levels at week 0. Figure 4.6C shows the significant 
differences amongst the groups. These reductions were statistically significant 
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when groups were compared with WT-chow fed mice at study week 24, IL-10 
levels were significantly reduced in WT cholesterol-fed (P<0.01), MSK 1/2 KO 
chow-fed (P<0.001) and MSK 1/2 KO cholesterol-fed(P<0.001) mice (Figure 
4.6C). MSK 1/2 KO cholesterol-fed mice also had significantly lower levels than 
WT cholesterol-fed mice (P<0.001) (Figure 4.6C). 
TNF-α increased significantly over 24 weeks in WT cholesterol-fed, MSK 1/2 
KO chow-fed and MSK 1/2 KO cholesterol-fed mice (P<0.001 for all) compared 
with levels at week 0. At 24 weeks, compared with WT chow-fed mice, levels of 
TNF-α were significantly greater in WT cholesterol-fed (P<0.001), MSK 1/2 KO 
chow-fed (P<0.01) and MSK 1/2 KO cholesterol-fed (P<0.001) mice (Figure 
4.6D). MSK 1/2 KO cholesterol-fed mice also had higher TNF-α levels than WT 
cholesterol-fed (P<0.01) and MSK 1/2 KO chow-fed (P<0.001) mice (Figure 
4.6D). At 24 weeks, E-selectin levels were significantly higher in MSK 1/2 KO 
cholesterol-fed mice compared with WT chow-fed (P< 0.001) and WT 
cholesterol-fed (P<0.01) and MSK 1/2 KO chow-fed (P<0.01) mice (Figure 
4.6E). No significant changes were seen in sICAM-1 from baseline levels or 
between the groups at 24 weeks (Figure 4.6F). 
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Figure 4.6. Week 24 inflammatory markers: Levels of inflammatory markers 
at week 24 in WT-chow (n =19), WT-cholesterol (n =19), MSK 1/2 KO-chow (n 
=18) and MSK 1/2 KO-cholesterol (n =18) fed mice. Results are group means 
±SE (pg/ml) (A) IL-1α, (B) IL-6, (C) IL-10, (D) TNF-α, (E) sE-Selectin, (F) 
sICAM-1. Two-way ANOVA. **P<0.01 ***P<0.001 
 
Aortic Lipid Deposition 
 In comparison with WT chow-fed mice (3.0±0.2%) cholesterol-fed WT mice 
showed a significantly higher lipid deposition (14.0±1.0%, P<0.001) (Figure 
4.7A). Similarly, MSK 1/2 KO mice fed chow and cholesterol displayed higher 
lipid deposition than WT-chow fed mice (6±1%, P<0.05 and 20.0±0.8%, 
P<0.001, respectively) (Figure 4.7A). Increased levels of lipid deposition were 
associated with poorer vascular function as shown by the significant negative 
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correlation between lipid deposition and the peak ACh response (week 24) (r= -
0.664, P<0.001) (Figure 4.7B).  
 
Correlations between Vascular Responses and Blood Markers 
Microvascular responses to ACh and localised heating at week 0 showed no 
significant correlations with cholesterol or any of the cytokines markers. In 
contrast, a number of significant correlations were observed at 24 weeks 
between blood markers and ACh responses, but not with the response to SNP 
or with the response to localised 44ºC heating. Peak ACh responses at 24 
weeks significantly correlated with IL-1α (r=  -0.514, P<0.001), IL-6 (r= -0.581, 
P<0.001), IL-10 (r= 0.651, P<0.001), TNF-α (r= -0.617, P<0.001), and E-
selectin (r= -0.424, P<0.001) (Figure 4.8). From the univariate correlations 
above, these were entered into a stepwise linear regression model. 
Independent determinants of ACh responses were IL-10 (β= 0.483, P<0.001) 
and IL-1α (β= -0.286, P<0.01). 
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Figure 4.7. Aortic lipid deposition:  Aortic lipid staining conducted by Jamie 
Turner. (A) Percentage (%) of aorta covered in lipid at 24 weeks in WT-chow (n 
=9), WT-cholesterol (n =8), MSK 1/2 KO-chow (n =8) and MSK 1/2 KO-
cholesterol (n =8) fed mice. Values are group means ±SE, Two-way ANOVA. 
***P <0.001 (B) Significant association between microvascular response to ACh 
in arbitrary units (AU) at study week 24 VS. Percentage lipid deposition in the 
aorta (r= -0.664, P<0.001) (in WT-chow (n =9), WT-cholesterol (n =8), MSK 1/2 
KO-chow (n =8) and MSK 1/2 KO-cholesterol (n =8) fed mice).  
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Figure 4.8. Correlations: The association between the ACh response (AU) at 
week 24 in WT-chow (n =19), WT-cholesterol (n =19), MSK 1/2 KO-chow (n 
=18) and MSK 1/2 KO-cholesterol (n =18) fed mice and (A) IL-1α, (B) IL-6, (C). 
IL-10, (D) TNF-α, (E) soluble E-selectin. 
 
 
 
Discussion  
The main findings from this study suggest  that MSK 1/2 deficiency in mice 
causes significant impairment in endothelium-dependent vasodilatation with 
increased systemic cytokine production. L-NAME administration showed that 
ACh responses were in part mediated via the actions of NO, and therefore, a 
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decrease in ACh responses in MSK 1/2 deficient mice was mediated via 
reduced NO. In contrast, WT animals fed a normal chow diet maintained normal 
plasma lipids and exhibited no significant changes in basal levels of 
inflammatory markers and had preservation of endothelium-dependent vascular 
responses over the 24 week study. Generalised vascular function, tested by 
iontophoresis of the endothelium-independent vasodilator SNP and maximum 
vasodilator capacity to localised 44ºC skin heating was not significantly different 
amongst the groups, suggesting that elevation of pro-inflammatory cytokines 
was specifically affecting vascular function at the level of the endothelium. 
These data suggest a possible functional role of MSK1/2 in the development 
and progression of atherosclerosis through an interaction between regulation of 
inflammatory cytokines and endothelial dysfunction. 
 
Baseline ACh responses were dependent on NO production in both WT and 
MSK 1/2 KO mice as shown by the significant reduction following pre-treatment 
with L-NAME. At 12 weeks however, while L-NAME still produced a significant 
decrease  in WT mice on a chow diet (confirming dependency on NO 
production), WT mice on a high cholesterol diet showed a lesser decrease in 
ACh response following L-NAME, and MSK 1/2 KO mice (on either diet) 
demonstrated no significant change. Thus, 12 weeks of cholesterol alone (i.e. in 
WT only) did not inhibit NO completely, whereas in MSK 1/2 KO mice there was 
a more significant reduction in NO as shown by no further reduction in ACh 
responses following L-NAME. Interestingly, in spite of a greater reduction in NO 
in MSK 1/2 KO mice, ACh responses in the presence of L-NAME were not as 
low as responses in WT cholesterol-fed mice post L-NAME. It is possible that 
the higher level of perfusion in the MSK 1/2 KO mice might be related to a 
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compensatory increase in ACh-induced production of endothelium-derived 
hyperpolarising factor (Verma et al., 2003). 
MSK 1/2 KO mice on a BALB/c Sv/129 mixed background do not reportedly 
display an altered phenotype, conversely in this study we report a lower age 
matched weight at 16 weeks of age on a C57BL/6 background. This translated 
to a mean difference of 2g which was considered negligible and would not 
significantly impact on the study outcome. At week 0, although elevations in 
pro-inflammatory markers in MSK 1/2 KO mice compared with WT mice were 
found (increased IL-1α, IL-6, E-selectin and reduced IL-10), there were no 
significant differences in ACh responses, perhaps indicating that the relative 
difference and potential duration of change in cytokine levels was not sufficient 
enough to impact significantly on vascular function at that time point. The 
difference in inflammatory cytokines between WT and KO strains at baseline 
may be mediated by environmental factors for example exposure to infectious 
agents. Mice were initially bred and maintained in a barrier facility and 
subsequently rehoused for vascular testing in a conventional unit, at which they 
could have been exposed to additional micro-organisms. The onset of CVD and 
induction of pro-inflammatory gene expression in immune compromised animals 
has previously been reported in non-pathogen free conditions when animals are 
challenged with high cholesterol feeding (Mallat et al., 1999). Previous findings 
show that high cholesterol feeding induces greater adverse changes in pro-
inflammatory cytokines (Belch et al., 2013), with resultant endothelial 
dysfunction in WT mice compared with chow fed mice (Meyrelles et al., 2011). 
Interestingly, we found that MSK 1/2 KO mice fed a normal chow diet over 24 
weeks also displayed elevations in pro-inflammatory cytokines and diminished 
responses to ACh. MSK 1/2 KO mice still can develop significant endothelial 
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dysfunction, to a degree similar to that seen with cholesterol feeding in WT 
mice. The exact mechanism for this dysfunction requires further scrutiny.  
It has previously been reported that MSK 1/ 2 KO mice have decreased 
production of IL-1ra (Darragh et al., 2010). IL-1ra KO mice display a significant 
elevation in plasma cholesterol due to impaired cholesterol efflux through 
altered conversion of hepatic cholesterol to bile acids. This is mediated by 
reduced expression of 7α-hydroxylase (CY7A1) the rate limiting step in bile acid 
synthesis (Isoda and Ohsuzu, 2006). MSK 1/ 2 KO mice require further study to 
assess the exact mechanism of altered cholesterol homeostasis and the 
resultant impact on systemic cytokine expression and endothelial function, as 
evidenced by the significant elevation in plasma cholesterol of MSK 1/ 2 KO-
cholesterol fed mice when compared to WT-cholesterol fed mice. 
Ananieva et al (Ananieva et al., 2008) reported on the anti-inflammatory effects 
of the MSK 1/2 kinases. In response to LPS, MSK1/2 double KO macrophages 
produced elevated levels of TNF-α and IL-6 but decreased amounts of IL-10 
relative to WT cells. Similar results were also obtained when plasma cytokine 
levels were measured following i.p. injection of LPS. These results are in 
agreement with our findings in which animals with compromised immune 
function (MSK 1/2 KO mouse) display higher plasma levels of pro-inflammatory 
molecules and a decreased IL-10 capacity compared with WT (chow-fed) 
control mice. 
Ananieva et al (Ananieva et al., 2008) also demonstrated that the increased 
production of IL-6, and to a lesser extent TNF, was dependent on the ability of 
MSKs to regulate IL-10 production. IL-10 has a potential protective role in 
atherosclerosis and can be produced by macrophages. IL-10 inhibits pro-
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inflammatory cytokine expression through a JAK/STAT3 dependent pathway 
(Pattison et al., 2012). Aortic ring relaxation from IL-10 KO mice display 
significantly blunted endothelium-dependent responses to ACh, mediated by a 
decrease in eNOS expression after incubation with TNF-α (Zemse et al. 2010). 
Zimmerman et al (Zimmerman et al., 2004) demonstrated the potential 
therapeutic benefits of exogenous IL-10 in WT animals subjected to carotid 
injury, and observed amplified intimal hyperplasia in WT controls that did not 
receive exogenous IL-10. Other studies in vitro have demonstrated that 
increased IL-10 levels appear  to be anti-atherogenic by increased uptake and 
efflux of cholesterol, reducing levels of cell death and progression of 
atherosclerotic lesions (Han et al., 2010). Loss of the protective role of IL-10 in 
the silencing of inflammatory responses in our MSK 1/2 KO mice and WT 
cholesterol fed mice may indirectly lead to the perpetuation of inflammation. 
Although IL-6 was not an independent determinant of ACh responses, it did 
exhibit a univariate association with endothelium-dependent responses. IL-6 
has been linked to an increased risk of adverse cardiovascular events (Naya et 
al., 2007, Ridker et al., 2000a) and can be synthesized by a number of cells 
including macrophages. IL-6 inhibits eNOS activation and attenuates 
vasodilation by increasing caveolin-1, resulting in more eNOS binding, leading 
to reduced NO (Hung et al., 2010). 
Although MSK 1/ 2 KO mice demonstrated a similar degree of endothelial 
dysfunction to WT mice fed on high cholesterol, they displayed a greater extent 
of lipid deposition within the aorta, indicating that elevation of pro-inflammatory 
cytokines together with high cholesterol produces a more profound effect on 
lipid accumulation within vessel walls than elevations in pro-inflammatory 
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cytokines alone. Thus, early intervention to promote the MSK 1/2 pathway could 
potentially limit or restore to some extent, alterations in endothelial function 
before excessive lipid accumulation within the vessel wall.  
One possible explanation for this observed differences between MSK 1/2 chow 
and cholesterol fed mice could be secreted IL-1α. IL-1α is synthesised by 
activated endothelial cells and is released early in the atherosclerotic process 
and mediates the expression of cell adhesion molecules responsible for 
capture, rolling and subsequent transmigration into the sub-endothelial space 
(Shreeniwas et al., 1992). IL-1α levels are specifically up regulated in 
cholesterol fed animals. These regulatory and synthetic roles of IL-1 are 
associated with a number of physiological events including macrophage 
activation, endothelial proliferation (Hoge and Amar, 2007), myocardial cell 
damage and endothelial dysfunction through increased oxidative stress and 
inflammation (Chi et al., 2004, Chamberlain et al., 2006). Thus the cholesterol 
diet may further stimulate IL-1α release, resulting in a greater accumulation of 
macrophages in the arterial wall and a greater accumulation of lipid (Isoda and 
Ohsuzu, 2006, Isoda et al., 2004, Isoda et al., 2003). 
Significant correlations between microvascular responses to ACh and levels of 
cytokines at 24 weeks were observed. Demonstrating that this methodology for 
assessment of microvascular function in the skin is sensitive and reflective of 
systemic inflammation and similar to what we have reported in patients. We 
additionally found a significant correlation between impairment in ACh-mediated 
vascular responses and the percentage of lipid deposition in the aorta at 24 
weeks which provides supportive evidence that early measurements of 
endothelial dysfunction in the skin microcirculation reflect early atherosclerosis 
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burden using this mouse model. Of the significant univariate correlations 
between microvascular responses to ACh and cytokine levels, IL-10 proved to 
be the strongest independent determinant of ACh response in a multivariate 
regression model with IL-1α also proving to be an independent determinant, 
albeit to a lesser degree.  
In conclusion MSK 1/2 plays an important role in limiting pro-inflammatory 
signalling downstream of TLRs, and the present study shows that deletion of 
MSK 1/2 produces a marked inflammatory state with consequent early 
endothelial dysfunction, reduced NO and increased early atherosclerotic 
burden. This study also shows that the changes in skin microvascular function 
are representative of early atherosclerotic burden and therefore the 
experimental set-up can provide a useful tool for exploring specific pathways 
and mechanisms underlying development and progression of CVD. Targeting 
the MSK 1/2 pathway, and in particular with agents that selectively activate 
MSK1 and MSK 2, might provide a useful therapeutic option for combating 
inflammation-induced endothelial dysfunction and atherosclerosis.  
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Chapter 5 
MyD88 Activation in Inflammation Induced Endothelial Dysfunction 
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Introduction 
The previous chapter detailed the onset on endothelial dysfunction in vivo in 
MSK 1/2 KO mice on rodent chow and when challenged with a cholesterol rich 
diet. MSK 1/ 2 can be are activated downstream of TLRs. TLR activation is 
complex and is dependent on trans-cytoplasmic signalling. As previously 
discussed in the Introduction (Toll-like Receptors), MyD88 is a universal adaptor 
molecule and is used by TLR2/4 to induce pro-inflammatory gene expression. 
TLR activation is associated with CVD and atherosclerotic lesions (Ananieva et 
al., 2008, Arthur, 2008, Darragh et al., 2010, Kawai et al., 1999, Mullick et al., 
2005, Tobias and Curtiss, 2007). Abrogation of TLR signalling by amelioration 
of MyD88 is atheroprotective (Bjorkbacka et al., 2004), however the role of 
MyD88 in endothelial dysfunction and systemic cytokine expression in vivo has 
not been described. 
 
Aim 
To address the role of MyD88 activation in endothelial dysfunction in vivo and to 
better understand how TLR activation is mediated through MyD88 activation 
and the systemic release of cytokines. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
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Animals 
Animals from the breeding strain MyD88 were randomly allocated into four 
groups: WT control mice fed normal rodent chow, WT mice on a pro-
atherogenic diet and MyD88 KO mice on chow and pro-atherogenic diet. 
 
Body Weight 
Animals were weighed at study baseline and at 20 weeks. 
 
Longitudinal Assessment of Vascular Function 
In vivo assessment of endothelium-dependent, endothelium-independent and 
maximal vasodilator capacity were assessed, the following time points were 
used for vascular function testing: baseline (study week 0), 8 weeks, 12 weeks 
and 20 weeks as described. 
 
Spleen Mass 
Spleen mass was assessed at study end point (20 weeks). Spleen mass has 
previously been used to assess systemic inflammatory burden (Nanda et al., 
2011) and enlarged spleens are associated with chronic inflammatory diseases 
such as SLE. Spleen mass was used to assess systemic inflammatory burden 
in this and subsequent studies. 
 
Cardiac Hypertrophy 
Cardiac hypertrophy was assessed at study end point (20 weeks) 
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Plasma Cholesterol 
LDL/vLDL and HDL measurements were made at 20 weeks only. 
 
Cytokine Expression 
Measurements were made at study baseline and 20 weeks. 
 
Results 
Baseline Body Weight 
MyD88 KO (27±1g) mice were significantly heavier than WT (25±1g) animals at 
study baseline (P<0.01) (Figure 5.1). The mean group difference was 2g. 
 
Figure 5.1. Baseline body weight: Baseline body weight in (12 weeks of age) 
WT (n =23) and MyD88 KO (n =16) animals. Results are group means ±SE in 
grams (g). Unpaired Student’s t-test. ** P<0.01 
 
20 Week Measurement of Body Weight  
Animals in all groups significantly increased in body weight over the study 
duration: WT-chow (baseline 26±1 g VS. week 20 29±1g, P<0.001), WT-
cholesterol (baseline 25±1g VS. week 20 30±1g, P<0.001) KO-chow (baseline 
27±1g VS. week 20 32±1g, P<0.05) and KO-cholesterol (baseline 26±1g VS. 
week 20 30±1g, P<0.001). 
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Week 20 body weights were not significantly different amongst the groups 
(Figure 5.2). 
 
Figure 5.2. Week 20 body weights: Week 20 measurements of body weights 
in WT-chow (n =10), WT-cholesterol (n =14), MyD88 KO-chow (n =8) and 
MyD88 KO-cholesterol (n =8) fed animals. Results are group means ±SE in 
grams (g). Two-way ANOVA. 
 
Baseline Vascular Function 
There were no significant differences for baseline vascular responses to 
endothelium-dependent agonist ACh (WT 334±8 AU VS. KO 327±7 AU, 
P>0.05) (Figure 5.3A) or maximal dilator capacity (WT 453±15 AU VS. 467±13 
AU, P>0.05) between WT and MyD88 KO animals (Figure 5.3B). 
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Figure 5.3. Baseline vascular function: Microvascular responses in arbitrary 
units (AU) at study baseline (week 0) to (A) endothelium-dependent ACh and 
(B) maximal dilator capacity in WT (n =24), MyD88 KO (n =17) animals. Results 
are group means ±SE. Unpaired Student’s t-test. 
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Baseline Cytokines 
There were no significant differences for baseline inflammatory markers 
between WT and KO animals: IL-1α, IL-6 and IL-10 (Figure 5.4A-C 
respectively). 
 
Figure 5.4. Baseline inflammatory markers: Baseline plasma cytokines for 
(A) IL-1α (B) IL-6, and (C) IL-10 in WT (n =20) and MyD88 KO (n =20) mice 
(pg/ml). Results are group means ±SE. Unpaired Student’s t-test. 
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Spleen Mass 
There were no significant differences between groups for spleen weight (WT-
chow 105±28 mg, WT-cholesterol 107±10 mg, KO-chow 124±19 mg and KO 
cholesterol 161±37 mg) (Figure 5.5).  
 
Figure 5.5. Spleen mass: Spleen weight (mg) in WT-chow (n =10), WT-
cholesterol (n =14), MyD88 KO-chow (n =8) and MyD88 KO-cholesterol (n =8) 
fed animals. Results are group means ±SE. Two-way ANOVA. 
 
Cardiac Hypertrophy 
Cardiac mass was similar between the groups (WT-chow 160±5 mg, WT-
cholesterol 146±3 mg, KO-chow 162±6 mg and KO-cholesterol 150±4 mg) 
(Figure 5.6A).  
There were no significant differences amongst the groups for tibia length (WT-
chow 18.0±0.2mm, WT-cholesterol 18.0±0.1mm, KO-chow 18.0±0.1mm, KO-
cholesterol 18.0±0.4mm) (Figure 5.6B).  
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No significant differences were found for measurements of cardiac hypertrophy 
amongst the groups (WT-chow 9.0±0.3 ratio, WT-cholesterol 8.0±0.2 ratio, KO-
chow 9.0±0.4 ratio, and KO-cholesterol 8.0±0.3 ratio) (Figure 5.6C). 
 
Longitudinal Vascular Responses 
Endothelium-dependent 
There were no significant differences between the groups for ACh mediated 
vasodilatation at study baseline (week 0) (WT-chow 329±11 AU, WT-cholesterol 
337±11 AU, KO-chow 331±12 AU and KO-cholesterol 322±5 AU). 
Significant differences were found at study week 8; WT-cholesterol fed mice 
had significantly poorer microvascular responses to endothelium dependent 
agonist ACh (292±7 AU) when compared to age matched WT-chow fed (342±6 
AU, P<0.05) animals. Responses to ACh at study week 8 were greater in 
MyD88 KO-chow (330±22 AU ) and KO-cholesterol fed mice when compared to 
WT-cholesterol animals, however these observations did not reach statistical 
significance (P>0.05) (Figure 5.6A). 
WT-cholesterol fed mice had significantly poorer microvascular responses to 
ACh at study week 12 (275±8 AU) when compared to WT-chow (324±12 AU, 
P<0.05), KO-chow (336±4 AU, P<0.01) and KO-cholesterol (331±23, P<0.05 
AU) fed mice (Figure 5.6A).   
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Figure 5.6. Cardiac hypertrophy: Cardiac mass (mg) (A), tibia Length (mm) 
(B) and cardiac hypertrophy (cardiac mass (mg)/average tibia length (mm)) (C) 
in WT-chow (n =9), WT-cholesterol (n =11), MyD88 KO-chow (n =6) and MyD88 
KO-cholesterol (n =8) fed mice. Results are group means ±SE. Two-way 
ANOVA. 
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12 measurements of vascular function remained statistically significant at week 
20. WT-cholesterol fed mice had poorer microvascular responses (275±5 AU) 
when compared to WT-chow (320±7 AU, P<0.001), KO-chow (333±8 AU, 
P<0.001) and KO-cholesterol fed (336±6 AU, P<0.001) mice (Figure 5.6A). 
 
Endothelium-Independent  
There were no significant differences in responses to endothelium-independent 
responses to SNP amongst the groups (WT-chow 351±21 AU), WT-cholesterol 
(371±22 AU), KO-chow (348±15 AU) and KO-cholesterol (331±9 AU) (Figure 
5.6B). 
 
Plasma Cholesterol  
LDL/vLDL 
Cholesterol feeding (14±2 mg/dl) in WT mice significantly increased plasma 
levels of LDL/vLDL lipoproteins when compared to WT-chow fed animals (3±1 
mg/dl) (P<0.01) (Figure A). MyD88 KO-chow (6±1 mg/dl) fed animals had 
similar LDL/vLDL plasma cholesterol when compared to WT-chow fed animals. 
MyD88 KO-cholesterol (24±4 mg/dl) fed mice had significantly greater 
LDL/vLDL plasma lipoproteins when compared to WT-chow (P <0.001), WT-
cholesterol (P<0.05) and KO-chow (P<0.001) (Figure 5.8A). 
 
HDL 
There were no significant differences for week 20 plasma HDL measurements 
amongst the groups (Figure 5.8B) (WT-chow 18±1 mg/dl, WT-cholesterol 15±2 
mg/dl, MyD88 KO-chow 15±2 mg/dl and MyD88 KO-cholesterol18±1 mg/dl). 
144 
 
 
 
Figure 5.7. Longitudinal microvascular responses:  (A) Microvascular 
responses in arbitrary units (AU) over 20 weeks to (B) endothelium-dependent 
ACh and (B) week 20 responses to endothelium-independent SNP in WT-chow 
(n =9), WT-cholesterol (n =15), MyD88 KO-chow (n =9) and MyD88 KO-
cholesterol (n =8) fed animals. Results are group means ±SE. Two-way 
ANOVA. 
*P<0.05, ***P<0.001 comparing genotypes  
#P<0.05, ##P<0.01 comparing diet. 
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Figure 5.8. Plasma cholesterol: Week 20 measurements of (A) low density 
lipoproteins and very low density lipoproteins (LDL/vLDL) and high density 
lipoproteins (HDL) in the plasma of WT-chow (n =10), WT-cholesterol (n =11), 
MyD88 KO-chow (n =8) and MyD88 KO-cholesterol fed mice (n =8) (mg/dl). 
Results are group means ±SE. Two-way ANOVA. **P<0.01, ***P<0.001. 
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20 Week Measurement of Plasma Cytokines 
WT-cholesterol fed mice (3042±120 pg/ml) had significantly greater levels of IL-
1α at 20 weeks when compared to WT-chow (1524±23 pg/ml, P<0.001), MyD88 
KO-chow (1470±22 pg/ml, P<0.001) and MyD88 KO-cholesterol (1505±25 
pg/ml, P<0.001) mice (Figure 5.9A). 
IL-6 at 20 weeks were significantly greater in WT-cholesterol fed mice 
(3109±120 pg/ml) compared to WT-chow (1374±9 pg/ml, P<0.01), MyD88 KO-
chow (1592±187 pg/ml, P<0.01) and MyD88 KO-cholesterol (1425±223 pg/ml, 
P<0.01) mice (Figure 5.9B). 
Plasma levels of IL-10 at 20 weeks were not significantly different between WT-
chow (212±6 pg/ml) and WT-cholesterol (219±6 pg/ml) fed mice or between 
MyD88- KO-chow (227±9 pg/ml) and MyD88 KO-cholesterol (249±16 pg/ml) fed 
mice (Figure 5.8C). 
 
Correlations 
Microvascular responses to ACh and localised heating at week 0 showed no 
significant correlations with any of the cytokines markers. In contrast a negative 
association was found for ACh and plasma levels of IL-1α (r= -0.826, P<0.001) 
and IL-6 (r= -0.804, P<0.001) at 20 weeks.  
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Figure 5.8. Week 20 measurements of inflammatory markers: Plasma 
cytokines (pg/ml) (A) IL-1α, (B) IL-6 and (C) IL-10 WT-chow (n =10), WT-
cholesterol (n =10), MyD88 KO-chow (n =10) and MyD88 KO-cholesterol fed (n 
=10) mice. Results are group means ±SE. Two-way ANOVA. ***P<0.001. 
 
 
 
Discussion 
The main findings from this study show that MyD88 KO mice fed a cholesterol 
diet maintain endothelium-dependent vasodilatation in vivo over 20 weeks, 
unlike WT-cholesterol fed mice. Cholesterol feeding in WT mice reduces NO, as 
evidenced in the previous chapter. Generalised vascular function testing by the 
iontophoresis of endothelium-independent vasodilator SNP was not significantly 
different amongst the groups, suggesting that the elevation in inflammatory 
markers observed in WT-cholesterol fed mice was significantly affecting the 
endothelium. These data suggest that there is a potential functional role for 
MyD88 in the development and progression of CVD, an interaction that is 
potentially mediated by MyD88, cholesterol, cytokine synthesis and the 
endothelium. 
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Despite this apparent protection against CVD MyD88 KO-cholesterol fed mice 
displayed significantly greater levels of LDL/vLDL in plasma, when compared to 
WT-cholesterol fed animals. Hosoi et al (2010) has previously reported a similar 
dyslipidaemia profile in MyD88 KO mice in the context of diabetes. MyD88 KO 
high fat diet (HFD) fed mice display significantly higher plasma cholesterol than 
WT animals on the same diet, (Hosoi et al., 2010), a phenotype that is not 
dependent on body weight, visceral fat, locomotion or food intake. In the same 
study Hosoi et al also showed up regulation of LDLr in the liver of MyD88 
deficient mice when compared to WT controls on the same diet, suggesting a 
positive feedback mechanism, a potential autocrine attempt to clear lipids from 
the blood stream. The increased plasma levels of circulating lipid in MyD88 
HFD fed mice are thought to be mediated by an increase in expression of HMG-
CoA reductase, an enzyme that is rate limiting in the biosynthesis of cholesterol 
and targeting this pathway with statins has shown favourable results in human 
trials (Davignon, 2004) by reducing plasma cholesterol. In contrast Bjorkbacka 
et al (2004) (Bjorkbacka et al., 2004) has previously reported a modest 
elevation in plasma cholesterol that was not significantly different in 
MyD88/ApoE deficient mice. However in agreement with Bjorkbacka et al, the 
elevation observed by double KO ApoE/MyD88 mice was due to elevated LDL 
and not HDL (Bjorkbacka et al., 2004).  
Previous studies have established the rate limiting step of MyD88 in 
atherosclerosis. This is in part mediated by reduced MCP-1 expression, an 
important chemoattractant protein in monocyte recruitment and a significant 
(53%) reduction in the MCP-1 receptor, CCR2. Previous studies have sought to 
establish the role of MCP-1 in monocyte infiltration into the aortic sinus and 
peritoneal cavity, deficiency of MyD88 produced an 80% and 45% reduction in 
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infiltration F4/80 positive cells respectively, showing that MyD88 activation is 
needed for monocyte recruitment. 
MCP-1 can be synthesised by endothelial cells and is dependent on MyD88 (Yu 
et al., 2014). Thus deficiency of MyD88 in this study may have preserved 
vascular function through reduced recruitment of monocytes into the vessel 
wall, an established early event in plaque formation. In support of this it has 
previously been shown that MyD88 is not an essential mediator of foam cell 
formation, through no significant differences in uptake and degradation of 
oxLDL in MyD88 deficient cells when compared to controls (Bjorkbacka et al., 
2004, Park et al., 2012). 
MyD88 KO-cholesterol fed mice also displayed reduced plasma levels of IL-6 
unlike WT-cholesterol fed mice in the present study. The role of IL-6 in 
endothelial dysfunction has previously been described (Barnes et al., Barnes et 
al., Esteve et al., 2007, Esteve et al., 2006, Fernandez-Real et al., 2000, 
Hashizume and Mihara, Huber et al., 1999, Hung et al., Mihara et al., Naya et 
al., 2007). Hung et al (2010) reported IL-6 can specifically inhibit the release of 
NO, by increasing the effects of calveolin-1. Increased caveolin-1 reduces 
eNOS activity by attenuating the eNOS activation pathway, though reduced 
phosphorylation at Ser1177, an established phosphorylation site implicated in 
endothelial dysfunction (Matsumoto et al., 2014). 
MyD88 KO-cholesterol fed mice displayed reduced levels of IL-1α when 
compared to WT-cholesterol fed mice. IL-1α has been implicated in early 
atherosclerotic plaque formation through modulation of cell adhesion molecules. 
Damaged endothelial cells can release IL-1α and enhance VSMC proliferation. 
Conversely IL-1ra has shown favourable results by limiting plaque formation 
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and reducing plasma lipids in mouse models and reduced restenosis in humans 
after angiography (Chi et al., 2004, Francis et al., 2001, Isoda and Ohsuzu, 
2006, Isoda et al., 2004, Isoda et al., 2003).  
The release of inflammatory cytokines into the vessel wall after recruitment of 
myeloid cells has shown to perpetuate vascular inflammation and 
atherosclerotic plaque formation. MyD88 deficiency has previously shown 
protection in a model of myocardial reperfusion injury in mice.  Feng et al (2008) 
(Feng et al., 2008b) studied the effects of MyD88 in vivo and ex vivo using a 
model of myocardial injury. The detrimental effects of MyD88 activation are 
dependent on blood components such as the presence of myeloid cells, a 
response that can be prevented by using an ex vivo system that is devoid of 
circulating white blood cells. These observations are consistent with the role of 
TLR4 in the pathogenesis of CVD (Riad et al., 2008a, Riad et al., 2008b, Riad 
et al., 2012, Tobias and Curtiss, 2007). TLR4 KO mice have shown improved 
left ventricle function after MI, through reduced left ventricle remodelling, and for 
this reason TLR4 inactivation is thought to be a promising future therapeutic tool 
(Riad et al., 2008b).  
Yu et al (2014) (Yu et al., 2014) studied endothelial cell (EC) specific MyD88 
KO and myeloid cell (MC) specific deficient mice and showed protection against 
diet induced insulin resistance. EC specific KO mice only showed partial 
protection against insulin resistance in adipose tissue when compared to MC-
MyD88 KO mice. Unlike the present study these authors report no significant 
difference in plasma cholesterol of endothelial cell specific and MC-MyD88 KO 
mice. However the findings from Yu et al are consistent with Bjorkbacka et al. 
Both studies used the ApoE KO CVD-prone model for their experiments and the 
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altered lipid effect may be dependent on the ApoE KO mouse, unlike the 
observations in the present study.  
EC and MC-MyD88 deficiency protected against atherosclerotic lesion 
formation on a chow diet in the study by Yu et al, with respective reductions in 
the expression of TNFα, IL-6 and IL-1 compared with littermate controls, 
findings that are consistent with the present study. MC-MyD88 deficient mice 
show greater protection to pro-inflammatory responses when compared to EC-
MyD88 KO mice, this phenotype is potentially mediated through the differences 
in cells response to stimuli. MC are more susceptible to the production of 
inflammatory markers due to their role in phagocytosis and immunity, 
suggesting that MC are more central to the onset of systemic chronic 
inflammation as observed in WT-cholesterol fed mice in this study and 
subsequently more prone to endothelial dysfunction. OxLDL can activate TLR 
signalling and leads to the recruitment of MyD88, to initiate downstream 
signalling such as the activation of NF-kB and MAPK p38 to induce the 
production of pro-inflammatory cytokines associated with atherosclerosis. Yu et 
al reported MyD88 dependent signalling in EC, dependently releases 
granulocyte macrophage –stimulating factor (GM-CSF), which can induce pro-
inflammatory polarisation of macrophages in the arterial wall, a phenomenon 
associated with atherosclerotic plaque formation. However, MyD88 deficiency in 
the present study preserved endothelial function in the presence of dietary 
cholesterol a known cardiovascular risk factor, potentially through a similar 
pathway (reduced cell recruitment). TLR downstream signalling is otherwise 
associated with the expression of pro inflammatory genes and atherosclerosis, 
the present study shows protection against endothelial dysfunction when this 
signalling pathway is blocked. 
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In conclusion, MyD88 plays a critical role in the development of endothelial 
dysfunction through the activation of innate inflammatory pathways. Targeting 
TLRs in particular MyD88 with agents that block its effects could provide a novel 
tool for combating inflammation-induced endothelial dysfunction, systemic 
cytokine expression and early CVD. 
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Chapter 6  
Mitogen Activated Proteins Kinases Activated-protein 2/3 in Endothelial 
Dysfunction 
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Introduction 
The previous chapter detailed protection against endothelial dysfunction in 
MyD88 KO mice fed dietary cholesterol, potentially through abrogation of trans 
cytoplasmic signalling. Other novel downstream protein kinase targets have 
been described to sequester inflammation. As previously described in the 
Introduction (Mitogen Activated Protein Kinases Activated-protein) the MAPKAP 
2/3 are substrates of the stress activated MAPK p38. In vitro cell based assay 
studies have shown that these kinases are important in inflammatory gene 
expression, through regulation of cytokines including IL-6.  
 
MAPKAP 2/3 induce prolonged expression of inflammatory cytokines by 
modulating the stability of mRNA. This is achieved through targeting of the 
3’untranslated region of mRNA of cytokines such as IL-6 through 
phosphorylation of RNA stability regulators. MAPKAP 2/3 deficient mice have 
been previously described and do not show a discernible phenotype unlike the 
upstream target p38, that is embryonically lethal. Importantly MAPKAP 2/3 are 
potential targets for future therapy. In vivo models of inflammation such as the 
LPS induced septic shock model, the collagen-induced RA model and a 
neuroinflammation model of Parkinson’s disease have conferred protection from 
the onset of pathophysiology in MAPKAP deficient mice (Hegen et al., 2006, 
Kotlyarov et al., 1999, Thomas et al., 2008). The role of this pathway in the 
development of endothelial dysfunction and systemic cytokine expression has 
not been described. 
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Aim 
To explore the role of MAPKAP 2/3 activation in the release of systemic 
cytokine expression and endothelial function in vivo. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
 
Animals 
Animals from the breeding strain MAPKAP 2/3 were randomly allocated into 
four groups: WT control mice fed normal rodent chow, WT mice on a pro-
atherogenic diet and MAPKAP 2/3 KO mice on chow and pro-atherogenic diet. 
 
Body Weight 
Animals were weighed at study baseline and 20 weeks. 
 
Longitudinal Assessment of Vascular Function 
In vivo assessment of endothelium-dependent, endothelium-independent and 
maximal vasodilator capacity were assessed, the following time points were 
used for vascular function testing: baseline (study week 0), 8 weeks, 12 weeks 
and 20 weeks as described. 
 
Spleen Mass 
Spleen mass was assessed at study end point (20 weeks).  
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Cardiac Hypertrophy 
Cardiac hypertrophy was assessed at study end point (20 weeks) 
 
Plasma Cholesterol 
LDL/vLDL and HDL measurements were made at 20 weeks only. 
 
Cytokine Expression 
Measurements were made at study baseline and 20 weeks. 
 
Results 
Baseline Body Weight  
WT (27±1g) animals were significantly heavier than KO mice at study baseline 
(23±1g) (12 weeks of age) (P<0.001) (Figure 6.1). The mean group difference 
was 4g.  
 
Figure 6.1.  Baseline body weight: Baseline body weight in (12 weeks of age) 
WT (n =32) and MAPKAP 2/3 KO (n =29) mice. Results are group means ±SE 
in grams (g). Unpaired Student’s t-test. *** P<0.001 
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20 Week Measurement of Body Weight 
WT-chow (20 week weight 27±.1g, P<0.01), WT-cholesterol (20 week weight 
31±1g, P<0.001) and KO-cholesterol (20 week weight 26±1, P<0.001) fed mice 
significantly increased in body weight over the study duration. KO-chow (20 
week weight 25±1g) fed animals did not significantly increase in body weight 
over the study duration (P>0.05). Body weights between KO-chow and KO-
cholesterol were not significantly different. 
WT- cholesterol fed animals were significantly heavier than WT-chow (P<0.01), 
KO-chow (P<0.001) and KO-cholesterol fed animals (P<0.001) (Figure 6.2) 
 
Figure 6.2. Week 20 measurements of body weights: WT-chow (n =13), WT-
cholesterol (n =11), MAPKAP 2/3 KO-chow (n =12) and MAPKAP 2/3 KO-
cholesterol (n =13) fed animals body weights at 20 weeks. Results are group 
means ±SE. Grams (g). Two-way ANOVA. **P<0.01, *** P<0.001 
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Spleen Mass 
There were no significant differences for spleen mass amongst the groups (WT-
chow 120±10 mg, WT-cholesterol 110±8 mg, MAPKAP 2/3 KO-chow 149±49 
mg and MAPKAP 2/3 KO-cholesterol 133±19 mg (Figure 6.3).  
 
 
 
Figure 6.3. Spleen mass: Spleen weight (mg) in WT-chow (n =11), WT-
cholesterol (n =10), MAPKAP 2/3 KO-chow (n =11) and MAPKAP 2/3 KO-
cholesterol fed (n =12) animals. Results are group means ±SE. Two-way 
ANOVA. 
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Baseline Vascular Function 
There were no significant differences for vascular function at study baseline 
between WT and KO mice for endothelium-dependent vasodilatation to 
iontophoresis of ACh (WT 333±7 AU VS. KO 331±7 AU, P>0.05) (Figure 6.4A) 
or maximal vasodilator dilator capacity to localised skin heating (WT 438±9 AU 
VS. KO 420±10 AU, P>0.05) (Figure 6.4B).  
 
Figure 6.4. Baseline vascular function: Microvascular responses in arbitrary 
units (AU) at study baseline (week 0) to (A) endothelium-dependent ACh and 
(B) maximal dilator capacity in WT (n =24) and MAPKAP 2/3 KO (n =17) 
animals. Results are group means ±SE. Unpaired Student’s t-test. 
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Plasma Cholesterol 
LDL/vLDL 
WT-cholesterol (10±1 mg/dl) and KO-cholesterol fed (10±1 mg/dl) mice had 
significantly greater LDL/vLDL in terminal measurements of plasma when 
compared to WT-chow fed mice (5±1 mg/dl) (P<0.001, P<0.01 respectively) 
(Figure 6.5A). KO-chow (5±1 mg/dl) fed animals had similar levels of LDL/vLDL 
in measurements of plasma when compared to WT-chow fed mice. KO-chow 
fed animals had statistically lower LDL/vLDL than KO-cholesterol (P<0.001) 
animal (Figure 6.5A). 
 
HDL 
There were no significant differences between the groups for measurements of 
HDL (WT-chow 19±1 mg/dl, WT-cholesterol 16±2 mg/dl, KO-chow 14±3 mg/dl 
and KO-cholesterol 17±2 mg/dl) (Figure 6.5B). 
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Figure 6.5. Plasma cholesterol: 20 week measurements of (A) low density 
lipoproteins and very low density lipoproteins (LDL/vLDL) and (B) High density 
lipoproteins (HDL) in the plasma of WT-chow (n =10), WT-cholesterol (n =9), 
MAPKAP KO-chow (n =9) and MAPKAP KO-cholesterol fed mice (n =10) 
(mg/dl). Results are group means ±SE. Two-way ANOVA. ***P<0.001. 
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Cardiac Hypertrophy 
Cardiac mass was not significantly greater in WT-cholesterol fed mice (171±9 
mg) when compared to WT-chow (151±4 mg) (Figure 6.6A). There were no 
significant differences between WT-chow and WT-cholesterol for tibia length 
(WT-chow 18.0±0.1 mm, WT-cholesterol 18.0±0.1 mm) (P>0.05) (Figure 6.6B). 
WT-cholesterol (9.0±0.4 ratio) fed mice had a significantly greater 
cardiovascular hypertrophy measurement compared to WT-chow fed mice 
(8.0±0.8 ratio) (P<0.05) (Figure 6.6C). 
KO-chow fed animals had similar measurements of cardiac mass (149±4 mg) 
and cardiovascular hypertrophy (9.0±0.3 ratio) when compared to WT-chow fed 
animals (Figure 6.6A/C). KO-cholesterol fed mice had significantly lighter 
hearts (144±4mg) when compared to WT-cholesterol fed mice (171±9 mg) 
(P<0.01) but not a significantly lower cardiovascular hypertrophy measurement 
(KO-cholesterol 9.0±0.2 ratio) (Figure 6.6C). KO animals in both groups (KO-
chow 17.0±0.2 mm and KO-cholesterol 16.0±1.0 mm) had significantly shorter 
tibias when compared to WT animals (WT-chow 18.0±0.1 mm and WT-
cholesterol 18.0±0.1 mm) (Figure 6.6B). 
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Figure 6.6. Cardiac hypertrophy: Cardiac mass (mg) (A), tibia Length (mm) 
(B) and cardiovascular hypertrophy (cardiac mass (mg)/average tibia length 
(mm)) (C) in WT-chow (n =10), WT-cholesterol (n =10), KO-chow (n =10) and 
KO-cholesterol (n =13) fed mice. Results are group means ±SE. Two-way 
ANOVA. *P<0.05, ***P<0.001. 
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Longitudinal Vascular Responses 
Endothelium-dependent 
There were no significant differences between the groups at study baseline for 
endothelium-dependent responses (WT-chow 332±7 AU, WT-cholesterol 
334±13 AU, MAPKAP KO-chow 328±12 AU and MAPKAP KO-cholesterol 
333±5 AU) (Figure 6.7A). MAPKAP KO-chow (331±15 AU) and MAPKAP KO-
cholesterol (330±10 AU) fed mice had similar responses to WT-chow (339±8 
AU) at study week 8. WT-cholesterol fed animals had significantly poorer 
responses to ACh at study week 8 when compared to WT-chow fed animals 
(P<0.05) (Figure 6.7A). 
WT-cholesterol fed mice continued to have poorer microvascular responses to 
ACh at study week 12 when compared to WT-chow (P<0.05), KO-chow and 
KO-cholesterol fed animals, but these observations did not meet statistical 
significance (P>0.05) (Figure 6.7A).  Week 20 measurements to ACh were 
significantly better in WT-chow and KO-chow fed mice when compared to WT-
cholesterol fed mice (P<0.01, P<0.05 respectively). KO-cholesterol fed animals 
had greater endothelium-dependent vasodilation at 20 week measurements 
when compared to WT-cholesterol fed mice; however these observations did 
not meet statistical significance (P>0.05) (Figure 6.7A). 
 
Endothelium-independent  
There were no significant differences between vascular responses to 
endothelium-independent vasodilator SNP amongst the groups (WT-chow 
165 
 
354±20 AU, WT-cholesterol 334±10 AU, KO-chow 334±9 AU and KO-
cholesterol 337±15 AU) ((Figure 6.7B) 
Figure 6.7. Longitudinal microvascular responses: (A) Microvascular 
responses in arbitrary units (AU) over 20 weeks to endothelium-dependent ACh 
and (B) week 20 responses to endothelium-independent SNP only in WT-chow 
(n =17), WT-cholesterol (n=12), MAPKAP 2/3 KO-chow (n =11) and MAPKAP 
2/3 KO-cholesterol (n =13) fed animals. Results are group means ±SE. 
Changes were analysed by two-way ANOVA  
**P<0.01 comparing genotypes 
 
#P<0.05, ##P<0.01 comparing diet 
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Effect of NO Inhibition on Endothelium-dependent Responses 
L-NAME administration to MAPKAP 2/3 KO-cholesterol fed mice at 20 weeks 
caused significant attenuation in the peak ACh response compared with the 
response without L-NAME (231±7 AU VS. 319±8 AU, P<0.001) and in WT-chow 
fed mice (242± 21 AU VS. 330±17 AU, P<0.05). 
 
Baseline Cytokines 
There were no significant differences between WT and KO mice for baseline 
inflammatory markers IL-1α (WT 885±76 pg/ml, KO 994±90 pg/ml), IL-6 (WT 
1543±4 pg/ml, KO 1550±8 pg/ml), and IL-10 (WT 218±3 pg/ml, KO 218±3 
pg/ml) (Figure 5.8 A-C). 
 
Figure 6.8. Baseline inflammatory marker: Study baseline plasma cytokines 
(pg/ml) (A) IL-1α, (B) IL-6 and (IL-10) in WT (n =20) and MAPKAP 2/3 KO (n 
=20) mice. Results are group means ±SE. Unpaired Student’s t-test. 
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20 Week Measurement of Plasma Cytokines 
Cholesterol feeding in WT mice significantly increased levels of inflammatory IL-
1α (1707±12 pg/ml) and IL-6 (1994±10 pg/ml) when compared to WT-chow fed 
mice (IL-1α 1075±12 pg/ml (P<0.001), IL-6 1547±7 pg/ml (P<0.001).  
Week 20 measurements of IL-1α levels were significantly greater in WT-
cholesterol fed animals when compared to KO-chow and KO-cholesterol fed 
mice (Figure  6.9A). Levels of IL-6 were significantly higher in WT-cholesterol 
fed mice when compared to other groups (Figure 6.9B). Anti-inflammatory IL-
10 in WT-chow fed mice as similar to KO-chow and KO-cholesterol fed mice 
however WT-cholesterol fed mice had lower 20 week measurements of IL-10 
but this did not reach statistical significance (Figure 6.9C). 
 
Correlations 
Microvascular responses to ACh and localised heating at week 0 showed no 
significant correlations with cholesterol or any of the cytokines markers. In 
contrast, a number of significant correlations were observed at 20 weeks, IL-6 
measurements negative correlated with ACh responses at 20 weeks (r = -0.524, 
P<0.01), cardiac mass (r = 0.495, P<0.01) and measurements of cardiac 
hypertrophy (r = 0.675, P<0.001). ACh response at week 20 also correlated with 
plasma levels of IL-10 (r = 0.517, P<0.01), IL-6 (r = -0.524, P<0.01), LDL/vLDL 
plasma cholesterol (r = -0.22, P<0.01) and measurements of cardiac 
hypertrophy (r = -0.372, P<0.05). 
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Figure 6.9. Week 20 measurements of inflammatory markers: Plasma 
cytokines (pg/ml) (A) IL-1α, (B) Il-6 and (C) IL-10 in WT-chow (n =10), WT-
cholesterol (n =10), MAPKAP 2/3 KO-chow (n =10) and MAPKAP 2/3 KO-
cholesterol fed (n =10) mice. Results are group means ±SE. Two-way ANOVA, 
***P<0.001. 
 
 
Discussion 
The major findings from this study show that MAPKAP 2/3 KO-cholesterol fed 
mice displayed greater endothelium-dependent vasodilatation in vivo over 20 
weeks. Importantly, although vascular responses to ACh were not statistically 
higher in MAPKAP 2/ 3 KO-cholesterol fed mice when compared to WT-
cholesterol fed animals, MAPKAP 2/3-cholesterol fed mice had perseveration of 
NO, unlike WT-cholesterol fed mice as detailed in previous chapters. 
 
WT-cholesterol fed mice displayed numerous dysfunctions when compared to 
other groups. In particular WT-cholesterol fed mice displayed significantly 
blunted endothelium-dependent responses to ACh; however VSMC reactivity 
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was unaffected as endothelium-independent responses  to SNP were similar 
amongst the experimental groups, suggesting localised damaged to the 
endothelium. In previous chapters it has been shown that attenuated 
vasodilatation to ACh in WT-cholesterol fed mice is mediated via reduced NO  
(Belch et al., 2013). L-NAME administration MAPKAP KO-cholesterol fed mice 
significantly blunted ACh mediated vasodilatation, showing that NO was 
preserved in MAPKAP 2/3 KO-cholesterol fed mice after 20 weeks of 
cholesterol feeding. Furthermore L-NAME administration in WT-chow fed mice 
in this study also significantly blunted endothelium-dependent vasodilatation, 
confirming the preservation of NO in these mice over time (with age). 
The activation of MAPKAP 2 has previously been described in the endothelium 
and in macrophage rich regions of aorta taken from LDLr KO mice (Jagavelu et 
al., 2007). Conversely an absence of MAKAP 2 has been reported in VSMCs, 
suggesting an intimate relationship between inflammation, the vascular 
endothelium and MAPKAPs. Double back crossing of MAPKAP 2 KO mice and 
LDLr KO mice has previously shown a significant reduction in lipid accumulation 
in the aorta and reduced macrophage infiltration (up to 50 and 60% 
respectively) (Jagavelu et al., 2007). MAPKAP 2 deficiency has further shown 
reduced foam cell formation in vitro and in vivo, in part this was due to reduced 
expression of scavenger receptor A, reduced aortic expression of VCAM-1 and 
chemokine MCP-1 (Jagavelu et al., 2007).  Whereas Jagavelu et al reported 
that ICAM-1 staining does not significantly differ between LDLr KO and double 
MAPKAP 2/LDLr KO mice. MCP-1 is a chemoattractant protein important in 
macrophage accumulation in tissues (Oh et al., 2012), whereas VCAM-1 
induces firm adhesion of monocytes to the endothelium and is significantly up 
regulated expressed in vascular tissue after cholesterol feeding (Li et al., 1993). 
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Thus an inability to express these molecules in MAPKAP 2/3 KO mice could 
have the potential to suppress vascular inflammation and preserve NO. 
The protective role of MAPKAP 2/3 deficiency on NO in this study of vascular 
dysfunction is thought to be mediated in part by attenuated expression of IL-6 in 
the presence of dyslipidaemia, unlike WT-cholesterol fed animals. Circulating 
levels of IL-6 is a central mediator of the acute phase response and induces the 
production of CRP in hepatocytes, both molecules are established risk factors 
for CVD (Barnes et al., 2011, Hashizume and Mihara 2012, Fernandez-Real et 
al., 2001). 
At 20 weeks MAPKAP 2/3 cholesterol fed mice had reduced plasma levels of 
IL-6 when compared to WT-cholesterol fed mice. Hung et al (2010) has 
previously reported the molecular consequences of IL-6 in the context of eNOS 
signalling. eNOS modulates basal vascular tone through the release of NO, 
inducing relaxation of VSMCs. IL-6 can specifically inhibit the release of NO, by 
increasing the potency (half-life) of calveolin-1. Increased caveolin-1 activity 
reduces eNOS activity by attenuating the eNOS activation pathway, though 
reduced phosphorylation at Ser1177, an established phosphorylation site 
implicated in endothelial dysfunction (Matsumoto et al., 2014) 
There was a significant up regulation of IL-1α in WT-cholesterol fed mice, 
although levels were not significantly lower in MAPKAP 2/3 KO-cholesterol fed 
mice.  IL-1α has been implicated as a marker of endothelial cell senescence 
(Mariotti et al., 2006), senescent endothelial cells have been observed on 
atherosclerotic plaques.  IL-1α has been implicated in early atherosclerotic 
plaque formation through modulation of cell adhesion molecules. The IL-1ra has 
further shown inhibition of early atherosclerotic lesions in ApoE KO mice and 
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has important roles in the efflux of plasma cholesterol (Isoda and Ohsuzu, 2006, 
Isoda et al., 2004)  
Previous reports have shown that MAPKAP 2/3 KO mice do not show 
generalised cardiovascular disease/dysfunction, when compared to WT control 
mice under basal, un-stimulated conditions, as evidenced by no significant 
changes in heart mass (standardised to body weight), no significant increases 
in cardio myocyte cell volume or length and no significant elevation in protein 
expression markers of pathological hypertrophy such as atrial natriuretic factor 
peptide (ANP) and brain natriuretic peptide (BNP) (Scharf et al., 2013, Kong et 
al., 2005). MAPKAP 2/3 KO-cholesterol fed mice displayed a near significant 
protection against cholesterol induced cardiac hypertrophy and lower cardiac 
mass, whereas WT-cholesterol fed mice had greater cardiac mass and a 
greater standardised measurements of cardiac hypertrophy. These results show 
that MAPKAP 2/3 promote cardiac hypertrophy potentially through the release 
of cytokines such as IL-6. 
Dietary cholesterol induced significant dyslipidaemia in both WT and KO mice in 
this study. In agreement with previous reports there were no significant 
differences between HDL levels in MAPKAP 2/3 KO and WT mice on either diet 
(Jagavelu et al., 2007). However, previous reports have detailed significant 
increases in apoB lipoproteins, a sub class of LDL associated with CVD 
(Contois et al., 2009). Jagavelu et al described MAPKAP 2 deficient mice on an 
LDLr KO background in contrast to MAPKAP 2/ 3 KO (C57BL/6) mice used in 
this study. The current study did not find significant differences for LDL/vLDL 
plasma cholesterol between WT and KO mice fed cholesterol. The reason 
behind the differences observed between these two studies remains unknown; 
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it is possible that the double KO described by Jagavelu et al is more susceptible 
to lipid accumulation. One potential mechanism for this observed difference 
could be cholesterol efflux. LDLr KO mice display elevated LDL plasma 
cholesterol due to defective plasma clearance, whereas the MAPKAP 2/3 KO 
mice used in this study should have no endogenous depletion in this lipid 
receptor and thus dietary cholesterol is cleared by efflux, under normal 
homeostatic control 
Previous reports have not found significant differences in body weights between 
WT and MAPKAP 2/3 KO mice, however in this study, MAPKAP 2/3 KO mice 
showed significantly lower baseline and terminal body weights (chow and 
cholesterol fed) when compared to WT mice. The reason behind these 
differences remains unknown. The significant differences in size between 
MAPKAP 2/3 and WT mice were further confirmed by measurement of tibia 
lengths. It is possible that the repeated inbred backcrossing of the MAPKAP 2/3 
KO mice is one reason for the observed differences. 
In conclusion MAPKAP 2/3 are important signalling molecules in cytokine 
synthesis and deficiency preserves NO in mice fed dietary cholesterol in vivo. 
Targeting the MAPKAP 2/3 pathway, with agents that block their action might 
provide a useful therapeutic option for inhibiting inflammation induced 
endothelial dysfunction and CVD. 
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Chapter 7 
An Important Role for ABIN1 in Inflammation-Mediated Endothelial 
Dysfunction 
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Introduction 
Previous chapters have detailed studies where the role of sub-clinical 
inflammation resulted in endothelial dysfunction through MAPK activation and 
explored how this can be abrogated through truncation of innate immune 
pathways. As discussed in the Introduction (NF-ĸB Regulation in Inflammation), 
TLR activation can also activate NF-κB, inducing nuclear translocation and 
gene expression. The A20-binding inhibitors of NF-κB (ABINs1-3) are 
suppressors of inflammation (Figure 1.9).  Recent work suggests that ABIN1 
restricts the activation of the canonical IKK complex and MAP kinases by 
binding to Lys63-linked and linear ubiquitin chains (Nanda et al., 2011). The 
ABIN1[D485N] knock-in mouse shows significant expansion of myeloid cells in 
various organs, but the role of this mutation in CVD has not been reported. 
 
Aim 
To determine the role of ABIN1 in the development of endothelial dysfunction 
through assessment of microvascular responses in ABIN1[D485N] mutant 
defective mice. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
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Animals 
The ABIN1[D485N] mice were originally described on a 129SvJxC57B/6 
background (Nanda et al., 2011). Animals were subsequently backcrossed on a 
C57BL/6 background for at least 8 generations.  Group allocations were 
randomly assigned as follows: WT control mice fed normal rodent chow, WT 
mice on a specifically tailored pro-atherogenic diet, ABIN1[D485N] mice on 
rodent chow and a pro-atherogenic diet.  
 
Vascular Responses 
Endothelium-dependent and endothelium-independent responses, maximum 
vasodilator response to localised skin heating were measured at study baseline 
(week 0) and 4 weeks later. Skin perfusion in the present study is expressed in 
AU ±SE and calculated using propriety software (MoorLDI software, version 
5.2) as a percentage (%) change over baseline. ABIN1[D485N] mice displayed 
elevated skin perfusion compared to WT matched littermate controls, and it was 
necessary to normalise baseline perfusion to assess vascular differences 
between ABIN1[D485N] mice and WT mice. 
 
Plasma Cholesterol 
Plasma was used to quantify HDL and LDL/vLDL fractions at study week 4 only. 
 
Cytokine Expression 
Plasma was analysed at study baseline and 4 weeks. 
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Cardiac Hypertrophy 
In cholesterol fed animals only, cardiac hypertrophy was assessed at study 
week 4. 
 
Spleen Weight 
In cholesterol fed animals only spleen mass was assessed at study week 4. 
 
Results 
Baseline Weight  
WT animals were significantly heavier (24g±1) than ABIN1[D485N] mice 
(23g±1) at study week 0 (P<0.01) (12 weeks of age) (Figure 7.1). The mean 
group difference was 2g.  
 
Figure 7.1. Baseline body weight: Body weights (12 weeks of age) in WT 
(n=18) and ABIN1[D485N]  (n =15) mice. Differences between the groups were 
tested by unpaired Student’s t-test. Results are group means in grams (g) ±SE.  
**P<0.01.  
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4 Week Measurements of Body Weight 
WT animals significantly increased in weight during the study (4 weeks 26±1 g) 
(P<0.001) as did ABIN1[D485N]  (4 weeks 25±1 g) (P<0.001) mice. Cholesterol 
feeding in WT mice (27±1 g) did not significantly alter terminal body weight 
compared with WT-chow fed mice (27±1g) (Figure 7.2).  At the study end point 
(4 weeks) there were no significant differences in body weights for 
ABIN1[D485N]-chow (27±1 g) and ABIN1[D485N]-cholesterol fed mice (25±1 g) 
(Figure 7.2). 
 
 
Figure 7.2. 4 Week measurements of body weight: Body weights (study 
week 4) in WT-chow (n =15), WT-cholesterol (n =14), ABIN1[D485N]-chow 
(n=12) and ABIN1[D485N]-cholesterol (n =14) fed mice. Two-way ANOVA. 
Results are group means in grams (g) ±SE.   
 
Baseline Cytokines  
Significant differences for baseline inflammatory markers were found between 
WT and ABIN1[D485N] animals. IL-1α was significantly greater in 
ABIN1[D485N] mice (WT 1376±42 pg/ml VS. ABIN1[D485N] 1658±66 pg/ml, 
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P<0.01) as was anti-inflammatory IL-10 (WT 213±10 pg/ml VS. ABIN1[D485N] 
335±27 pg/ml, P<0.001) (Figure 7.3 A/B respectively). Whilst levels of IL-6 (WT 
1325±74 pg/ml VS. ABIN1[D485N] 1684±267 pg/ml) were not significantly 
different (P>0.05) (Figure 7.3 C). 
 
 
Figure 7.3. Baseline inflammatory markers: Baseline (12 weeks of age) 
plasma cytokines (pg/ml) for (A) IL-1α (B) IL-6 and (C) IL-10 in WT (n =10) and 
ABIN1[D485N] (n =9) mice. Differences were tested by unpaired Student’s t-
test. Results are group means ±SE. **P<0.01, ***P<0.01 
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Baseline Vascular Responses 
Baseline (study week 0) vascular responses were not significantly different 
between WT and ABIN1[D485N] animals for endothelium-dependent responses 
or maximal dilator capacity (Ach: WT 21±3 % change ABIN1[D485N]  24±4 % 
change P>0.05; maximal dilator capacity: WT 86±7 % change ABIN1[D485N] 
92±7 % change, P>0.05) (Figure 8.3 A/B respectively). 
 
Figure 7.4. Baseline vascular function: Baseline microvascular responses in 
WT and ABIN1[D485N] animals: (A) endothelium-dependent responses (WT n 
=14, ABIN1[D485N] n =10) and (B) maximal dilator capacity (WT n =17, 
ABIN1[D485N] n =15). Unpaired Student’s t-test. Results are group means ±SE 
(% change).  
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Plasma Cholesterol 
LDL/vLDL 
WT-cholesterol fed (9±1 mg/dl) mice had significantly greater LDL/vLDL at 4 
week measurements when compared to WT-chow (5±1 mg/dl) (P<0.05). 
ABIN1[D485N]-chow fed animals had similar levels of LDL/vLDL when 
compared to WT-chow fed mice (5±1 mg/dl) (Figure 7.5A). There was no 
significant difference in LDL/vLDL in ABIN1[D485N]-cholesterol fed mice (5±1 
mg/dl) when compared to WT-chow and ABIN1[D485N]-chow animals (Figure 
7.5A). However levels of LDL/vLDL were higher in WT-cholesterol fed mice 
when compared to ABIN1[D485N]-chow (P<0.01) and ABIN1[D485N]-
cholesterol (P<0.01). 
 
HDL 
WT-chow (21±2 mg/dl) fed animals had significantly greater HDL in 4 week 
measurements of plasma when compared to ABIN1[D485N]-chow (2±1 mg/dl, 
P<0.001) and ABIN1[D485N]-cholesterol (2±1 mg/dl, P<0.001) fed mice (Figure 
7.5B). There were no significant differences between WT-cholesterol (16±1 
mg/dl) mice for plasma HDL when compared to WT-chow fed animals 
(Figure7.5B). 
Levels of HDL were not significantly different between ABIN1[D485N]-chow and 
ABIN1[D485N]-cholesterol fed mice. HDL levels were significantly greater in 
WT-cholesterol mice when compared to ABIN1[D485N]-chow (P<0.001) and 
ABIN1[D485N]-cholesterol (P<0.001) animals (Figure 7.5B).  
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Figure 7.5. Plasma cholesterol: Study week 4, low density lipoproteins and 
very low density lipoproteins (LDL/vLDL) (A) and high density lipoproteins (HDL) 
(B) plasma WT-chow (n =8), WT-cholesterol (n =6), ABIN1[D485N]-chow (n =9) 
and ABIN1[D485N]-cholesterol fed mice (n =9). Results are group means (mg/dl 
±SE). Two-way ANOVA, **P<0.01, **P<0.001 
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4 Weeks Measurements of Cytokines 
Levels of IL-1α (4 weeks1457±49 pg/ml), IL-6 (4 weeks1533±10 pg/ml) and IL-
10 (4 weeks 222±9 pg/ml) did not significantly change in WT-chow fed animal’s 
over time, when compared to baseline values showing that WT-chow fed mice 
do not show age-related alterations, that  would otherwise be associated with 
increased CVD risk. 
Cholesterol feeding in WT mice caused adverse changes in inflammatory 
markers when compared to baseline values. There was a significant increase in 
IL-1α (4 weeks 16591±10, P<0.001) and IL-6 (4 weeks 1726±48, P<0.01). 
Cholesterol feeding in WT mice for 4 weeks did not significantly reduce levels of 
anti-inflammatory IL-10 (4 weeks 230±11, P>0.05) (Figure 7.6A-C). 
Levels of IL-1α did not significantly increase further at 4 week measurements in 
ABIN1[D485N]-chow (1704±22 pg/ml) fed mice. However IL-1α remained 
significantly greater in ABIN1[D485N]-chow fed mice when compared to WT-
chow fed animal (P<0.001) at study end point. Cholesterol feeding in 
ABIN1[D485N] mice did not result in a further significant increase in IL-1α 
(1672±8 pg/ml). Baseline and 4 week measurements of IL-1α in ABIN1[D485N] 
(on either diet) animals were similar to 4 weeks measurements obtained from 
WT-cholesterol fed mice (Figure 7.6A). 
ABIN1[D485N]-chow fed animals displayed a significant increase in IL-6 (4 
week 1739±21, P<0.001) in study end point measurements, a significant 
increase over time. This was similar to levels observed in WT-cholesterol fed 
animals.  Levels of IL-6 significantly increased further in ABIN1[D485N]-
cholesterol mice (1998±111 pg/ml), this was statistically greater than WT-chow 
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(P<0.001), ABIN1[D485N]-chow (P<0.01) and a near significant difference for 
WT-cholesterol fed mice (P>0.05) (Figure 7.6B). 
4 weeks measurements of levels of IL-10 did not significantly change in 
ABIN1[D485N]-chow fed mice (414 57 pg/ml) when compared to baseline 
values. However IL-10 levels remained significantly greater in ABIN1[D485N]-
chow animals when compared to WT-chow (P <0.01) and WT-cholesterol 
(P<0.05) fed (242±15 pg/ml) mice. (Figure 7.6C). Cholesterol feeding in 
ABIN1[D485N] mice (459±61 pg/ml) did not have significantly alter plasma IL-10 
when compared to ABIN1[D485N]-chow animals (P>0.05). IL-10 levels in 
ABIN1[D485N]-cholesterol mice were significantly greater than WT-chow 
(P<0.01), WT-cholesterol (P<0.05) but not ABIN1[D485N]-chow (P>0.05). 
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Figure 7.6. 4 week measurement of inflammatory markers: WT-chow (n 
=10), WT-cholesterol (n =7), ABIN1[D485N]-chow (n =10) and ABIN1[D485N]-
cholesterol (n =10) fed animals for (A) IL-1α, (B) IL-6 and (C) IL-10. Results are 
group means (pg/ml ±SE). Two-way ANOVA. *P<0.05, **P<0.01, ***P<0.001. 
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Vascular Responses  
Endothelium-dependent 
WT animals on standard rodent chow diet did not show any significant changes 
in ACh mediated vasodilatation over the study duration (baseline 20±3 % 
change vs. 4 weeks 22±4 % change, P>0.05). WT mice fed cholesterol for four 
weeks have poorer ACh mediated microvascular responses when compared to 
baseline values (9±2 % change, P<0.05) and WT age matched mice on 
standard rodent chow (P<0.01). 
Endothelium-dependent responses in ABIN1[D485N] animals fed chow (9±2 % 
change) were significantly attenuated when compared to values obtained at 
baseline (study week 0) (P<0.01). These were significantly lower than WT mice 
on the same diet (P<0.05) at 4 week measurements, but were similar in 
magnitude to those observed in WT cholesterol fed mice (P>0.05) (Figure 8.7). 
Cholesterol feeding in ABIN1[D485N] mice further attenuated ACh 
microvascular vasodilatation (0.03±0.03% change) when compared to 
ABIN1[D485N]-chow fed animals (P<0.001). Responses to ACh were 
significantly poorer in ABIN1[D485N]-cholesterol fed animals when compared to 
WT chow (P<0.001) and WT-cholesterol (P<0.001) fed mice (Figure 7.6).  
 
 
 
 
 
 
 
 
187 
 
 
 
Figure 7.6. Study end point vascular function: Microvascular responses to 
(A) endothelium-dependent acetylcholine and (B) endothelium-independent 
sodium nitroprusside in WT chow (n =11), WT cholesterol (n =11), 
ABIN1[D485N]-chow (n =10) and ABIN1[D485N]-cholesterol (n =10) fed mice. 
Results are group means (% change ±SE). Two-way ANOVA. **P<0.01, 
***P<0.001. 
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Endothelium-independent  
Endothelium-independent responses were not significantly different between 
the groups (WT-chow 23±3 % change, WT-cholesterol 22±9 % change, 
ABIN1[D485N]-chow 24±5 % change, ABIN1[D485N]-cholesterol 23±2 % 
change, P>0.05 for all comparisons) (Figure 7.6B). 
 
Cardiac hypertrophy 
In cholesterol fed animals cardiac mass was not significantly different between 
the groups (WT 127±4 mg VS. ABIN1[D485N] 147±13 mg mice (P>0.05) 
Figure 7.7A.  
There were no significant differences in the length of tibias between WT 
(18±1mm) and ABIN1[D485N] (18±2mm) mice (P>0.05) Figure 7.7B. 
ABIN1[D485N] mice had a significantly greater cardiac hypertrophy 
measurement when compared to WT mice (WT 7.1±0.2 VS. ABIN1[D485N] 
8.2±0.7 P<0.05) (Figure 7.7C) 
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Figure 7.7. Cardiac hypertrophy: Cardiac hypertrophy measurement in WT (n 
=14) and ABIN1[D485N] mice (n =13) cholesterol fed mice: (A) cardiac mass 
(mg), (B) tibia length (mm) and (C) cardiac mass (mg)/tibia length (mm). Data 
are group means ±SE. Unpaired Student’s t-test. *P<0.05 
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Spleen Weight 
Splenic mass in cholesterol fed ABIN1[D485N] mice (460±20 mg)  was greater 
when compared to WT-cholesterol fed animals (104±30 mg) (P<0.001) (Figure 
7.8). 
 
Figure 7.8. Spleen weight: WT (n =6) and ABIN1[D485N] (n =7) cholesterol 
fed animals. Results are group means Milligrams (mg ±SE). Student’s t-test. 
***P<0.0001 
 
 
Correlations 
Several significant associations were found at 4 week measurements to ACh 
responses, these negatively correlated with spleen mass (r= -0.722, P<0.05) 
and 4 week measurements of plasma cytokines for IL-1α (-.0764, P<0.01).  
HDL negatively correlated with IL-1α (r= -0.501, P<0.01) and IL-6 (r= -0.558, 
P<0.001). 
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Discussion  
The main finding from this study is the onset of early CVD (endothelial 
dysfunction) in the polyubiquitin-binding-defective ABIN1[D485N] mice, a 
phenotype that is further exacerbated by cholesterol feeding. There were no 
significant differences in endothelium-independent responses, suggesting that 
VSMC activity was not compromised and indicates localised damage to the 
endothelium. Furthermore this study shows a significant reduction in plasma 
HDL of ABIN1[D485N] mice, an established risk factor for CVD. 
 
It has previously been reported that ABIN1[D485N] mice have enhanced IKK 
and MAPK activity in B-cells, bone marrow derived macrophages and dendritic 
cells and display significant expansion of myeloid cells in spleen and lymph 
nodes (Nanda et al., 2011). Consequently, these mice bear a SLE-like 
phenotype as early as 3-4 months of age. Endothelial dysfunction is an early 
event in the development of CVD and this study shows it is present in 
ABIN1[D485N] mice at 4 months of age. Endothelial dysfunction was further 
exacerbated by dietary cholesterol showing elevated dysfunction when risk 
factors are combined (chronic inflammation and cholesterol). 
 
Selective inhibition of NF-κB in endothelial cells has been shown to be 
protective against atherosclerotic lesion formation in CVD prone ApoE KO mice 
(Gareus et al., 2008). This data supports the notion that increase IKK activity, 
and hence increased NF-ĸB activation, has significant negative effects on the 
cardiovascular system. The activation of TLRs, in particular TLR-2 and TLR-4, 
is associated with atherogenesis whereas blockade of this signalling, achieved 
by amelioration of the MyD88, has shown atheroprotection (Bjorkbacka et al., 
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2004). Similarly the SLE phenotype of the ABIN1[D485N] mice is abrogated 
when they are expressed on a MyD88-deficient background (Nanda et al., 
2011), indicative of overlap in the signalling pathways involved in the 
development of  SLE and CVD. 
 
There was a significant increase in IL-1α in plasma of ABIN1[D485N] mice at 
the study baseline, although there was no apparent difference in vascular 
responses between the two groups, suggesting that the relative differences and 
duration of change was not sufficient to impact on vascular function at this time 
point. The differences in inflammatory markers between ABIN1[D485N] and WT 
mice are presumably mediated by the hyperactivation of NF-ĸB and MAPKs. 
Commensal gut flora can activate TLRs and stimulate NF-ĸB (Rakoff-Nahoum 
and Medzhitov, 2008, Rakoff-Nahoum et al., 2004) predisposing to chronic 
inflammation in ABIN1[D485N] mice.  
 
The exact mechanism responsible for the onset of endothelial dysfunction in 
ABIN1[D485N] mice requires further investigation; however this may be 
mediated by IL-6. There was a significant increase in IL-6 over time in 
ABIN1[D485N] mice, and this was further exacerbated by cholesterol feeding in 
ABIN1[D485N] mice, which displayed the poorest endothelium-dependent 
responses. IL-6 is an established cardiovascular risk factor (Ridker et al., 
2000b, Naya et al., 2007). Levels of IL-6 in WT-cholesterol mice at the end-
point were similar to those observed in ABIN1[D485N]-chow mice, even though 
the latter group was not exposed to a major cardiovascular risk factor 
(cholesterol). A negative association between vascular responses and plasma 
levels of IL-6 has been described previously (Esteve et al., 2007). Taken 
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together these data suggest that the mutation in ABIN1[D485N] mice 
predisposes to CVD in part via increasing levels of IL-6. 
 
As previously discussed IL-6 can inhibit activation of eNOS and attenuate 
vasodilation by increasing the half-life of caveolin-1, resulting in more eNOS 
binding and reducing NO.  A loss in NO is associated with diseases such as 
hypertension (Moss et al., 2004) and is regarded as an early phase of 
atherosclerotic plaque formation (Hadi et al., 2005).  
 
In previous chapters it has been established and reported in the literature that 
skin microvascular responses to ACh are mediated through the NO and that this 
is diminished by cholesterol feeding in WT mice (Belch et al., 2013). The loss of 
NO in the peripheral skin microcirculation increases total peripheral resistance. 
Reduced lumen diameter through attenuated vasodilatation (diminished NO) 
can lead to development of left ventricular hypertrophy, an adaptive response to 
increased cardiac load (greater force is needed to pulsate blood through narrow 
arteries). This adaptation is essential for survival, and inhibition of cardiac 
hypertrophy in mice shows increased mortality through pressure overload and 
heart failure (Dickhout and Austin, 2006). Thus cardiac hypertrophy in 
ABIN1[D485N]-cholesterol fed mice may be an adaptive response to diminished 
peripheral microvascular function. 
 
It is important to note that under pathophysiological conditions cytokines are 
released from numerous cell types, including activated endothelial cells. 
Stimulated endothelial cells express IL-1α which is also associated with CVD 
(Isoda et al., 2003). This cytokine can contribute to atherosclerosis through the 
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expression of cell adhesion molecules (VCAM-1 and ICAM-1).  Adhesion 
molecules are needed for the tethering of macrophages to the endothelial lining, 
for subsequent transmigration into the sub-endothelial space, an early phase in 
atherosclerotic plaque formation. 
 
Surprisingly, plasma levels of the anti-inflammatory IL-10 were significantly 
greater in ABIN1[D485N] mice, an unreported finding. The exact mechanism 
and role of this remains unknown, however the higher levels of IL-10 may be a 
counter mechanism in ABIN1[D485N] mice in an attempt to attenuate pro-
inflammatory responses in an autocrine loop. IL-10 can be synthesised by 
macrophages and attenuates pro-inflammatory cytokine expression through a 
JAK/STAT3 pathway (Pattison et al., 2012). Forsberg et al (Forsberg et al., 
2007) have previously reported similar findings, showing increased levels of IL-
10 in intra-epithelial lymphocytes in the context of coeliac disease. The ability to 
maintain these elevated levels of IL-10 are of particular interest and it needs to 
be established whether they can be sustained over a longer period of time (with 
greater age), and to establish whether ablation or sequestering of endogenous 
IL-10 in ABIN1[DN485] mice would further exacerbate the observed pathology 
in this and previous studies. 
 
IL-10 levels are anti-atherogenic, facilitating the uptake and efflux of cholesterol, 
which in turn is associated with reduced cell death and progression of 
atherosclerotic lesions (Han et al., 2010). This may in part explain why 
ABIN1[D485N]-cholesterol fed mice, despite being fed dietary cholesterol for 4 
weeks, did not display elevated LDL/vLDL unlike WT-cholesterol fed mice. 
Pinderski et al (Pinderski Oslund et al., 1999) have previously reported a lower 
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plasma cholesterol level in animals over expressing IL-10 compared with both 
C57BL/6 WT mice and homozygous IL-10 null animals fed cholesterol, although 
these observations were not statistically significant.  In healthy individuals the 
efflux of cholesterol from the arterial intima is modulated by HDL and prevents 
lipid oxidation. Thus despite profound reductions in HDL ABIN1[D485N] mice 
may be able to efflux LDL/vLDL cholesterol through an IL-10-dependent 
mechanism to prevent significant accumulation in the blood stream. The 
mechanism behind the low plasma levels of HDL in ABIN1[D485N] remains 
unknown and requires further study. 
 
This study aimed to establish a role for a mutation in ABIN1 in inflammatory-
induced CVD development through assessment of endothelial function and 
measurement of systemic cytokine expression.  Understanding the 
pathophysiological mechanisms and pathways responsible for early 
development of CVD in ABIN1[D485N] mice has potentially important clinical 
implications. The induction of chronic inflammation, endothelial dysfunction and 
cardiac hypertrophy by a single protein malformation highlights the need for 
selective therapeutic targets of inflammation to limit multi-organ disease, and 
the ABIN1 pathway might be one potential therapeutic target. Importantly, using 
a similar experimental approach in humans, previous studies have shown that 
RA patients have attenuated endothelium-dependent responses in the skin 
microcirculation, and that the degree of attenuation is related to the expression 
of systemic inflammatory cytokines(Galarraga et al., 2008), findings that are 
similar to those in the present study. Since endothelium-dependent responses 
in the microcirculation of the skin are indicative of defective coronary function 
(Khan et al., 2008) and future cardiovascular sequelae before clinical 
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presentation (Khan et al., 2005), data from the present study point to a 
potentially important role for ABIN1 in the development and progression of 
inflammation-induced CVD. The findings in this study are in agreement with 
irregularities in the NF-ĸB pathway that have previously been implicated for the 
onset of CVD. 
 
In conclusion, this is the first in vivo observation to document the early 
development of CVD (endothelial dysfunction) as a result of a single protein 
mutation involved in NF-ĸB signalling, relevant to previously reported clinical 
genome wide association studies for SLE. The data suggest that ABIN1 
dysfunction could be mechanistically involved in the early development of 
inflammation-induced CVD risk. 
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Chapter 8 
Can Vitamin D Supplementation Reduce Inflammation and Improve 
Endothelial Function? 
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Introduction 
There remains a need for better therapies targeted at reducing inflammatory 
mediated CVD burden. Synthetic molecules require vigorous pre-clinical and 
clinical testing as demonstrated by the MAPK p38 inhibitor SB-203580 to 
ensure safety (Lee et al., 2000). Therefore favourability is given to endogenous 
molecules that are present within physiological systems.  Vitamin D is most 
often associated with bone metabolism; recent findings have shown vitamin D 
deficiency is associated with a number of chronic inflammatory disease 
conditions including RA (Kostoglou-Athanassiou et al., 2012)  and 
atherosclerosis (Kassi et al., 2013). However, causality has been more difficult 
to prove. The role of vitamin D as an anti-inflammatory agent for the treatment 
of inflammatory disease conditions has previously been discussed in range of 
disease conditions including CVD (Holick and Chen, 2008, Ku et al., 2013, 
Lavie et al., 2011, Mangge et al., 2013). It is estimated that 25-50% of the world 
population are deficient in vitamin D. 
Vitamin D is a biologically active steroid, and vitamin D receptors (VDRs) are 
widely expressed; importantly they are found on all cells associated with 
atherosclerotic lesions including endothelial cells, VSMCs and immune cells, 
extending the physiological roles of vitamin D beyond regulation of Ca2+ and 
phosphorus in the metabolism of bone.  
Vitamin D broadly refers to a number of biologically active compounds. Vitamin 
D3 is produced when light is absorbed through the skin (UV-B, 290-315nm) by 
the precursor 7-dehydrocholesterol (Figure 8.1). Ergocalciferol (vitamin D2) is 
found in plants and is ingested through supplementation either as a tablet or in 
enriched dairy products. Both D2 and D3 are hydroxylated in the liver by the 
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enzyme 25-hydroxylase yielding the circulating form 25-hydroxy vitamin D 
(25(OH)D) (Figure 8.1). 25(OH)D is biologically inactive and requires further 
hydroxylation in the kidneys forming the compound 1,25-dihydroxy vitamin D 
(Calcitriol) through enzymatic action of 1-α-hydroxylase (Figure 8.1). 
 
Figure 8.1. Vitamin D metabolism: Sun exposure of ultra violet (UV) B light 
produces 25-hydroxy vitamin D that undergoes hydroxylation in the liver and 
then in the kidneys, before being released into the systemic circulation as  
biologically active 1, 25hydroxy vitamin D (Calcitriol). 
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Although biologically potent, under clinical screens Calcitriol is not measured 
and levels of 25(OH)D are recorded, there is no general consensus on absolute  
levels of vitamin D in healthy individuals, but levels below 20-30 ng/ml are 
regarded as vitamin D deficient (VDD) (Ku et al., 2013). The major contribution 
to VDD is attributed to the lack of sun light exposure, UV-B light is readily 
absorbed by melanin in the skin, thus individuals of South Asian and African 
descent are commonly VDD (Darling et al., 2013). Vitamin D is highly fat 
soluble, therefore a deficiency of vitamin D is also associated with obesity and 
has been correlated with decreased insulin sensitivity, two existing risk factors 
for CVD (Grineva et al., 2013).  
Vitamin D supplementation has shown to exert reduction in blood pressure 
through modulation of the renin angiotensin system, reinstating vitamin D as a 
therapeutic agent for CVD, suggesting vitamin D supplementation and 
potentially even treatment with systemic analogues of vitamin D maybe cardio-
protective. Whereas VDD induces left ventricular hypertrophy and proliferation 
of VSMCs (Lavie et al., 2011), events proceeding endothelial dysfunction. Some 
clinical trials have shown favourable results with vitamin D treatment improving 
endothelial function in patients (Sugden et al., 2008, Borges et al., 1999). 
Recent studies have conversely produced apparently conflicting results.  The 
role of vitamin D in cardiac failure, myocardial infarction and stroke is showing 
either no association or only a weak beneficial effect dependent on age (Ford et 
al., 2014). Studies have also reported no clear relationship between vitamin D 
levels when comparing healthy volunteers to SLE patients for subclinical 
atherosclerotic burden (Jung et al., 2014) and in some cases studies have 
shown increased early atherosclerotic burden (greater intima-media thickness) 
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with elevated levels of plasma vitamin D (van Dijk et al., 2014). Furthermore 
there have been reports of no association between plasma levels of vitamin D 
and risk of thromboembolism (van Dijk et al., 2014, Folsom et al., 2014). 
Although limitations are widely discussed the underlying cause for these 
disparities remains unknown. 
In the context of inflammation the exposure of sunlight in the treatment of 
microbial infections such as tuberculosis has shown favourable results by 
abrogating pathology, the likely mechanism is thought to be macrophage TLRs 
and increased expression of vitamin D 1-α-hydroxylase genes, increasing 
systemic levels of the biologically active Calcitriol (Liu et al., 2006). 
Calcitriol can bind to VDRs and stimulate transcription to modulate gene 
expression of the antimicrobial agent cathelicidin (Yin and Agrawal, 2014). The 
VDR has a hormone and DNA-binding domain that can interact with the 
retinoid-X receptor forming a heterodimer, activating gene transcription. Studies 
have previously shown that macrophage TLR expression is reduced in the 
presence of VDD and this results in an inflammatory phenotype through the 
expression of pro-inflammatory cytokines TNF-α and IL-6 in healthy human 
patients (Ojaimi et al., 2013). Nonetheless conflicting data has been reported in 
an inflammatory disease cohort with the down regulation of mRNA for TLR2/4 
after vitamin D dosing (Do et al., 2008). The reason for the apparent differences 
between these two studies remains unknown and further studies in vivo are 
needed to fully elucidate the potential benefits of vitamin D supplementation in 
health and in CVD. 
Animal models of CVD and Calcitriol or paracalcitriol (synthetic VDR activator) 
supplementation have shown favourable results with improved cardiac function 
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(Artaza et al., 2011, Mancuso et al., 2008, Bodyak et al., 2007). However 
specific pathway studies have not been designed to explore the role of Calcitriol 
supplementation in an in vivo animal model relevant to inflammation. Vitamin D 
has shown to inhibit stress kinases p38, JNK and reduce TNF-α production in 
keratinocytes (Ravid et al., 2002). Such anti-inflammatory effects support a role 
for vitamin D in the treatment of dermatological disorders. As previously 
discussed in the Introduction (Mitogen Activated Protein Kinases) DUSP-1 can 
deactivate MAPK p38 attenuating pro-inflammatory responses. MSK 1/ 2 KO 
mice have an endogenous depletion in DUSP-1 giving one explanation for the 
hyper-inflammatory responses observed in MSK 1/ 2 KO mice and a potential 
mediator for the onset of microvascular dysfunction in these mice. Calcitriol has 
previously shown to increase the expression of DUSP-1 in bone marrow derived 
macrophages, thus attenuating MAPK p38 activation (Zhang et al., 2012). This 
study also showed an anti-inflammatory effect of Calcitriol treatment in the 
reduction and the release of pro-inflammatory cytokines TNF-α and IL-6. 
Evidencing the anti-inflammatory properties of Calcitriol on the innate immune 
system. Calcitriol has also shown to up regulate the production of anti-
inflammatory molecule IL-10 (Heine et al., 2008) another deficiency in MSK 1/ 2 
KO mice when compared to WT controls. The MSK 1/ 2 KO mouse model might 
therefore be suitable for the study of vitamin D in CVD, through assessment of 
endothelial function and systemic inflammation.  MSK 1/ 2 KO mice display 
endogenous depletions in IL-10 and DUSP-1, described targets for Calcitriol. 
Furthermore MSK 1/ 2 KO mice display endothelial dysfunction and systemic 
inflammation, both which have been shown by others (Sugden et al., 2008, 
Borges et al., 1999) to be attenuated by vitamin D dosing. 
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Aim 
To better understand the role of vitamin D supplementation in inflammatory 
prone MSK 1/ 2 KO-cholesterol fed mice in vascular function, blood pressure 
and systemic cytokine expression. 
 
Methods 
The methods description below is intended to provide an overview of 
experimental techniques used in this study. Further experimental details are 
described in Materials and Methods Pages 62-92. 
 
Animals 
Animals from the breeding strain MSK 1/ 2 were randomly allocated into two 
groups both were fed a pro-atherogenic diet. 
 
Pharmacological Intervention  
Standardised samples containing 200 ng Calcitriol (Cambridge Bioscience, UK) 
/250µL 0.5% carboxy meythcellulose were prepared and stored at -20oC until 
used. This concentration has been used previously in an animal model of CVD 
(Takeda et al., 2010). Animals were gavaged twice weekly for the study 
duration (16 weeks) using a steel needle and a 1ml syringe. 0.5% carboxy 
meythcellulose was used as a vehicle control and administered to the control 
group. 
 
Body Weight 
Animals were weighed at study baseline and 16 weeks. 
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Longitudinal Assessment of Vascular Function 
In vivo assessment of endothelium-dependent and endothelium-independent 
responses were assessed at study end point only (16 weeks) due to equipment 
availability. 
 
Spleen Mass 
Spleen mass was assessed at 16 weeks. 
 
Cardiac Hypertrophy 
Cardiac hypertrophy was assessed post mortem at 16 weeks. 
 
Plasma Cholesterol 
Measurements for LDL/vLDL and HDL were made at 16 weeks only. 
 
Cytokine Expression 
Measurements were made at study baseline and 16 weeks. 
 
Blood Pressure 
Blood pressure parameters (systolic, diastolic and mean arterial blood pressure 
and heart rate) were assessed in vivo at 16 weeks, due to equipment availability 
blood pressure was not assessed in previous studies and was only used for 16 
week measurements in this study. 
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Results 
Body Weights 
MSK 1/ 2 KO mice in Calcitriol and vehicle treated groups had similar baseline 
(vehicle 27±1g VS. Calcitriol 28±1g, P>0.05) (Figure 8.2A) and 16 week 
measurements for body weights (Figure 8.2B) (vehicle 28±1g VS. Calcitriol 
28±1g, P>0.05). 
 
Figure 8.2. Body weights: Baseline (week 0) (A) and end point  (16 weeks) (B) 
body weights in grams (g) in MSK 1/ 2 KO-cholesterol fed mice treated with 
vehicle (n =12) and Calcitriol (n =12). Results are group means ±SE. Unpaired 
Student’s t-test. 
 
Cardiac Hypertrophy 
Calcitriol supplemented mice had significantly less cardiac mass (142±4 mg) 
when compared to vehicle treated animals (151±3 mg) (P<0.05) (Figure 8.3A).  
There were no significant differences between tibia lengths between the groups 
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(vehicle 18.0±0.2mm vs Calcitriol 18.0±0.1mm, P>0.05) (Figure 8.3B). Calcitriol 
treated mice had a significantly lower cardiovascular hypertrophy measurement 
(7.8±0.2) when compared to vehicle treated mice (8.9±0.1, P<0.05) (Figure 
8.3C). 
 
Figure 8.3. Cardiac hypertrophy: (A) cardiac mass (mg) (B) average tibia 
length (mm) and (C) cardiac hypertrophy  (cardiac mass (mg)/ average tibia 
length (mm) in MSK 1/ 2 KO-cholesterol fed mice treated with vehicle (n =12) or 
Calcitriol (n =11). Results are group means ±SE. Unpaired Student’s t-test 
 
Spleen mass 
Calcitriol treated mice had lighter spleens (117±8 mg) when compared to 
vehicle treated animals (133±8 mg) however these observations did not meet 
statistical significance (P >0.05) (Figure 8.4). 
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Figure 8.4. Spleen mass: Spleen weight (mg) at 16 weeks in MSK 1/ 2 KO-
cholesterol fed mice treated with vehicle (n =12) or Calcitriol (n =10). Results 
are group means ±SE. Unpaired Student’s t-test. 
 
Blood Pressure 
Systolic Blood Pressure 
Terminal systolic blood pressure was lower in Calcitriol treated animals (117±4 
mmHg) when compared to vehicle treated mice (127±5 mmHg) however this did 
not reach statistical significance (P >0.05) (Figure 8.5A). 
 
Diastolic Blood Pressure 
Terminal diastolic blood pressure was significantly lower in Calcitriol treated 
animals (82±4 mmHg) when compared to vehicle treated mice (93±4 mmHg) (P 
<0.05) (Figure 8.5B). 
 
Mean arterial pressure (MAP) 
Terminal MAP was significantly lower in Calcitriol treated animals (82±4 mmHg) 
when compared to vehicle treated mice (93±4 mmHg) (P<0.05) (Figure 8.5C). 
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Figure 8.5. Blood Pressure: 16 week measurement of (A) diastolic blood 
pressure, (B) systolic blood pressure and (C) mean arterial pressure (MAP) 
(mmHg ±SE) in MSK1/ 2 KO-cholesterol fed mice supplemented with vehicle (n 
=10) and Calcitriol (n =11). Results are group means ±SE. Unpaired Student’s t-
test. *P<0.05. 
 
 
Vascular Function 
Endothelium-dependent 
Endothelium-dependent vasodilatation to ACh was significantly greater in 
Calcitriol treated mice (296±6 AU) when compared to vehicle treated animals 
(272±6 AU) (P<0.01) (Figure 8.6). 
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Endothelium-Independent  
There were no significant differences for endothelium-independent responses 
between the groups (vehicle 326±9 AU VS. Calcitriol 339±15 AU, P>0.05) 
(Figure 8.6B).  
 
Figure 8.6. Vascular function: 16 week measurement of (A) endothelium-
dependent and (B) independent responses (AU) in MSK 1/ 2 KO-cholesterol fed 
supplemented with vehicle (n =10) and Calcitriol (n =11). Results are group 
means ±SE Unpaired Student’s t-test. **P<0.01 
 
Plasma Cholesterol 
HDL 
There were no significant differences for HDL between the groups (vehicle 15±2 
mg/dl vs Calcitriol 16±3 mg/dl, P>0.05) (Figure 8.7A). 
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LDL/vLDL 
There were no significant differences for LDL/vLDL between the groups (vehicle 
10±1 mg/dl vs Calcitriol 13±2 mg/dl, P>0.05) (Figure 8.7B). 
 
Figure 8.7. Plasma cholesterol: 16 weeks measurements of plasma (A) high 
density lipoprotein (HDL) and (B) low density lipoprotein and very low density 
lipoproteins (LDL/vLDL) in MSK 1/ 2 KO-cholesterol fed vehicle(n =10)  and 
Calcitriol (n =10) supplemented mice. Results are group means ±SE. Student’s 
t-test 
 
Baseline Cytokines 
There were no significant difference for baseline cytokines between the groups 
for IL-6 (vehicle 1344±18 pg/ml VS. Calcitriol 1408±37 pg/ml, P>0.05) and IL-10 
(vehicle 175±6 pg/ml VS. Calcitriol 198±19  pg/ml, P>0.05), however there was 
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a significant differences for IL-1α (vehicle 1170±8 pg/ml vs Calcitriol 1211±17 
pg/ml, P<0.05) between the groups (Figures 8.8 A-C respectively). 
 
Figure 8.8. Study baseline inflammatory markers: Baseline plasma 
inflammatory markers (A) IL-1α, (B) IL-10 and (C) IL-6 (pg/ml) in MSK 1/ 2 KO-
cholesterol fed, vehicle (n =10)  and Calcitriol (n =11) treated mice. Results are 
group means ±SE. Unpaired Student’s t-test. *P<0.05 
 
 
16 Week Measurement of Cytokines 
There were no significant differences in cytokine expression between vehicle 
and Calcitriol treated mice for IL-1α and IL-10, (Figure 7.7A/B respectively). 
However IL-6 (vehicle 1285±9 pg/ml VS. Calcitriol 1356±32 pg/ml, P<0.05) was 
significantly greater in the Calcitriol supplemented group (Figure 7.7-C). 
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Figure 8.9. Week 20 plasma measures of cytokines: Week 16 measurement 
of (A) IL-1α, (B) IL-6 and (C) IL-10 (pg/ml) in MSK 1/ 2 KO-cholesterol fed, 
vehicle (n =11)  and Calcitriol (n =8) treated mice. Results are group means 
±SE. Unpaired Student’s t-test. *P<0.05 
 
 
Correlations 
 
At study endpoint several significant correlations for spleen weight VS.: cardiac 
mass   (r= 0.480, P<0.05), cardiac hypertrophy measurement (r= 0.464, P<.05) 
and plasma HDL (r= -0.499, P<0.05) were found.  ACh responses correlated 
with 16 week measurements of IL-10 (r= -0.604, P<0.05). 
 
Discussion  
The main findings from this study show that MSK 1/ 2 KO-cholesterol fed mice 
supplemented with Calcitriol have better endothelium-dependent vasodilatation 
in vivo as evidenced by measurements of skin microvascular responses to ACh. 
Maximal dilatory capacity to localised skin heating was not significantly different 
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between groups, suggesting modulation at the level of the endothelium. 
Calcitriol supplemented animals had lower systemic blood pressure, lower 
cardiac mass and lower cardiovascular hypertrophy. These data suggest a 
possible protective role for vitamin D in the development and progression of 
inflammation induced CVD.  
Takeda et al (Takeda et al., 2010) have previously shown reduced 
atherosclerosis in ApoE KO mice when supplemented with Calcitriol orally 
(200ng). In agreement with the current study, showing preserved endothelial 
function, an early event in atherosclerotic plaque formation. The frequency of 
administration and dose were similar in this and the previous study by Takeda 
et al. However, Takeda et al also found reduced levels of tissue macrophages 
and increased levels of IL-10, findings that are not consistent with the present 
study.  Zhang et al (2012) reported that vitamin D was able to specifically up 
regulate DUSP-1 and attenuate the expression of TNF-α and IL-6 in peripheral 
blood monocytes from humans and in mouse bone marrow derived 
macrophages. MSK 1/ 2 KO mice display reduced levels of DUSP-1 and this in 
part is thought to mediate their hyper-inflammatory predisposition to endotoxin 
shock when challenged with a bolus injection of LPS (Ananieva et al., 2008, 
Zhang et al., 2012).  
The present study sought to establish the role of vitamin D in inflammatory 
cytokine expression; there were no significant differences between plasma 
levels of IL-1α and IL-10 between the experimental groups in this study. 
However plasma levels of IL-6 were significantly greater in Calcitriol 
supplemented mice, an unexplained finding. Previous studies have shown 
reduced mRNA expression of TNF-α, IL-6 and IFN-gamma in Calcitriol 
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supplemented cells, an effect that can be blocked with the addition of the 
vitamin D receptor antagonist TEI-9647 (Diaz et al., 2009). Previous studies 
have also shown that anti-inflammatory levels of IL-10 are associated with 
increased plaque formation (Mallat et al., 1999) in mice. Barrera et al (2012) 
showed that Calcitriol supplementation to trophoblasts (the outer layer of cells in 
a blastocyst that provides nutrients to the growing embryo) reduced IL-10 
expression. This is in contrast to the hypothesis that the anti-inflammatory 
effects of Calcitriol supplementation in the context of CVD are mediated by the 
resolution of inflammation, through increased expression of negative regulators 
of inflammation such as IL-10 and DUSP-1. The reduced effects of IL-10 
expression in a study by Barrera et al were also associated with reduced TNF-α 
production. It is believed Calcitriol contains a DNA binding domain and it is 
hypothesised that Calcitriol can negatively regulate inflammatory responses 
through the vitamin D receptor (Barrera et al., 2012, Takeda et al., 2010). These 
findings however are not consistent with the present in vivo study, where there 
were no significant differences in plasma cytokines for IL-1α, IL-10 but a 
significant increase in plasma IL-6. 
One possible explanation for the unaltered levels of IL-10 in this study may be 
in part mediated by the MSK 1/ 2 KO phenotype. These mice display 
significantly reduced levels of IL-10 when compared to WT mice (Ananieva et 
al., 2008) and the Calcitriol supplementation may not have been sufficient to 
restore the genetic defect mediated through a loss of MSK 1/ 2. Importantly the 
study end point measurements for IL-10 between this and the study (plasma IL-
10) conducted by Takeda et al (IL-10 mRNA) were different and it is possible 
that vitamin D dosing  in MSK 1/ 2 KO mice may have induced differences in 
mRNA levels but not translated in to plasma protein levels. Furthermore the 
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previous studies detailing the anti-inflammatory Calcitriol may not be applicable 
in this model (MSK 1/ 2 KO mice). The predisposition to hyper-inflammation 
may be greater in MSK 1 2 KO mice such that they may mask the anti-
inflammatory effects mediated by Calcitriol. 
The immune modulator effects of the vitamin D receptor, a super family of 
vitamin A receptors is through gene regulation. The biologically active hormone, 
Calcitriol binds to the VDR and associates with specific sequences called 
vitamin D responsive elements (VDRE) that are found in the promoter region of 
genes and thus functions as an inducible transcription factor. Binding to the 
ligand-binding domain (LBD) of the VDR induces dimerization with retinoid X 
receptors. Resulting heterodimers bind DNA to VDRE and up regulate gene 
expression. The VDR-LBD interaction is this essential for ligand dependent 
transcription (Ito et al., 2013). Humans and animals aberrant in vitamin D 
display a higher risk of infection (Thornton et al., 2013, Thornton et al., 2014) 
(Cantorna et al., 2004) and this is thought to be mediated by deficient 
macrophage function. Therefore the protective effects of Calcitriol as noted by 
previous studies on the regulation of gene expression may be more applicable 
to subclinical acute inflammation. The MSK 1/ 2 KO mouse model is indicative 
of low grade, sub clinical inflammation when challenged with a cholesterol diet, 
however this phenotype as characterised in a previous chapter is inherently 
chronic, resulting in the progressive deterioration of microvascular function and 
the current dose and dosing period of Calcitriol may not have been sufficient to 
significantly affect protein levels of pro-inflammatory cytokines. Previous studies 
have shown dose dependent inhibition of TNF-α production in peripheral blood 
monocytes from patients (Panichi et al., 1998), a similar experimental approach 
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using mouse bone marrow derived macrophages may yield better mechanistic 
insight the role of vitamin D in inflammatory gene expression. 
In contrast to these reports Sun and Zemel (2008) shows pro-inflammatory 
effects of Calcitriol supplementation in adipocytes and macrophages. Using the 
mouse macrophage cell line RAW 264.7  Sun and Zemel (2008) shows that 
Calcitriol can up regulate TNF, IL-6 and MCP-1 in a Ca2+ dependent manner, 
through attenuated expression after using the calcium channel inhibitor 
Nifedipine (Sun and Zemel, 2008). It is however important to note that this study 
was conducted in an isolated, in vitro setting that is devoid of humoral factors in 
the blood and tissue, and may not be representative of in vivo effects of vitamin 
D as observed in the present study. 
TLR activation also induces the activation of NF-kB. Previous studies have 
reported reduced chemokine expression after Calcitriol supplementation in vitro, 
an effect mediated by inhibition of IkB phosphorylation and NF-kB activation 
(Kavandi et al., 2012). Although not addressed in the current study, it is possible 
that the apparent protective vascular and cardiovascular phenotype observed in 
Calcitriol treated mice is in part through the modulation of other transcription 
factors such as NF-kB (De Filippo et al., 2013), therefore it is important to note 
that the results from this in vivo study may be multi-modal.  
Vitamin D has been described to have pleiotropic effects , in particular vitamin D 
supplementation has shown protection from hydrogen peroxide (H2O2) 
formation in endothelial cells in vitro (Polidoro et al., 2013) (Kallay et al., 2002, 
Wu et al., 2011), a contributor to endothelial dysfunction. The protective blood 
pressure effects observed in this study through Calcitriol supplementation may 
be mediated through preserved endothelial function in the peripheral circulation. 
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Peripheral resistance increases as the small blood vessels (such as the skin 
microcirculation) become dysfunctional; a loss of NO would result in an altered, 
more constricted vascular lumen. Great force is needed to pulsate blood to 
distal tissues through narrow arteries and thus cardiac hypertrophy is one 
mechanism by which this achieved. Specific cardiac myocyte deletion of the 
VDR results in cardiac hypertrophy in the hearts of mice through potential 
suppression the pro-hypertrophic pathways and increased expression of arterial 
natriuretic peptide (Chen et al., 2011).  
In conclusion, this study shows that Calcitriol supplementation to inflammatory 
prone MSK 1/ 2 KO-cholesterol fed mice resulted in a degree of CVD-
protection. Measured by endothelium function, cardiac mass, blood pressure 
and cardiac hypertrophy. The protection observed is not supported by the 
resolution of plasma inflammatory molecules and thus further work is required 
to better understand the role of Calcitriol in vascular dysfunction relevant to the 
MSK 1/ 2 pathway. Targeting specific components of the Calcitriol pathways 
may offer a novel therapeutic option for inflammatory mediated pathologies 
such as CVD. These data are in line with conflicting data previously published. 
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Chapter 9 
Discussion and Future work 
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Aim of Thesis 
The aim of this thesis was to develop the understanding of the inflammatory 
pathways involved in early CVD development through assessment of vascular 
function in vivo. 
 
Key Findings 
The studies in this thesis show that the changes in skin microvascular function 
are representative of underlying pathophysiology and therefore the novel 
experimental set-up can provide a useful tool for exploring specific pathways 
and mechanisms underlying the development and progression of CVD in animal 
models. Importantly attenuated responses in the skin microcirculation to ACh 
are indicative of the changing systemic inflammatory burden through the 
release of pro-inflammatory cytokines into the systemic circulation, as 
evidenced by cholesterol feeding in WT mice and assessment of vascular 
function and cytokine levels in the plasma of MSK 1/ 2 KO and ABIN1(DN485) 
mice. The key findings are summarised in Figure 9.1. 
 
The novel finding that deletion of MSK 1/2 produced a marked inflammatory 
state with consequent early endothelial dysfunction and reduced NO, without 
overt clinical disease offers an innovative avenue for therapeutic intervention to 
limit CVD in humans. Activators of MSK 1/ 2 may be used to address a wide 
range of inflammatory mediated pathologies relevant to CVD including MI and 
stroke. Furthermore, studies interrogating irregularities in the MSK 1/ 2 pathway 
may in part contribute to the knowledge of why there is significant disease 
heterogeneity in human CVD, and may in part explain the onset of CVD in 
otherwise healthy individuals that do not display traditional risk factors such as 
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high plasma cholesterol or obesity. This hypothesis is supported by the onset of 
microvascular dysfunction in MSK 1/ 2 KO-chow fed mice that were not 
exposed to a CVD risk factor, dietary cholesterol.   
 
 
Figure 9.1. Summary of key findings: Myeloid differentiation primary responses 
88 (MyD88), mitogen-activated-protein kinase activated proteins 2/ 3 (MAPKAP 
2/ 3), mitogen and stress activated kinases 1 /2 (MSK 1/ 2), A20-binding 
inhibitor of NF-ĸB-1 (ABIN1). 
 
An inability to negatively regulate pro-inflammatory signals after TLR stimulation 
can therefore be associated as a CVD risk factor as evidenced by the second 
unique finding in this thesis that polyubiquitin-binding-defective ABIN1[D485N] 
mice are prone to CVD. The phenotype in ABIN1(DN485) mice was further 
exacerbated by cholesterol feeding, a conclusion that offers additional 
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therapeutic promise to limit  inflammation induced CVD relevant to patient 
cohorts (SLE and RA) that displays enhanced CVD risk, a currently unexplained 
phenomenon. A cessation or strict regulation of saturated fats and dietary 
cholesterol that is associated with an increased risk of CVD in rheumatoid 
patients may help reduce the significant CVD burden.  Data in this thesis 
support the notion that increased NF-ĸB activation has significant negative 
effects on the cardiovascular system. TLR2 and TLR4 activation is regarded as 
a key event in the pathophysiology of CVD (Bjorkbacka et al., 2004, Cole et al., 
2013, Falck-Hansen et al., 2013, Mullick et al., 2005, Tobias and Curtiss, 2007) 
and is associated with atherogenesis, whereas blockade of this signalling 
pathway, achieved by amelioration of the MyD88, has shown atheroprotection  
previously (Bjorkbacka et al., 2004). Similarly the SLE phenotype of the 
ABIN1[D485N] mice is abrogated when they are expressed on a MyD88-
deficient background (Nanda et al., 2011), indicative of overlap in the signalling 
pathways involved in the development of  SLE and CVD.  
 
More broadly applicable to the onset of CVD, truncation of cytokine signalling 
through knock-down of innate immune signalling in this thesis (MyD88 and 
MAPKAP 2/3 KO) show preserved endothelial function through abrogated 
systemic cytokine expression and preserved NO . Conferring with the notion 
that blockade of innate immune signalling relevant to reduced atherosclerotic 
plaque formation in previous studies also protects against endothelial 
dysfunction in vivo through diminished systemic cytokine production  and 
preservation of NO (Bjorkbacka et al., 2004, Jagavelu et al., 2007). 
Numerous studies have focused their investigation on inflammatory stimuli that 
can initiate the activation of innate immune responses and the release of pro-
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inflammatory mediators, such that there is now a broad literature base showing 
the activation of specific TLRs (Kawai and Akira, 2009). The studies in this 
thesis support with the notion that that TLR activation in excess is detrimental to 
vascular function as evidenced by the onset of early CVD in MSK 1/ 2 KO and 
ABIN1(DN485) mutant defective mice.  
The physiological importance of endogenous negative feedback mechanisms 
after the activation of TLR in MSK 1/ 2 KO and ABIN-1 mutant defective mice 
demonstrates the essential need for successive deactivation of effector 
pathways after receptor stimulation. This notion, that cytokine expression is 
detrimental to vascular function is supported by the MyD88 and MAPKAP 2/ 3 
KO mouse studies; an inability to stimulate cytokine expression confers 
vascular protection in the face of an established risk factor, dietary cholesterol.  
Selectively targeting these pathways may provide a novel tool to limit 
inflammatory mediated CVD. The ability to manipulate these intrinsic 
mechanisms holds great therapeutic potential, allowing selective activation of 
mediators that suppress inflammation without blocking inflammatory pathways 
of host defence to pathological organisms. In particular TLRs are important in 
host defence for the detection of bacterial products for clearance, blockade of 
these signals would compromises host immunity such that it would resemble 
the clinical scenario of a patient on immunosuppression therapy or individuals 
suffering from the human immunodeficiency virus. The work detailed in the 
previous chapters highlights the lack of therapeutic targets in clinical medicine 
that selectively target endogenous pathways and sequentially promote the 
resolution of inflammation, however these studies offer a unique therapeutic 
approach that will be broadly be applicable to numerous inflammatory mediated 
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pathologies including MI and stroke. In particular it will be of key importance to 
establish the role of MSK 1/ 2 in MI.  The bi-phasic monocyte response 
observed after the myocardium becomes ischaemic is a key contributor to 
myocardial damage and a contributor to heart failure after infarction. The cell 
polarity of MSK 1/ 2 KO macrophages must be established in CVD as selective 
activators may promote healing (through the resolution of inflammation) of the 
myocardium after an acute event, similar reports have been shown through the 
use of angiotensin inhibitors (Leuschner et al., 2010a).  
Similar approaches in CVD testing in humans have previously shown that RA 
patients have attenuated endothelium-dependent responses in the skin 
microcirculation. In addition, the degree of attenuation is related to the 
expression of systemic inflammatory cytokines (Galarraga et al., 2008), these 
findings are similar to those presented in this thesis. Since endothelium-
dependent responses in the microcirculation of the skin are indicative of 
defective coronary function (Khan et al., 2008b) and future cardiovascular 
sequelae before clinical presentation (Khan et al., 2005), the findings from this 
thesis highlight the important role for innate immunity in the development and 
progression of inflammation-induced CVD.  The technique described in this 
thesis offers a mode of research translation, allowing CVD in patients to be 
studied further with the use of animal models, answering key questions in the 
pathophysiological complexity of human CVD. 
 
The studies in this thesis aimed to establish a role for candidate kinases in 
inflammatory-induced CVD development through assessment of endothelial 
function and measurement of systemic cytokine expression.  In conclusion, 
these are the first in vivo observations to document the early development of 
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CVD (endothelial dysfunction) as a result of a single protein mutation involved in 
NF-ĸB signalling. Similarly MSK 1/ 2 are mediators of vascular dysfunction and 
targeting the MAPKAP 2/3 pathway and/or selective inhibition of TLRS through 
MyD88 inhibition, with agents that block their action might provide a useful 
therapeutic option for inhibiting inflammation induced endothelial dysfunction 
and CVD. 
 
Limitations 
Rodent models of LDI 
Genetically altered mice were used in these investigations to better understand 
the role of innate immune signalling cascades in the pathogenesis of endothelial 
dysfunction. It is important to note that rodent skin varies considerably to that of 
humans and responses to the iontophoresis of vasoactive chemicals may be 
significantly different when compared to similar experimental approaches in 
clinical cohorts. For example mice have a densely packed fur coat, which they 
maintain through grooming. The density of hair follicles in rodent skin is greater 
than that of human skin, an important limitation to note as ion movement during 
iontophoresis is facilitated through hair follicles and therefore the rodents used 
in studies detailed in this thesis may have shown a greater vasodilator capacity 
when compared to humans, through a greater net movement of ions through 
hair follicles. Nonetheless ion movement during iontophoresis is largely 
dependent on the duration of current (the length of the iontophoresis protocol) 
and it is important to note that the studies in this thesis used a protocol that was 
similar to those used in humans clinical studies and that animals of the same 
genetic background were used to reduce variability in drug iontophoresis 
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responses. Importantly values obtained from rodent studies in this thesis are 
comparable to attenuated responses obtained in human studies. Thus reduced 
responses as observed by attenuated vasodilator responses to endothelium-
dependent agonist ACh in the skin microcirculation in mice are comparable to 
the human clinical scenario, however a direct comparable study is needed for 
validation.  A study by Schuler et al (2014) has previously compared 
endothelium-dependent responses in the mouse using Doppler flow-mediated 
vasodilatation and concludes that the physiology observed in the mouse is 
similar to that in humans, re-instating the high suitability of non-invasive 
techniques for the measurements of endothelial function in both humans and 
mice. 
 
Murine model systems have grown in popularity due to a greater operator 
control of pathophysiology through combined genetic alterations and diet 
interventions, similar to the studies in this thesis where genes of interest can be 
deleted, mutated and animals can be fed specifically tailored diets. The 
sequencing of the human and mouse genome has revealed 300 genes that are 
uniquely expressed in both humans and mice, Mestas and Hughes (2004) have 
previously discussed the major differences between the two species in relation 
to the immune system and the short comings of using rodent models for 
modelling human clinical disease. The major differences between the mouse 
and the human physiology have previously been widely reported, such that 
there are numerous studies that have shown effective therapies in mice but 
limited efficacy in humans. Human circulating blood is neutrophil rich and this is 
contrary to murine blood that is lymphocyte dense. The studies in this thesis 
have focused on the ability of the vascular endothelium to respond to stimuli 
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and induce endothelial cell activation, a pre-requisite for the tethering of 
monocytes for subsequent transmigration. Monocytes respond to environmental 
stimuli through numerous receptor mediated pathways and the TLRs are the 
predominately studied system for pro-inflammatory responses. There are a 
number of differences between mouse and human TLR expression, firstly the 
number of discovered TLRs in the human and mouse vary, as previously 
discussed in the ‘Introduction – Toll like receptors and inflammation’ and 
illustrated in Figure 1.4 (extracellular and intracellular expression of TLRs) 
humans have 10 TLRs and the mouse 13. Nonetheless the ability to purify 
proteins from rodents is easier and has facilitated research in solving the 
structure of the TLRs, importantly murine TLRs provide a framework for 
understanding the biochemical basis for receptor function in the absence of 
human evidence.  Although the mouse may be a suitable model for some 
pathological disease processes such as atherosclerotic plaque formation and 
MI, murine studies investigating hypersensitivity have been limited. The 
ectodomain of TLR4 an important ligand in inflammation mediated CVD in 
humans and in mice does not respond to nickel sensitisation in mice, unlike 
humans who can develop contact dermatitis upon exposure. In humans, nickel 
atoms can chelate histidines residues found in the ectodomain of TLR4 and 
induce activation of the receptor, these histidines are absent in the mouse and 
rodent models of human pathology must therefore carefully selected. Schuler et 
al (2014) demonstrated the fundamental similarity in endothelium-dependent 
vasodilatation in humans and mice and confirmed the dependency of the 
response on eNOS and NO. Furthermore genetic alteration and knock-down of 
innate immune protein has allows researchers to precisely map the function of 
immune proteins (Bryant  and Monie, 2012). Thus the use of the mouse in 
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scientific investigation can be both useful and limiting. Subsequent 
investigations modelling human clinical disease should be carefully monitored 
for physiological and biochemical similarity.  
 
Barrier Breeding Facility VS. Conventional Unit. 
Animals were initially bred and maintained in a barrier breeding facility and 
subsequently transferred to a conventional unit for vascular function testing. It is 
possible that the acute stress induced from transferring the animals from the 
barrier breeding facility to another site for vascular testing, coupled with their 
hyper-inflammatory phenotype is responsible for the initial differences in body 
weights and plasma cytokines in the various studies. Animals were allowed a 
minimum of 7 days to acclimate before commencement of vascular studies and 
it is possible that animals like the ABIN1(DN485) and the MSK 1/ 2 KO mice 
may need a longer habitualisation period than their WT counter parts. Rudd et 
al (2013) has previously reported a loss in appetite in mice subjected to 
inflammation both acutely and chronically. The immune induced anorexia 
response is dependent on MyD88 in myeloid cells. It has previously been 
shown that ABIN-1 (D485N) mice crossed on to an MyD88 deficient background 
are rescued from the SLE phenotype and work within this thesis shows that 
MyD88 KO mice had significantly higher body weights than their WT counter 
parts at study baseline, unlike MSK 1/ 2 and ABIN1(DN485) mice. Further 
studies examining the role of inflammation on appetite regulation in response to 
acute stress may therefore be favourable.  
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Cholesterol Challenge 
C57BL/6 WT mice have endogenously high levels of HDL. Dietary cholesterol 
does not significantly impair (reduce) HDL plasma in C57BL/6 WT mice, a 
reduction otherwise associated with an increased risk for CVD.  Diets that are 
routinely used in metabolic studies are higher in fat (>40% fat) and may 
therefore be tested in this model of vascular pathophysiology, to assess 
whether a similar pattern of dysfunction is observed.  
 
Mouse Model Generation 
Animal models used in this thesis were specifically generated from embryonic 
stem cell lines from 129S2/SvPasCrl animals and subsequently backcrossed to 
C57BL/6 mice. A documented passenger gene locus effect has previously been 
described (Lusis et al., 2007). Genes that contain significant polymorphisms 
from the embryonic mouse to the backcross mouse strain may affect the overall 
phenotype, allowing conclusions to be drawn that at not inherently based on a 
KO or induction of a transgene, with the possible introduction of numerous 
‘sister’ genes and/ or deletions. In order to better understand the effect of 
passenger genes on the described phenotypes, animals may therefore be 
backcrossed onto other mouse lines and retested for the onset of endothelial 
dysfunction. 
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Future work 
Technique Development 
Development of Iontophoresis 
Future work could establish additional iontophoresis protocols for bradykinin, 
methacholine and histamine, vascular agonists that are used routinely in ex vivo 
research. These molecules have shown specificity for vascular pathways of 
vasodilatation, however their in vivo effects remain poorly defined in animal 
models of inflammation.  In conjunction with the development of other agonist 
based protocols and the use of inhibitors such as indomethacin would allow 
further interrogation of the skin microvascular network. Mechanisms such as 
prostaglandins, an eicosanoids derived from cyclooxygenase produced by 
mammalian cells with a role in local tissue homeostasis. Importantly 
prostaglandins can modulate vascular tone under basal conditions and platelet 
aggregation, therefore the role of the described inflammatory pathways in 
relation to prostaglandin induced vasodilatation may offer further insights in to 
the multimodal nature of endothelial dysfunction in vivo.  
Imaging 
LDI in the context of small animal vascular research could further be developed 
for the application of full field laser perfusion imaging (FLPI), known as laser 
speckle contrast imaging. FLPI uses video frame rate acquisition, where 25 
images per second can be recorded for transient changes in flow, something 
not possible by standard LDI. This may permit the use of a shorter vascular 
(iontophoresis protocol) reducing the length of time that an animal is under 
general anaesthetic and allow faster more transient changes in flow to be 
monitored. 
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Future Studies 
Sex Dependent Studies 
All studies described in this thesis were specifically carried out on C57BL/6 
male mice. The use of LDI and iontophoresis in humans has shown impairment 
of the skin microcirculation in the context of preeclampsia, animal models of the 
hypertensive disorder have been described previously (Davisson et al., 2002), 
however the in vivo effects on endothelial function in this model have not been 
addressed. Furthermore research reveals that women are more likely to suffer 
an adverse cardiovascular event than males and diseases such as SLE are 
more prevalent in females. Thus application of this technique into sex specific 
pathologies would therefore be favourable. 
 
Backcrossing 
The animal models used in this thesis were specifically maintained on a 
C57BL/6 background for the study of endothelial dysfunction, however the MSK 
1/ 2 and ABIN1 models could provide further insight into the atherosclerotic 
process. The hyper-inflammatory phenotype observed in these models would 
suggest exacerbated atherosclerotic plaque formation. However the 
mechanisms by which this may manifest would be highly valuable and could be 
achieved through backcrossing with the ApoE / LDLr KO models of 
dyslipidaemia, in combination with therapeutics agents such as vitamin D to 
limit the progression of the disease. 
 
Conclusion 
LDI and the iontophoresis of vasoactive chemicals may provide a useful 
physiological technique for the non-invasive assessment of CVD in animal 
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models. MSK 1/ 2 and ABIN1 are novel kinase targets that may help limit CVD 
in the human population, further study is required to address the involvement of 
these pathways in CVD in patients and individual who are regarded as at risk of 
CVD.  
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Available online 31 October 2012Endothelial dysfunction is associated with early development of cardiovascular disease, making longitudinal
measurements desirable. We devised a protocol using laser Doppler imaging (LDI) and iontophoresis of ace-
tylcholine (ACh) and sodium nitroprusside (SNP) to assess the skin microcirculation longitudinally in mice
every 4 weeks for 24 weeks in two groups of C57BL/6 mice, chow versus high-cholesterol diet(known to in-
duce endothelial dysfunction). LDI measurements were compared with vascular function (isometric tension)
measured using wire myography in the tail artery in response to ACh and SNP. Microvascular responses to
ACh were significantly reduced in cholesterol-fed versus chow-fed mice from week 4 onwards (Pb0.005,
ANOVA). Pre-treatment with N(G)-nitro-L-arginine methyl-ester-hydrochloride (L-NAME) showed a signifi-
cant reduction in ACh response compared with vehicle-treated animals (Pb0.05) at baseline and at 12 weeks.
In cholesterol-fed mice, ACh responses were 226±21 and 180±21 AU (P=0.03) before and after L-NAME,
respectively. A reduction in ex-vivo ACh response was detected in the tail artery in cholesterol-fed mice, and
a significant correlation found between peak microvascular ACh response and maximum ACh response in the
tail artery (r=0.699, P=0.017). No changes were found in SNP responses in the microvasculature or tail ar-
tery. Using this protocol, we have shown longitudinal decreases in microvascular endothelial function to cho-
lesterol feeding. L-NAME studies confirm that the reduced vasodilatation to ACh in cholesterol-fed mice was
mediated partly through reduced NO bioavailability. Wire myography of tail arteries confirmed that in-vivo
measurements of microvascular function reflect ex-vivo vascular function in other beds. Longitudinal assess-
ments of skin microvascular function in mice could provide a useful translatable model for assessing early en-
dothelial dysfunction.
© 2012 Elsevier Inc. All rights reserved.Introduction
Endothelial dysfunction is an early event in the development of
atherosclerosis and is closely associated with cardiovascular disease
(CVD), thus making it a key measurement in CVD studies (Bonetti et
al., 2003; Esper et al., 2006). The endothelium consists of the inner-
most layer of cells in blood vessels and is involved in many areas of
vascular biology including thrombosis, angiogenesis, inflammation
and also plays a vital role in controlling vascular tone (Sumpio etlar disease; LDI, Laser Doppler
ydrochloride; NO, Nitric oxide;
ld-type.
Diseases Research Unit, Centre
s Hospital and Medical School,
h), N.Akbar@dundee.ac.uk
etrie@glasgow.ac.uk (J. Petrie),
.uk (F. Khan).
rights reserved.al., 2002). An established method for assessing endothelial function
is to measure endothelium-dependent changes in vascular tone in
response to vasoactive drugs such as acetylcholine (ACh) (Khan et
al., 2008; Ludmer et al., 1986; Morris et al., 1995; Panza et al.,
1990; Turner et al., 2008). In animal studies, this is carried out by
intra-vital microscopy, or more commonly by ex-vivo wire
myography, which allows investigators to examine functional re-
sponses and vascular reactivity of isolated resistance arteries
(Shafaroudi et al., 2005). This technique has been utilized successful-
ly in vessels from various species (Argyle andMcGrath, 2000; Arribas
et al., 1997; Docherty et al., 2001; Jones et al., 2003; Symons et al.,
2001), including transgenic models (Eichhorn et al., 2009;
Sainsbury et al., 2004), and in pathological disease states (Sharifi et
al., 1998). A major limitation of using such methodology is that ani-
mals need to be culled in order to harvest the required vascular tis-
sue. Thus, only a ‘snapshot’ of vascular function at a set time can be
obtained in a given animal and limits longitudinal study involving
multiple sample points. It can also limit the ability to examine early
changes in vascular function and monitor disease progression over
87J.J.F. Belch et al. / Microvascular Research 85 (2013) 86–92time. As with all in-vitro techniques, it also suffers from the limita-
tion that the tissue is kept in a controlled environment outside nor-
mal physiological conditions and therefore may not always be
translatable to in-vivo conditions.
Some clinical studies relating to endothelial function testing have
utilized the cutaneous microvasculature. It has been established that
there are implications for microvascular function in a range of dis-
eases including diabetes (Khan et al., 2000;Morris et al., 1995), rheu-
matoid arthritis (Galarraga et al., 2008) and in patients with
cardiovascular risk factors (Huang et al., 2007; Ijzerman et al.,
2003; Khan et al., 2003). Therefore, it may prove to be potentially
very useful to be able to measure early microvascular dysfunction
in animal studies of these diseases, and also in mouse models in
which the genotype has been altered. However, there is a relative
lack of studies longitudinally measuring early changes in endothelial
function in animals in-vivo. We therefore aimed to devise a method
for using laser Doppler imaging and iontophoresis of vasoactive
chemicals to measure endothelial function longitudinally over time
in the skin microvasculature of mice. The laser Doppler imager
(LDI) allows measurement of changes in cutaneous perfusion in re-
sponse to vasoactive drugs that work through the endothelium
(e.g. ACh) and which can be delivered locally to an area of skin by
iontophoresis. The primary aim of this study was to use LDI and ion-
tophoresis of vasoactive drugs to measure early changes in endothe-
lial function in two groups of ‘wild-type’ (WT)mice, one fed a regular
mouse ‘chow’ diet and the other fed a high-cholesterol ‘atherogenic’
diet, which is known to induce endothelial dysfunction. This was a
longitudinal study with skin microvascular function measured
monthly in the same animals over a period of 24 weeks. One of the
secondary aims was to compare our in-vivomeasurements of micro-
vascular function using the LDI methodology with the established
wire myography technique for assessing vascular function in the
mouse tail artery, a resistance vessel which is representative of the
skin circulation given its role in thermoregulation. Since previous stud-
ies in humans have shown that microvascular responses in the skin
might be representative of generalised vascular function in other vascu-
lar beds (Cracowski et al., 2006), this would allow us to assess whether
our in-vivo measurement of skin microvascular function in mice was
representative of ex-vivo vascular function in another vascular bed. Hy-
percholesterolemia is known to produce a reduction in nitric oxide
(NO) bioavailability, and therefore a further secondary aim was to con-
firm that in our in vivo experimental method ACh-mediated vasodilata-
tion reflected NO-mediated changes in normal chow-fed animals and
that a reduced vasodilator response to ACh in hypercholesterolemic an-
imals reflected reduced NO bioavailability.
Methods
All work was carried out under a valid U.K. Home Office project li-
cence by a U.K. Home Office Personal Licence holder, and after ap-
proval from the institutional animal ethics committee. All animals
in the study were an inbred C57BL/6 strain; male, aged between 16
and 28 weeks, housed in groups of up to five. Following baseline
measurements of skin microvascular function, animals were ran-
domly separated into groups according to their diet regime and
followed-up for 24 weeks. A group of 19 mice remained on the ‘nor-
mal’ rodent chow while the remaining 19 were given a specially
designed ‘atherogenic’ diet (TD.01383 diet, Harlan-Teklad), which
consisted of a standardized 18% protein rodent chow with added
cholesterol (2% by weight cholesterol). Group numbers were based
on previous studies conducted by Sigaudo-Roussel et al. (2004).
However, given the longitudinal nature of our study we anticipated
the possibility of a small risk of animal death by repeated anaesthe-
sia. Thus to account for any loss we increased our numbers as a safe
guard. However we reported no loss of animals due to the experi-
mental design.Laser Doppler Imaging and Iontophoresis
Iontophoresis of vasoactive compounds requires clean contact
with the epidermis; similarly, LDI measurements are most accurate
on hair-free, unblemished skin. Therefore, 24–36 hours prior to
measurements of microvascular perfusion, the animals' skin was
prepared by first shaving the hair from both flanks using an electric
shaver. Remaining hair was removed using a depilatory cream
(Veet®, Reckitt-Benckiser).
General anesthesia of animals was required to prevent body move-
ments creating artefacts during skin perfusion measurements. Induc-
tion of anesthesia was achieved using a 5% combination of Isoflurane
(Abbott Laboratories) in oxygen (2 L/minute) delivered via standard
Boyle's Apparatus into a small Perspex (induction) chamber. Anesthesia
was maintained using a 1.5%–2% concentration of Isoflurane in oxygen
(1.5 L/minute) delivered via a nose cone. The level of anesthesia was
determined by testing of rear foot reflexes. During all procedures the
animal's body temperature was maintained at 37 °C using a heat mat
with core body temperature monitored using an electric temperature
probe inserted into the animal's rectum.
Animals were housed and experiments conducted in a laboratory
with a room temperature set at 22±2 °C. A LDI (moorLDI, Moor Instru-
ments, Axminster, UK) was used to measure microvascular perfusion.
LDI utilizes a stable helium neon (HeNe) laser source (633 nm)
(2 mW nominal power). The region of interest (ROI) was determined
by the size of the iontophoresis chamber. A scan area of 4 cm2 was
used for all measurements. Scan resolution was set at 10 ms/pixel,
equating to an average scan time of 49 seconds, with an upper cut off
frequency of 15 kHz and direct current (DC) for normalization.
Anesthetised animals were laid on their sidewith the left side flank fac-
ing upwards. An iontophoresis chamber (ION6 probe, Moor Instru-
ments Ltd, Devon, UK), consisting of a 20 mm internal diameter ring
with a wire electrode running round the inner surface, was attached
to a 3.2 cm2 area of the lower flank (between the ribs and legs) using
double-sided adhesive tape, forming a watertight seal with the skin. A
second ‘reference’ electrode pad was attached to the underside of the
animal in order to complete the iontophoresis circuit. The 2 electrodes
were attached to an iontophoresis controller (MIC2 Iontophoresis Con-
troller, Moor Instruments Ltd, Devon, UK). This study involvedmeasur-
ing cutaneous microvascular responses repeatedly in the same animals
at 4-week intervals over 24 weeks and therefore effort wasmade to en-
sure repeatedmeasureswere taken from the sameflank and at a similar
site. Due to the area (3.2 cm2) required for placement of the iontopho-
resis chamber, and the relatively small size of the animal, the iontopho-
resis chamber could only be positioned realistically in one area and so
we are confident that the measurement site was similar on repeated
testing.
The laser scanner was placed over the mouse at a distance of 30 cm
and set to scan continuously. Perfusion was expressed as a function of
the number of red blood cells multiplied by their mean velocity and
an output in relative perfusion in arbitrary units (AU) was obtained
using the proprietary software (moorLDI software, version 5.2). The
iontophoresis chamberwas initially filledwith ~2 ml of a 1% concentra-
tion of the α1-adrenergic receptor agonist, phenylephrine (PE) and
sealed with a clear Perspex cap. Three initial baseline scans were
taken (without current applied), with each scan taking approximately
1 minute. To standardize baseline perfusion, skin blood vessels were
pre-constricted by iontophoresis of PE for 6 minutes using an anodal
current strength of 100 μA. Following normalized baseline measure-
ments of pre-constricted skin microvessels, a 2% solution of ACh was
iontophoresed continuously for approximately 10 minutes (using an
anodal current strength of 100 μA) to provide a cumulative dose–re-
sponse. Iontophoretic dose is defined as current multiplied by time of
application Dose (μA/second)=current (μA) x time (seconds), and
the amount of drug delivered is directly proportional to the iontopho-
retic dose applied (Turner et al., 2008).
Fig. 1. Total plasma cholesterol levels in chow- and atherogenic diet-fed mice (n=19 for
each group). Samples were analyzed at baseline (Week 0), study mid-point (Week 12),
study end-point (Week 24).
88 J.J.F. Belch et al. / Microvascular Research 85 (2013) 86–92At a different site on the opposite flank of the animal, sodium
nitroprusside (SNP) was used as an endothelium-independent con-
trol to assess the function of the vascular smooth muscle. As with
ACh, initial baseline measurements were taken before the blood ves-
sels of the skin were pre-constricted using iontophoresis (100 μA) of
PE for 6 minutes. Further normalized baseline measurements were
taken for 3 minutes followed by the continual iontophoresis of a 2%
solution of SNP using a cathodal current strength of 100 μA for
10 minutes. To reduce the amount of time that each animal was
under general anesthetic, and to limit the amount of drug exposure,
endothelium-independent responses to SNP were only measured at
the end point of the study (24 weeks).
Role of nitric oxide in the response to acetylcholine
In order to determine the contribution of endothelium-derived NO
toACh-mediated vasodilatation, 8 additional animals fed normal rodent
chowwere studied at baseline (week 0) and were pre-treated with the
non-selective inhibitor of nitric oxide synthase (NOS), L-NAME (Sigma
Chemicals) before iontophoresis of ACh. L-NAME was delivered
according to a previous protocol (Jones et al., 2003) whereby a dose of
20 mg/kg was given via an intraperitoneal (i.p.) injection 30 minutes
prior to laser Doppler measurement (iontophoresis protocol as
above). The drug vehicle (de-ionised, sterile water) was administered
via i.p. injection to a further separate group of 7 and served as controls.
Following baseline measurements, mice were randomly assigned to re-
ceive normal chow (n=4) or the atherogenic diet (n=4) for 12 weeks
after which the experiments (ACh-mediated vasodilatation in
L-NAME-treated mice) were repeated.
Assessment of tail artery function using wire myography
At the end point of the study; ex vivo functional vascular studies were
performed in 11 chow-fed mice and 11 cholesterol-fed mice on a
Mulvany–Halpern four-channel wire myograph (Danish MyoTech).
Group numbers were determined by previously published protocols for
small resistance vessels (Chotani et al., 2000; Faraci et al., 1998;
Sainsbury et al., 2004). Animals were culled by CO2 exposure delivered
in an increasing concentration within a perspex chamber. Tails were
immediately removed and arteries dissected under a dissecting micro-
scope and transferred immediately to ice-cold PSS (physiological saline
solution: 119 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4.
24.8 mM Na HCO3, 2.5 mM CaCl2, 11.0 mM glucose). Approximately
2 mm length (200–300 μm in diameter) segments were isolated from
the tips and stored in PSS overnight at 4 °C. Arterial segments were
mounted on two 40 μm diameter stainless steel wires attached to a
force transducer and micrometer, respectively. The temperature was
raised to 37 °C, and a gas mixture (5% CO2/95% O2) was bubbled in for
the duration of the experiment. After 30 min of equilibration, each vessel
was set to an optimal normalized internal diameter. Arteries were then
preconstricted with 10−7 M U-46619 (a thromboxane A2 mimetic) and
then relaxed with 1 μM of ACh. Vessel segments that showed at least
70% relaxation were deemed viable and considered for further experi-
ment. Isometric tension was measured and concentration–response
curves were plotted for the endothelium-dependent dilator agonist ACh
(10−9 to 10−4 M) and the endothelium-independent dilator agonist
SNP (10−9 to 10−4 M).
Measurement of total plasma cholesterol levels
A colorimetric assay [Biovision, Catalog #K603-100] was used to
measure total cholesterol in the plasma of mice. Blood samples of up
to 200 μl were taken via the tail vein at each measurement time-point
from which approximately 100 μl of plasma was obtained. Plasma
levels of total cholesterol were measured at baseline (Week 0), mid-
point (Week 12) and endpoint (Week 24).Post-mortem lipid staining of aorta
En-face staining of animals' aorta with Oil Red O was carried out
to assess the atherogenic response of the animals to their respective
diets. Oil Red O is a stain used to determine lipid deposition on the
vessel wall. The entire aortic treewas dissected, with fat and connective
tissue carefully removed. The aorta was cut longitudinally, pinned onto
a paraffinblock, stainedwith oil redO anddigitally scanned. Atheroscle-
rotic lesion area was assessed using Adobe Photoshop software and
expressed as a percent of the total surface area encompassed by the
aortic arch, thoracic aorta, abdominal aorta, or total aorta as indicated.
Data analysis
Longitudinal changes in skin perfusion over 24 weeks and dose–re-
sponse curves were analyzed using ANOVA for repeated measures,
followed by post-hoc Bonferroni tests. Results for skin microcirculation
responseswere analysed using SPSS version 15.0. Statistical analysis for
myography data was carried out using GraphPad Prism (Version 5).
Non-linear regression was utilized to produce dose–response graphs
and EC50 values. The association between LDI skin microvascular re-
sponses andmyographymeasurements and lipid depositionwas tested
using Pearson correlation coefficients. The null hypothesis was rejected
at P=b0.05.
Results
Plasma levels of total cholesterol and body weight
Fig. 1 shows that total cholesterol levels remained constant for the
duration of the study in the normal chow-fed animals. In the atherogen-
ic diet-fed mice, there was a significant increase in total cholesterol
from baseline to 12 and 24 weeks (Pb0.01, respectively for both).
Therewas no significant difference in bodyweights between the groups
at baseline (26.72±2.40 g vs. 25.67±2.22 g; chow and atherogenic
fed, respectively, P>0.05) or at the end of study (33.22±2.16 g vs.
34.28±4.47 g; chow and atherogenic fed, respectively, P>0.05).
Baseline skin microvascular responses to acetylcholine
Basal skin perfusion was not significantly different in mice assigned
to receive chow (251.4±24.0 AU) or the atherogenic diet (240.3±
27.2 AU). In both groups there was a reduction in skin perfusion in re-
sponse to iontophoresis of 2% PE, giving a stable corrected baseline
Fig. 3. Longitudinal assessment of microcirculation response to ACh in mice fed an ath-
erogenic diet (n=19) vs. normal chow diet (n=19) over 24 weeks. Skin microvascu-
lar responses to ACh (AU) were significantly reduced (Pb0.05) from week 4 in animals
fed an atherogenic diet compared with the chow-fed animals. *Pb0.01, **Pb0.001
(post-hoc analysis). Error bars are SEM.
89J.J.F. Belch et al. / Microvascular Research 85 (2013) 86–92(234.4±17.7 AU versus 210.0±19.7 AU, respectively, P>0.05). This
corrected baseline was sustained until 2% ACh was administered. Pilot
work showed that the PE-induced preconstriction persists for at least
30 minutes and therefore covers the duration of the ACh protocol.
Fig. 2 shows that skin microvascular response to iontophoresis of ACh
were not significantly different in the both groups of mice at baseline
(week 0).
Longitudinal changes in microvascular responses to ACh in mice fed an
atherogenic vs. normal chow diet over 24 weeks
Fig. 3 shows that in comparison to baseline responses at week 0,
there were no significant changes in the response to ACh in mice
fed a chow diet over 24 weeks. A significant reduction (Pb0.005,
ANOVA) in ACh responses was seen in the atherogenic diet-fed
mice compared with chow-fed mice group. The ACh response was
reduced in atherogenic diet-fed mice at week 4 (Pb0.01 post-hoc
analysis comparing chow vs atherogenic diet) then a further reduction
at week 8 (Pb0.001 post-hoc analysis comparing chow vs atherogenic
diet). ACh responses in the atherogenic dietmice remained significantly
lower than in the chow-fed mice fromweek 8 to 24 (Pb0.001 post-hoc
analysis comparing chow vs atherogenic diet for all time points).
Microvascular responses to SNP in mice fed an atherogenic diet vs. normal
chow diet
The microvascular response to SNP in chow-fed mice at week 24
was 368±32 AU versus the atherogenic group response of 371±
21 AU, which was not significantly different.
Role of nitric oxide in hyperaemic response to acetylcholine
Fig. 4 shows the effect of blocking NOS by pre-treatment with
L-NAME (20 mg/kg, i.p) on ACh-mediated vasodilatation in mice
given normal chow at baseline (week 0). There was a significant reduc-
tion in ACh response in L-NAME treated animals comparedwith vehicle
treated animals (Pb0.05). At 12 weeks, mice fed normal chow showed
a similar reduction in peak ACh response following L-NAME (310±
33 AU vs 248±26 AU before versus after L-NAME, respectively, P=
0.02). In animals fed an atherogenic diet for 12 weeks, ACh-mediated
vasodilatation before L-NAME was 226±21 AU, and this response
was reduced to 180±21 AU (P=0.03) following L-NAME. The degree
of change in ACh response at 12 weeks following L-NAME was signifi-
cantly greater in animals fed normal chow compared with animals fed
an atherogenic diet (62 AU vs 46 AU, Pb0.05).Fig. 2. Skin perfusion response to ACh iontophoresis at the start of study (Week 0) show-
ing no significant difference in vascular response between animals assigned to receive
normal rodent chow (n=19) or an atherogenic diet (n=19). Cutaneous microvascula-
ture was preconstricted with phenylephrine as described in Methods. Skin perfusion
was measured in arbitrary units (AU). Error bars are SEM.Relaxation in the tail artery to ACh and SNP measured by wire myography
ex-vivo
The tail artery response to AChwas calculated as ameasure of endo-
thelial function in mice fed an atherogenic diet versus a normal chow
diet. The sensitivity of ACh response did not change as therewas no sig-
nificant change in EC50 across groups (chow; − log[6.6±0.1]M vs ath-
erogenic; -log[6.1±0.1]M, P>0.05) as shown in Fig. 5. However, the
extent of relaxation was reduced in the atherogenic diet group
(chow-fed, 75.7±4.8% vs atherogenic, 54.3±3.9%, Pb0.05).
There was no significant difference in tail artery response to SNP in
the atherogenic diet group compared with the chow-fed group
(Fig. 6). There was also no change in the sensitivity of SNP response in-
dicated by lack of significant change in EC50 across groups (chow;− log
[6.7±0.1]M vs atherogenic;− log[6.9±0.1]M, P>0.05).Correlations between microvascular response to ACh and tail artery
vascular function
We found a significant correlation when plotting the peak micro-
vascular response to ACh against the maximum ACh-mediated relax-
ation in the tail artery at week 24 (r=0.699, P=0.017). There was a
positive correlation between the microvascular response to SNP and
tail artery response at week 24 but this did not quite reach statistical
significance (r=0.347, P=0.173).Fig. 4. Effect of L-NAME (20 mg/kg, i.p., n=7) and vehicle (De-ionized water, i.p. n=7)
on microvascular response to ACh in chow-fed at baseline (week 0). Skin perfusion was
measured in arbitrary units (AU). Error bars are SEM.
Fig. 5. Ex-vivo measurement of tail artery relaxation to ACh, measured by wire
myography, in chow-fed mice (n=11) versus atherogenic diet mice (n=11). *Pb0.05. Fig. 7. Percentage of aortic vessel stained for lipid with Oil Red O stain in chow- and
atherogenic diet-fed mice (n=19 for each group).
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Fig. 7 shows the level of lipid deposition on the arterial wall through
en-face staining of the excised aorta with Oil Red O stain. Lipid deposi-
tionwas significantly (Pb0.01) greater in all areas of the aorta of athero-
genic diet-fed mice compared with chow-fed mice.
There were significant negative correlations between the percent-
age of entire aorta covered in lipid and iontophoretic responses to
ACh at 8 weeks (r=−0.751, Pb0.001) and at 24 weeks (r=−0.826,
Pb0.001).
Discussion
In this study, we have used LDI combined with iontophoresis of
vasoactive chemicals to measure in-vivo skin microvascular function
longitudinally over 24 weeks in response to an intervention (high
cholesterol diet) known to produce endothelial dysfunction and ath-
erosclerosis. Measurements of total plasma cholesterol confirm that
the atherogenic diet used in this study was successful in increasing
plasma cholesterol levels. The subsequent atherogenic response
was measured post-mortem and showed significant lipid deposition
in the aorta vessel wall. The main findings from our study are that,
using this technique, early development and progression of endothe-
lial dysfunction can be detected in the skin microcirculation of mice.
The significant correlation between impairment in ACh-mediated
vascular responses at 8 weeks and the percentage of lipid depositionFig. 6. Ex-vivo measurement of tail artery relaxation response to SNP, measured by
wire myography, in chow-fed mice (n=11) versus atherogenic diet mice (n=11).in the aorta at 24 weeks provides supportive evidence that early
measurements of endothelial dysfunction in the skin microcircula-
tion reflect atherosclerosis burden using this mouse model.
We found that in contrast to mice fed a standard chow diet, who
maintained ACh-mediated vasodilatation over 24 weeks, mice fed a
high-cholesterol, atherogenic diet showed significantly attenuated
skinmicrovascular responses to ACh after 4 weeks and continued to re-
main so for the remainder of the 24-week duration of the study. The
finding that microvascular responses to SNP, which provide a measure
of endothelium-independent smooth muscle cell function, remained
relatively intact in high cholesterol-fed mice throughout the 24-week
period supports the concept that the impairment inmicrovascular func-
tion was specifically at the level of the endothelium and not due to a
generalized reduction in vasodilator capacity.
ACh mediates endothelium-dependent vasodilatation via muscarinic
receptors on the endothelial cell surface. This leads to an increase in intra-
cellular calcium concentration, activation of endothelial NO synthase and
a subsequent increase in NO production. In ourmodel, the contribution of
endothelium-derived NO to the baseline ACh response at week 0 and at
12 weeks following normal chow feeding was confirmed as shown by
the significant reduction in the ACh following pre-treatment with
L-NAME, a non-selective inhibitor of NOS. In cholesterol-fed mice,
the microvascular response to iontophoresis of ACh at 12 weeks
was significantly reduced and pre-treatment with L-NAME produced
a smaller reduction in ACh-mediated vasodilatation than that ob-
served at baseline suggesting that NO bioavailability had been partly
compromised by the high cholesterol diet. However, since a signifi-
cant vasodilator response was still evident in L-NAME treated mice,
this suggests that additional mechanisms for ACh-mediated vasodi-
latation, independent of NO, must be in operation. In addition to
the contribution of NO to ACh-mediated vasodilatation, prostaglan-
dins and endothelium-derived hyperpolarizing factor are also
thought to make a contribution (Gaubert et al., 2007). We did not
carry out experiments to examine other possible pathways as the
primary purpose of this study was to use the LDI and iontophoresis
technique assess longitudinal changes in endothelial function to an
intervention known to induce atherosclerosis, rather than to tease
out the specific underlying mechanisms affected by the high choles-
terol diet.
To further examine whether evidence for the presence of endotheli-
al dysfunction measured in-vivo in the skin microvasculature using this
technique was representative of changes in endothelial function in
other vessels of the animal, we performed functional studies of the
mouse tail arteries ex-vivo using wire myography. The sensitivity of
ACh response in tail arteries did not change (indicated by no significant
change in EC50 across groups). However, the extent of relaxation was
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endothelial dysfunction. These results significantly correlated with
measurements in the microcirculation at 24 weeks, indicating that the
endothelial dysfunction was present in vascular beds other than the
skin within the high cholesterol diet group and that measurements
made in the skin were reflective of changes in vascular function in
other vascular beds. There was no difference in the extent of relaxation
or sensitivity of SNP response in the tail-artery response between the
diet groups, confirming the observation seen in-vivo in themicrovascu-
lature. There was a borderline significant correlation between the peak
SNP response in the skin microcirculation and tail artery response. It is
possible that this lack of correlation was due to the fact that the values
were at the top end of the dose–response curves where there was little
variability across groups meaning that our ability to pick up significant
relationshipsmight not have been sensitive enough, especially with the
relatively small number of mice in this study.
A limitation of this ex-vivo work was the use of U-46619 (a syn-
thetic analogue of prostaglandin PGH2) as a preconstrictor agent
for the myography experiments. This was in contrast to the in-vivo
laser Doppler methodology which used the α1-adrenergic receptor
agonist, PE to establish a pre-constricted baseline. This was due to
an incompatibility of the separate methodologies; there was no
way of delivering U-46619 iontophoretically in-vivo and similarly,
the myography protocol was not optimised to use PE. Future studies
could endeavour to synchronise the methodologies. A further limita-
tion is that more detailed exploration of the nature of endothelial
dysfunction could have been evaluated in the isolated vessels prepa-
ration ex vivo, however as stated above, the primary objective of the
current study was to test the ability to measure changes in endothe-
lial function longitudinally in-vivo over time.
The use of LDI to measure skin microcirculation response to ion-
tophoresis of vasoactive test drugs has been developed over a num-
ber of years and used in a variety of patient populations including
the elderly, diabetes, CVD and rheumatoid arthritis patients. Howev-
er there is still some disagreement about the most reliable protocol
(Cracowski et al., 2006; Turner et al., 2008). The use of the iontophoresis
and LDI procedures in mice meant that a number of physiological,
technical and operational issues had to be resolved and developed.
Technical considerations included the iontophoresis protocol (drug
concentration and iontophoresis current/duration), current-induced
vasodilatation and the location of the iontophoresis and scanning
area. Previous studies in humans have shown that current-induced hy-
peremia can be an issue with iontophoresis drug delivery, especially at
higher currents (Ǻsberg et al., 1999; Durand et al., 2002a,2002b;
Grossmann et al., 1995), and at the cathode (Abou-Elenin et al., 2002;
Berliner, 1997; Morris et al., 1995; Morris and Shore, 1996). In our
pilot work, we did not observe any current-induced vasodilatation dur-
ing iontophoresis of deionizedwater with anodal and cathodal currents
of 100 μA (unpublished results); therefore all measured increases in
skin perfusionwere drug-specific.Wealso found thatmoving the ionto-
phoresis and scanning site from one flank of the animal to the other
made no significant difference to the perfusion response. Indeed, one
of the advantages of using laser-Doppler imaging is that it eliminates
the spatial heterogeneity seen in single-point flowmetry studies
(Fagrell and Nilsson, 1995; Morris et al., 1995; Turner et al., 2008).
This was particularly important in this study where repeated measures
over time were required.
Previous work carried out in mice using laser Doppler technology
utilized a multi-fiber, single point laser Doppler probe in diabetic
mice Sigaudo-Roussel et al. (2004). In that study the authors found
that ACh delivered via iontophoresis produced an increase of 81±
25% in skin perfusion while SNP produced a 54±15% increase. They
have subsequently used this technique successfully in further studies
using mice (Demiot et al., 2006a,b; Garry et al., 2007; Gaubert et al.,
2007). Our results are comparable although by using LDI as opposed
to flowmetry, we appear to have reduced the variability of the resultswith a typical increase of 88.4±5.2% and 83.9±9.2% for ACh and SNP
respectively, further emphasizing the advantage of LDI over classical
Doppler flowmetry.
There are a number of methods currently used in animal studies for
measuring endothelial cell function in large arteries/blood vessels in-
cluding wire-myography, pressure-myography and organ-bath experi-
ments. Although these methods are reliable and fully established, they
require the culling of animals making longitudinal studies difficult. Ad-
ditionally, they remove tissue fromnormal physiological conditions and
do not necessarily reflect the status of themicrocirculation. Anesthetics
have the potential to induce changes in blood flow. The use of isoflurane
as an anesthetic in this study allowed the induction of adequate immo-
bilizationwith quick recovery. It has previously been reported that gas-
eous anesthesia produces less interference with themicrocirculation as
opposed to other agonists such as ketamine and benzodiazepine, which
require injection into the peritoneal cavity. Furthermore, it has been
shown that isoflurane causes no significant change in tissue perfusion
or oxygenation and maintains normal cardiac output (Baudelet et al.,
2004). In our own pilot work, we observed no significant change in
baseline perfusion before and after isoflurane.
In conclusion, we have used LDI in combination with iontophoresis
of vasoactive chemicals tomeasure longitudinal changes inmicrovascu-
lar endothelial cell function in-vivo and have shown that early changes
in skinmicrovascular function are representative of atherosclerotic bur-
den. In this regard, the skin microcirculation might provide a useful
platform to better understand the relationship between early endothe-
lial dysfunction and development and progression of atherosclerosis in
mice. The advantage ofmeasuring endothelial function in-vivo is that by
definition animals are kept alive during the procedure meaning that
multiple measurements can be made on the same animal over time,
thereby increasing the amount of data captured from each animal and
importantly limiting the number of animals culled. The observation
that early endothelial dysfunction measured in the skin microvascula-
ture may reflect endothelial dysfunction in other vascular beds is a po-
tentially important finding. This mirrors what has been observed in
humans (Bonetti et al., 2003), confirming the in-vivo measurement of
endothelial dysfunction using LDI as a translatable biomarker. However,
further studies will be required to confirm this observation. We believe
that this methodology could allow tracking of development of early en-
dothelial dysfunction in themicrovasculature in various animal models
of CVD, especially in transgenic mice models to allow a better under-
standing of specific pathways and mechanisms underlying develop-
ment and progression CVD.
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